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Abstract  
 
Inherited and acquired disorders of the neuromuscular junction are an important cause 
of muscle weakness and fatigability.  
In this thesis I focus on the autoimmune disorders of neuromuscular transmission.  
Myasthenia Gravis (MG) is the most common of these diseases and is typically caused 
by antibodies against the post-synaptic acetylcholine receptor.  Lambert Eaton 
Myasthenic Syndrome (LEMS) is a pre-synaptic disorder typically caused by antibodies 
against voltage gated calcium channels (VGCC).   
With regard to LEMS, my main aim was to gain a more complete understanding of the 
pathomechanisms of the disease.  To date, the direct effect of LEMS IgG on presynaptic 
neurotransmitter release had not been investigated in detail.  I examined how LEMS 
IgG affects neurotransmitter release by imaging action potential dependent vesicle 
exocytosis using a fluorescent dye.  I found that LEMS IgG significantly inhibited the 
rate of synaptic vesicle release but this effect was lost in synapses from a Cacna1a 
knockout mouse.  These data provide direct evidence that LEMS is caused by impaired 
neurotransmitter release due to an effect on P/Q-type VGCCs.  
With regard to MG, I studied the long-term outcome of patients with thymomatous and 
non-thymomatous MG after thymectomy and found that in general the outcome was 
favourable in the majority of patients with 34% of patients achieving complete stable 
remission.  I also reviewed the long-term outcome of patients after a severe 
exacerbation of MG requiring ITU admission.  Despite the significant mortality 
associated with severe exacerbations of MG, it was found that specialised neuro-
intensive care was associated with a good long-term prognosis in the majority of 4 
 
patients.  There were no significant differences in outcome in those with early or late 
onset MG.   
 
Overall the data presented in this thesis provide new insights into the pathomechanisms 
of LEMS IgG and provide new information regarding the long-term outcome of patients 
with MG. 
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In this thesis I focus on two specific autoimmune diseases of the neuromuscular 
junction, Myasthenia Gravis (MG) and Lambert Eaton Myasthenic Syndrome (LEMS).  
MG is the more common of the two disorders with a prevalence of approximately 7-15 
per 100,000 (Robertson et al., 1998, Carr et al., 2010), whilst LEMS is much less 
common with an incidence of approximately 0.048 per 100,000 and a prevalence of 0.2 
per 100,000 (Wirtz et al., 2003).  Both disorders present with muscle weakness due to 
impaired synaptic transmission at the neuromuscular junction.   
 
MG is a well-characterised autoimmune disease, most commonly due to antibodies 
directed against the postsynaptic acetylcholine receptor (AChR).  Antibodies against 
other antigens including Muscle Specific Tyrosine Kinase (MuSK) and low-density 
lipoprotein receptor related protein 4 (LRP-4) have also been described in MG patients. 
Approximately 10-15% of patients have no identifiable autoantibodies using standard 
radioimmunoprecipitation assays.  Anti-AChR antibodies can however be identified in 
up to 66% of these “seronegative” patients when a specific cell based assay using 
rapsyn clustered AChRs is performed (Leite et al., 2008).  MG typically presents with 
painless fatigable muscle weakness and in 15% of cases this is associated with a 
thymoma, a tumour of the thymus gland (Tsinzerling et al., 2007).   
 
LEMS, in contrast is typically associated with antibodies directed against presynaptic 
voltage-gated calcium channels (VGCCs) (Motomura et al., 1995, Takamori et al., 
2000) and presents with proximal muscle weakness and autonomic symptoms (Titulaer 
et al., 2011).  Approximately 50% of cases are associated with a malignancy, most often 
a small cell carcinoma of the lung (SCLC) (Titualer et al., 2011).  32 
 
 
The goals of this thesis were two-fold. First, to obtain a more direct insight into the 
mechanisms by which LEMS antibodies affect synaptic transmission; in particular to 
probe both the effect of LEMS Immunoglobulin G (IgG) on synaptic vesicle release and 
the specificity of LEMS antibodies for individual calcium channel subtypes.  Second to 
examine the long-term effects and outcome of patients with MG from the large cohort 
we have access to at the NHNN.  I was particularly interested in outcome after 
thymectomy and also wished to assess the progress of MG patients after a severe 
exacerbation of MG requiring Intensive Care Unit (ICU) admission.   
 
Firstly, I give an overview on the mechanisms of synaptic transmission, the clinical and 
pathological features of both MG and LEMS and outline the major unsolved questions 
that underlie this thesis. 
 
1.1 Synaptic transmission 
 
1.1.1 Electrical and chemical synapses 
Synaptic transmission forms the basis of information transfer in the nervous system.  
Until the late nineteenth century there was a belief that all neurons were directly 
connected and that an impulse from one nerve was directly carried to another through a 
physical connection (reviewed by Holz and Fisher, 1999).  Such synapses have 
subsequently been confirmed and are known as electrical synapses. They are composed 
of direct intercellular connections or gap junctions that allow the direct passive flow of 33 
 
electrons between cells.  The main function of electrical synapses is to synchronize 
electrical activity among populations of neurons (Bennett and Zukin, 2004).  
 
We now recognise that most synapses are chemical, and, unlike electrical synapses 
although close together, are not continuous.  Chemical neurotransmission involves the 
release of neurotransmitters or neuropeptides from the pre-synaptic cell, and their 
diffusion across a space or synaptic cleft, which typically measures between 15 and 25 
nm to act on postsynaptic receptors (Südhof, 1995).  The chemical neurotransmitters 
that are released from the presynaptic cell are packaged into synaptic vesicles in the 
presynaptic membrane.  These vesicles fuse with the presynaptic membrane, releasing 
the neurotransmitter into the synaptic cleft.  Various different types of chemical 
neurotransmitter exist; they can be divided up in terms of their structure- into amino 
acids (such as glutamate, γ-aminobutyric acid (GABA) and glycine), monoamines 
(including dopamine, noradrenaline and serotonin), peptides (including somatostatin, 
substance P and opioids) and others including acetylcholine, or in terms of their action – 
whether they are primarily excitatory or inhibitory.  Glutamate is the most important 
excitatory neurotransmitter in the central nervous system (CNS) (Purves et al., 2001), 
binding to multiple different receptors including N- methyl –D-asparte  (NMDA) 
receptors, -Amino-3-hydroxy-5-methyl4-isoxazolepripionic acid (AMP) receptors and 
kainate receptors – these are excitatory receptors that allow influx of positively charged 
ions and subsequent depolarisation of the postsynaptic neuron when opened.  
Acetylcholine (ACh) is the neurotransmitter responsible for excitatory 
neurotransmission at the neuromuscular junction and so has particular relevance to the 
study of LEMS and MG.  It also provides excitatory neurotransmission at various 34 
 
autonomic synapses including the vagus nerve, cardiac muscle and various visceral 
motor synapses and also at several sites in the CNS (Purves et al., 2001).   
 
Once a chemical neurotransmitter is released from the presynaptic membrane, it diffuses 
across the synaptic cleft and binds to specific receptors on the postsynaptic membrane.  
There are two major classes of postsynaptic receptors –ionotropic and metabotropic 
receptors.  Ionotropic receptors are linked directly to ion channels – these receptors have 
two functional domains; an extracellular site that binds the chemical neurotransmitter 
and the membrane spanning ion domain.  Binding of the neurotransmitter induces a 
conformational change in the postsynaptic receptor allowing ions to flow into the post 
synaptic cell causing postsynaptic current.  If this current is depolarizing and 
sufficiently large, it may trigger an action potential in the postsynaptic neuron.  
Neurotransmitters also act at metabotropic (G-protein coupled) receptors.  These 
receptors do not have ion channels as part of their structure; rather binding of the 
neurotransmitter induces activation of G proteins which then in turn leads to the 
opening or closing of ion channels (Purves et al., 2001)   
 
1.1.2 History of our understanding of chemical synaptic transmission  
The process of chemical neurotransmission was first described by the Austrian scientist 
Loewi in 1921 when he demonstrated that a chemical, released by the vagus nerve was 
able to alter heart rate- he termed this unknown chemical “vagusstoff” (Lowei et al., 
1921).  The nature of this “vagus substance” was characterised in a series of successive 
papers.  Lowei demonstrated that the transmitter appeared subsequent to nerve 35 
 
stimulation and was antagonised by cholinesterase (Loewi et al., 1926), thus identifying 
acetylcholine (ACh) as the first neurotransmitter.   
 
The process of chemical neurotransmission was subsequently recorded at the 
neuromuscular junction in the 1930s when it was shown that acetylcholine was released 
in response to a presynaptic nerve impulse and that this resulted in postsynaptic 
depolarization and muscle contraction (Dale et al., 1936).  In the 1950s, Bernard Katz 
and his colleagues used the frog neuromuscular junction to delineate the principles of 
neuromuscular transmission further by recording the response (the end plate potential – 
EPP) of a postsynaptic cell to the release of ACh using intracellular microelectrode 
recording (Fatt and Katz, 1951), allowing EPPs to be used as a sensitive monitor of 
ACh release from the presynaptic motor neuron (Augustine and Kasai 2007).  Further 
work identified small spontaneous depolarisations of the post synaptic membrane that 
occurred even when the motor neuron was not stimulated (Fatt and Katz, 1952) – these 
became to be known as “miniature end plate potentials” or “minis” (mEPPs) and are due 
to the spontaneous release of ACh from the presynaptic motor neuron (Fatt and Katz, 
1952).   
 
Statistical analysis of fluctuations in EPP amplitude and mEPPS allowed del Castillo 
and Katz to conclude that the EPP consists of multiple quanta of ACh that are released 
in response to a depolarisation in the nerve terminal (del Castillo and Katz, 1954).  They 
viewed the presynaptic nerve terminal as possessing a pool of such quanta – a 
proportion of which are released with each presynaptic nerve stimulation (Augustine 
and Kasai, 2007).   36 
 
 
It was later shown that synaptic transmission was heavily dependent on external Ca2+.  
Studies of the squid stellate ganglion showed that inward movement of Ca2+ was 
essential for synaptic vesicle release (Katz and Miledi, 1967).  Similar findings were 
seen at the frog (Dodge and Rahamimoff, 1967, Andreu and Barrett, 1980) and rat 
(Hubbard et al., 1968) neuromuscular junctions.   
 
1.1.3 Process of synaptic transmission  
The process of synaptic transmission has been described in detail and involves several 
steps (figure 1.1).  Firstly, the neurotransmitter is synthesised in the cell body or at the 
presynaptic terminal.  Neurotransmitters are then loaded into synaptic vesicles via active 
transport – an electrochemical gradient is created by a proton pump which transports H+ 
ions which in turn forces neurotransmitter uptake (Ahnert-Hilger, 2003).  The synaptic 
vesicles containing neurotransmitter then dock near the synaptic terminal adjacent to 
presynaptic Ca2+ channels, in a process that involves the various key proteins known as 
the Soluble NSF Attachment protein receptor (SNARE) proteins (Bennett et al., 1992) 
(see below).  The area where the synaptic vesicles cluster is known as the “active zone” 
an electron dense region directly opposite the postsynaptic density.  Typically 8-10 
vesicles are docked at small central glutamatergic synapses (Schikorski and Stevens, 
2001; Xu-Friedman et al., 2001) 
 
The depolarising current from the action potential at the presynaptic nerve terminal 
membrane triggers a conformational change in VGCCs, which allows entry of Ca2+ 
from the extracellular space (Katz and Miledi 1967; Miledi, 1973; Schneggenburger et 37 
 
al., 2005).  The subsequent increase in intracellular Ca2+ which, at the release site, 
reaches a concentration in the order of tens of micromoles per litre, activates sensors 
that subsequently trigger synaptic vesicle fusion with the presynaptic membrane and the 
release of neurotransmitter into the synaptic cleft (Katz, 1971) through exocytosis.  
Once the synaptic vesicles have fused with the presynaptic nerve terminal membrane, 
the neurotransmitters can diffuse across the synaptic cleft and subsequently bind to 
specific receptors on the postsynaptic membrane.   
 
In response to neurotransmitter binding, postsynaptic receptors undergo a 
conformational change that leads to a transmembrane channel opening directly or via a 
G protein signalling pathway.  Depending on the ion channel selectivity of these 
channels, certain ions can move into the channel along their electrochemical gradient.  
If the current is depolarising and of large enough magnitude, it will induce an action 
potential in the postsynaptic cell.   
 
After exocytosis vesicles undergo endocytosis and recycle and refill with 
neurotransmitter for a new round of exocytosis in a “trafficking cycle” (Südhof, 2004).  
This recycling process is important as presynaptic nerve terminals only contain a few 
hundred vesicles on average and an efficient recycling process is necessary to preserve 
synaptic transmission and synaptic morphology (Klingauf et al., 1998).  A number of 
different mechanisms of synaptic vesicle recycling have been proposed.  These include 
(1) so-called “kiss and stay” whereby vesicles are re-acidified and refilled with 
neurotransmitter without undocking (van Kempen et al., 2011), (2) “kiss and run” where 
vesicles undock and recycle locally to re-acidify and refill with neurotransmitter via a 38 
 
transient pore between the synaptic membrane and the vesicle (Ceccarelli et al., 1973; 
Klingauf et al., 1998; Richards et al., 2005; Haratata, 2006) and (3) a process by which 
vesicles endocytose via clathrin –coated pits and then refill with neurotransmitters either 
immediately or via an endosomal intermediate (Südhof , 2004).   
 
Figure 1.1 The Synaptic vesicle cycle: (1) Synaptic vesicles (green circles) are filled 
with neurotransmitter (grey particles) by active transport.  (2) Synaptic vesicles cluster 
near the active zone.  (3)Vesicles dock near the active zone in the vicinity of VGCCs.  
(4) Depolarisation of the plasma membrane activates VGCCs allowing influx of Ca2+.  
(5) Vesicles fuse with the plasma membrane allowing release of neurotransmitter.  (6) 
Neurotransmitter diffuses across synaptic cleft where it can activate postsynaptic 
receptors. (7) After fusion vesicles undergo endocytosis via either, kiss and run, clathrin 
mediated endocytosis with recycling via endosomes, or local reuse via kiss and stay  39 
 
 
1.1.4 SNARE proteins  
The synaptic vesicle cycle is the fastest and most tightly regulated cellular transport 
pathway (Südhof, 1995).  There are a number of important protein–protein interactions 
that control and facilitate the synaptic vesicle cycle and neurotransmitter release.  The 
SNARE proteins are required for docking of the vesicle at the active zone and fusion of 
the synaptic vesicle to the synaptic membrane.  The SNARE complex is composed of 
three membrane proteins – two of which, syntaxin-1 and SNAP-25 (synaptosomal 
associated protein 25), are located on the synaptic membrane – and VAMP (vesicle 
associated membrane protein or synaptobrevin) which is located on the vesicle 
membrane (Südhof, and Rothman, 2009; Groffen et al., 2010; Pang et al., 2006).  The 
SNARE proteins form a stable helical bundle composed of two helices from SNAP-25 
and one each from syntaxin-1 and VAMP that brings the synaptic vesicle membranes 
together, allowing them to fuse when triggered by Ca2+ influx (Südhof, 1995, 2004; 
Hanson et al., 1997; Weber et al., 1998).    
 
Synaptotagmin 1 is a vesicle protein that can bind SNARE proteins (Bennett et al., 
1992; Chapman et al., 1995) and it serves as the major Ca2+ sensor for regulated 
exocytosis.  It is required for Ca2+ triggering of synchronous neurotransmitter release 
(Geppert et al., 1994) and synaptic transmission is severely impaired in mice with 
synaptotagmin mutations (Geppert et al., 1994).   
 
Many hundreds of other proteins are involved in vesicular exocytosis forming a 
complex network of interactions (Südhof, 2004), for example, SM (Sec1.Munc18-like) 40 
 
proteins also have an important role in vesicular fusion – they bind to SNARE 
complexes and direct their fusogenic action (Südhof and Rothman, 2009).   
 
1.1.5 Pools of synaptic vesicles  
Synaptic vesicles in synaptic boutons are arranged into a number of different groups or 
“pools”, including the readily releasable pool (RRP), the recycling pool (RP) and the 
reserve pool (Rizzoli and Betz, 2005) (See figure 1.2).  The stimulation frequency at the 
presynaptic nerve terminal determines which pool of vesicles is released at any 
particular time.  When a nerve terminal is stimulated repeatedly at high frequency the 
release rate of synaptic vesicles will initially drop and eventually reach a lower steady 
state level.  This initial depression reflects the depletion of vesicles in the readily 
releasable pool (RRP).  The steady state level of release corresponds to the rate at which 
vesicles are replenished by recycling or are recruited from the reserve pool.   
 
The readily releasable pool (RRP) contains vesicles, which are immediately available 
for release on Ca2+ entry to the cell.  It is generally assumed that they correspond to 
vesicles that are docked in the active zone, in close proximity to the VGCCs and are 
primed for release (Schikorski and Stevens, 2001; Rizzoli and Betz, 2005).  At 
hippocampal boutons, the RRP is composed of 5-20 vesicles that can be can be depleted 
in 10s by high frequency (30 Hz) stimulation and can refill in one minute (Richards et 
al., 2003; Rosenmund and Stevens, 1996; Murthy and Stevens, 1999).  At the frog 
neuromuscular junction approximately 20% of the vesicles reside in the RRP (Richards 
et al., 2003).   
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The recycling pool (RP) vesicles maintain continuous synaptic vesicle release under 
moderate physiological stimulation (Richards et al., 2003; Kuromi and Kidokoro, 
2003).  It comprises 10-20% of the total number of vesicles although this is variable 
(Harata et al., 2001; Rizzoli and Betz 2005).  It is recycled continuously during 
physiological frequencies of stimulation and is refilled by newly recycled vesicles 
(Rizzoli and Betz 2005; Kuromi and Kidokoro, 2003; Harata et al., 2001; de Lange et 
al., 2003)  
 
The reserve pool is only recruited to release synaptic vesicles with high frequency 
stimulation. It constitutes 80-90% of the total number of vesicles in the synaptic bouton 
(Rizzoli and Betz, 2005) but vesicles are seldom recruited from the reserve pool under 
physiological conditions (Rizzoli and Betz 2005).  Although reserve pool vesicles are 
mixed with those from the recycling pool, they tend to be located further from the active 
zone as shown by Fei Mao (FM) dye staining of synaptic vesicles and electron 
microscopy (EM) (Schikorski and Stevens, 2001).   
 
Vesicles can mix between different pools but it has been argued that they are 
preferentially recycled to their own pools (Pyle et al., 2000).  The size of the synapse, 
active zone and total number of vesicles can be altered under certain conditions.  For 
example, the number of docked vesicles, the total number of vesicles per synapse and 
the size of the synapse have all been shown to increase after hippocampal synapses were 
pharmacologically silenced for several days (Murthy et al., 2001).   
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Figure 1.2 Pools of synaptic vesicles. Distribution and proportion of vesicle pools in a 
hippocampal presynaptic terminal. Readily releasable pool (RRP) in red ~ 5%, 
recycling pool (RP) ~20% (green), reserve pool ~75% (blue).  
 
1.1.6 Spontaneous neurotransmission  
The focus up to now has been on on evoked neurotransmission; synaptic vesicle release 
that occurs in response to a presynaptic nerve action potential.  However it is known 
that neurotransmission also occurs in the absence of presynaptic stimulation.  Fatt and 
Katz described small spontaneous depolarisations of the postsynaptic membrane 
potential that occurred even when the motor neuron was not stimulated – these 
miniature end plate potentials were found to result from spontaneous release of ACh 
from the presynaptic motor neuron (Fatt and Katz, 1952).  Action potential-independent 
neurotransmitter release occurs at low frequency at all synapses (Xu et al, 2009).  This 43 
 
synaptic vesicle release is maintained in the presence of tetrodotoxin (TTX), a sodium 
channel blocker that abolishes action potentials and inhibits evoked synaptic vesicle 
release (Xu et al., 2009).   
 
Spontaneous synaptic vesicle release was originally observed in muscle fibres as 
miniature end plate potentials (mEPPS) in 1952 (Fatt and Katz, 1952) but subsequently 
was recorded in central neurons as miniature inhibitory or excitatory postsynaptic 
currents (mIPSCs or mEPSCs) on patch clamping post synaptic cells (Simkus and 
Stricker 2002; 2002b).  These miniature potentials or “minis” represent the fusion of a 
single synaptic vesicle with the presynaptic membrane.  MEPP amplitude is typically 
about 1mV and the frequency at the NMJ is approximately 1/second (Lambert and 
Elmqvist, 1971). 
 
The physiological significance of spontaneous neurotransmitter release was initially 
questioned but it is now accepted that it does serve certain biological functions 
including maintenance of dendritic spines (McKinney et al., 1999), regulation of 
neuronal firing (Carter and Regher, 2002) and dendritic protein synthesis which has a 
role in stabilising synaptic function (Sutton et al., 2006).   
 
As described above, the process of action potential evoked synaptic vesice release is 
heavily dependent on the influx of Ca2+ through VGCCs.  It is also now recognised that 
the frequency of spontaneous vesicular release is reduced under conditions of low Ca2+ 
(Groffen et al., 2010; Xu et al., 2009) and that Ca2+ triggers a significant proportion of 
spontaneous neurotransmission (Xu et al., 2009; Groffen et al., 2010; Ermolyuk et al., 44 
 
2013), although spontaneous vesicular release that is Ca 2+ independent is also 
recognised (Maximov et al., 2007).   
 
The mechanism by which Ca2+ plays a role in spontaneous synaptic vesicle release is 
incompletely understood.  Synaptotagmin 1 is known to play a role in evoked synaptic 
vesicle release but is also thought to act as a Ca2+ sensor in spontaneous release (Xu et 
al., 2009).  The synaptotagmin analogue, Doc2B has also been suggested to act as a 
Ca2+ sensor for spontaneous synaptic vesicle release (Groffen et al., 2006) although this 
is controversial (Pang et al., 2011).   
 
It has also been suggested that spontaneous neurotransmitter release may, in part, be 
triggered by the release of Ca2+ from internal stores via Ryanodine receptors and other 
mechanisms (Llano et al., 2000; Emptage et al., 2001; Koizumi et al., 1999).  More 
recently it has been shown that VGCC can open spontaneously at resting membrane 
potentials (Awatramani et al., 2005; Yu et al., 2010).  Thehe opening of a single VGCC 
has been shown to be sufficient for a quantum of neurotransmitter to be released 
(Bennett et al., 2000).  
 
Previously, in our laboratory, it was shown that opening of VGCCs accounts for 
approximately 50% of all spontaneous glutamate release at rat hippocampal synapses 
(Ermolyuk et al., 2013).  The sensitivity of VGCC-dependent mEPSCs to the Ca2+ 
chelators EGTA and BAPTA is similar to that of action potential evoked exocytosis, 
suggesting that both evoked and spontaneous synaptic vesicle release are triggered by 45 
 
similar Ca2+ micro and nano domains which are sensed by the same Ca2+ sensor – 
synaptotagmin -1 (Ermolyuk et al., 2013).   
 
1.1.7. Study of synaptic transmission  
Synaptic transmission has been studied in a number of model systems including the 
neuromuscular junction (Katz and Miledi, 1969b), the calyx of Held (Schneggenburger 
and Forsythe, 2006), the chick ciliary ganglion (Stanley and Goping, 1991) 
synaptosomal preparations (Nicholls, and Sihra 1986), retinal bipolar cells (Neves et al., 
2001) and hippocampal mossy fibre terminals (Geiger and Jonas, 2000).   
 
Direct patch-clamp recordings have been performed at a number of larger synapses: 
hippocampal mossy fibre synapses, the calyx of Held and retinal bipolar cells (Geiger 
and Jonas 2000. Schneggenburger and Forsythe 2006; Forsythe 1994; Palmer 2010).  
However, it has been hitherto more difficult to study transmission at the small central 
synapses of the hippocampus (Branco et al., 2008) and other techniques such as 
synaptic vesicle imaging have been used.  I will discuss the use of FM imaging in the 
study of synaptic vesicle release in Chapter 3.   
 
Many studies evaluating neurotransmission have used the postsynaptic response such as 
the EPP as a marker of presynaptic vesicle release.  However, the “quantal content”, the 
number of quanta released in response to a presynaptic stimulus, cannot always be 
accurately estimated from end plate potentials.  Occasionally neurotransmitter release 
does not activate postsynaptic receptors; so called ‘silent synapses’ (Kullmann, 1994; 46 
 
Isaac et al., 1995).  Moreover, not every action potential that arrives at a nerve terminal 
is converted into a secretory signal – at hippocampal excitatory terminals, it has been 
estimated that only 10-20% of action potentials trigger release (Goda and Südhof, 1997; 
Sudhof 2004).   
 
1.2 Voltage Gated Calcium Channels  
 
1.2.1 Role of VGCCs in synaptic transmission 
Voltage gated Ca2+ channels (VGCCs) play an integral role in both evoked and 
spontaneous neurotransmission; the influx of Ca2+ through VGCCs is an obligatory step 
for excitation –secretion coupling during neurotransmission (Reid et al., 2003; Luebke 
et al., 1993).  As described above, an action potential invading the presynaptic terminal 
causes a conformational change in the VGCC voltage sensor – this opens the channel 
allowing an influx of Ca2+ ions.  The influx of Ca2+ ions remains quite local and very 
transient - a concentration of 5-20 μM is obtained at the release site but only briefly (4-
500 μs) due to effective endogenous buffering and diffusion (Neher 1998; Meinrenken 
et al., 2002; Bollmann et al., 2000).  Spontaneous neurotransmitter release has a Ca2+ 
dependent component (Xu et al. 2009; Groffen et al 2010) but can also occur in the 
absence of extracellular Ca2+ (Maximov et al., 2007).   
 
The influx of Ca2+ to the presynaptic nerve terminal triggers at least two components of 
neurotransmitter release that are mechanistically distinct – the first is a fast synchronous 
phasic component, induced 50 μs after a Ca2+ transient (Sabatini and Regher, 1996).  47 
 
The second component is a slower, more sustained elevation of release probability 
(Atluri and Regehr, 1998; Barrett and Stevens, 1972).  This slower release can in turn 
be separated into two components- one lasting for tens of milliseconds that is steeply 
calcium-dependent and one lasting for hundreds of milliseconds that is driven by low 
levels of calcium (Atluri and Regehr 1998).   
 
The proteins involved in synaptic vesicle exocytosis interact closely with VGCCs.  The 
synprint (synaptic protein interaction) motif on the II-III linker on P/Q- and N- type 
VGCCs physically interacts with the synaptic vesicle release proteins (including 
syntaxin1A and 1B, SNAP-25, synaptobrevin, synaptotagmin) (Jarvis and Zamponi, 
2005), a process proposed to allow for tight coupling between Ca2+ entry and synaptic 
vesicle exocytosis.  VGCC activity is in turn regulated by interaction with the 
presynaptic release machinery (Jarvis and Zamponi, 2005).   
 
VGCCs are ubiquitously expressed throughout the nervous system and have been 
identified in all excitable cells (Hagiwara and Byerly, 1981; Dolphin et al., 2006).  
VGCCs were first identified in crustacean muscle in the 1950s (Dolphin, 2003a; Fatt 
and Katz, 1953) and current through these channels was first recorded in cardiac 
myoctyes in the 1960s (Reuter, 1967).  Initially, it was assumed that Ca2+ channels were 
all quite similar.  However, we now recognise that VGCCs are a diverse family of 
proteins composed of pharmacologically distinct subtypes.  VGCCs are broadly 
classified into two main subgroups on the basis of their threshold of activation; high and 
low voltage activated (HVA and LVA) (Carbone and Lux, 1984; Benarroch, 2010).  
These groups are further divided into the following sub-types depending on their 48 
 
pharmacological profile; T-, L-, R-, N-, P- and Q- type (Wheeler et al., 1994; Tsien et 
al., 1988, Llinas et al., 1989; Dolphin et al., 2006).   
 
1.2.2 Structure of VGCCs 
The structure of voltage gated ion channels, including VGCCs is highly conserved.  
Biochemical purification has revealed that high voltage gated calcium channels are 
composed of four subunits including ʱ1, ʱ2δ, β and γ (Catterall, 2000) (Figure 1.3).   
 
The ʱ1 subunit is the pore forming unit and determines the biophysical and 
pharmacological properties of the channel.  The 1 subunit composed of 2000 amino 
acid residues with a transmembrane sequence organised into four repeated domains (I-
IV) which are each composed of six transmembrane sequences (S1-6) with a membrane 
associated loop between segments S5 and S6 (Catterall, 2000) which forms the pore.  
The external pore is lined by the pore loop, which contains a pair of glutamate residues 
that are required for Ca2+ selectivity.  Some pharmacological antagonists have receptor 
sites on the inner pore, which is lined by the S6 segment whereas other antagonists bind 
to different sites of the ʱ subunit – such as -agatoxin IVA (-aga) which binds to the 
S3-S4 linker domain (Winterfield and Swartz, 2000).   
 
There are three major families of ʱ1 subunit; Cav1, Cav2 and Cav3 (Benarroch, 2010).  
Each family is further divided into several subtypes.  Mutations in the ʱ1 subunit of 
different VGCC have been associated with human disease (see below) and have been 
described in various spontaneous murine mutations.    49 
 
 
 
 
 
Figure 1.3. Structure of a VGCC. VGCCs are composed of several subunits.  The ʱ1 
subunit is the main pore forming protein composed of four domains (I-IV) each divided 
into six transmembrane segments (S1-S6). The β and ʱ2ʴ are auxiliary subunits.  The γ 
subunit (not shown) is known to associate with skeletal muscle calcium channels 
(Arrikath and Campbell, 2003).  
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1.2.3 Different subtypes of VGCCS – the α1 subunits 
The pharmacological features of VGCCs are determined by the pore forming 1 subunit.  
The nomenclature of Ca2+ channels has changed a number of times but the VGCCs are 
grouped based on the  subunit with the accepted designation being CavX.X (Catterall 
et al., 2005).  (See table 1.1) 
 
The Cav1 family encodes for L-type or “long-lasting” VGCCs that activate and 
inactivate slowly.  They were first identified using dihydropyridines (DHPs) as Ca2+ 
channel blockers and are expressed in skeletal muscle cardiac muscle, endocrine cells 
and in neurons (Hess et al., 1984; Milani et al., 1990; Bean et al., 1989).  There are four 
different subtypes of this VGCC family.  The Cav1.1 subunit is expressed in the 
transverse tubules of skeletal muscle where it has an important role in excitation 
contraction coupling (Benarroch, 2010).  Mutations of this gene manifest as the 
condition of hypokalemic periodic paralysis (HypoPP) (Venance et al., 2006).  Cav1.2 is 
expressed in heart, smooth muscle and endocrine organs as well as dendrites and cell 
bodies throughout the CNS and has a role in long-term potentiation in the hippocampus 
and cortex (Ertel et al., 2000; Benarroch et al., 2010).  Cav1.3 is expressed in cochlear 
hair cells, the medium spiny neurons of the striatum and the substantia nigra pars 
compacta (Benarroch et al., 2010).  Cav1.4 VGCCs are the predominant type of calcium 
channel involved in glutamate release from rod photoreceptors in the retina and 
mutations in the gene can cause Congenital Stationary Night Blindness (Barnes and 
Kelly, 2002; Strom et al., 1998). 
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The Cav 2 family has three different isoforms that encode P/Q-, N and R type channels 
(Cav 2.1, Cav2.2 and Cav2.3 respectively) and these VGCCs are primarily expressed in 
neurons (Striessnig and Koschak, 2008).  N (for “neuronal” or non-L) type channels 
were identified using a peptide extracted from the Conus geographus snail; ω-conotoxin 
GV1A (Nowycky et al., 1985; McCleskey et al., 1987; Tsien et al., 1988).  Along with 
P/Q-type channels (see below), N- type channels play a role in triggering 
neurotransmitter release.  N-channels have roles in sensory and autonomic function and 
mouse knockout models have revealed a role for these channels in neuropathic pain 
(Striessnig and Koschak, 2008). 
 
The P- type VGCC was originally described in cerebellar Purkinje cells and is blocked 
by the peptide ω-agatoxin IVA, which comes from the funnel web spider Agelenopsis 
aperta (Llinas et al., 1989; Mintz et al., 1992).  Ca2+ currents recorded from cerebellar 
granule cells are also blocked by Agatoxin IVA, albeit at lower affinity (Randall and 
Tsien, 1995) and these channels were originally termed Q-type channels.  It is now 
thought that the pore forming subunit of both P- and Q-type channels are encoded  by 
the same gene (Bourinet et al., 1999; Richards et al., 2007) and these channels are 
generally referred to as P/Q- type VGCCs.  P/Q-type channels are the primary VGCC 
responsible for presynaptic Ca2+ entry and, consequently neurotransmitter release at the 
mammalian neuromuscular junction (NMJ) (Protti and Uchitel 1993, Uchitel et al., 
1992).  Synaptic transmission at central synapses is mediated mainly by P/Q-type 
channels with N-type channels playing a less prominent role (Cao and Tsien, 2010; 
Luebke et al., 1993; Takahashi and Momiyama 1993; Wheeler et al., 1994). 
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R-type VGCC were so named because they were “resistant” to DHP, conotoxin and 
agatoxin.  Since then, however, these channels have been found to be sensitive to the 
toxin SNX -482 (Newcomb et al., 1998; Giessel and Sabatini 2011) and have been 
found to have a major role in presynaptic long-term potentiation in the mossy fibre CA3 
synapse in the hippocampus (Benarroch 2010).  R-type channels also contribute to 
spontaneous exocytosis (Ermolyuk et al., 2013). 
 
The Cav3 family encodes for T type (tiny and/or transient) Ca2+ channels, which have a 
smaller channel conductance, are activated at more negative potentials and inactivate 
more quickly than other Ca2+ channels (Perez-Reyes et al., 1998).  T type VGCCs are 
present in a wide variety of cell types.  They play a role in pacemaker activity in the 
thalamus and are also involved controlling Ca2+ concentration in cells, which in turn 
acts as an important 2nd messenger in a variety of cellular processes (Hoffman et al., 
1994; Perez-Reyes, 2003).  
 
Disruptions of Ca2+ channel function either by genetic mutation, pharmacological or 
autoimmune alteration can cause a profound effect on the various Ca2+ signalling 
pathways including synaptic transmission.  Studies in vitro or in knockout mice have 
provided insights into the function of the different VGCCs (Benarroch, 2010; Striessnig 
and Koschak, 2008).  The different VGCC subtypes, the genes that encode ʱ subunits, 
the predominant channel function, the human diseases associated with them and their 
antagonists are summarised in Table 1.1.  53 
 
 
Table 1.1 VGCC subtypes 
(ω-aga; ω-Agatoxin IVA, ω-ctx; ω-Conotoxin GVIA, CNS; Central Nervous System, 
DHP, dihydropyridine; EA2; Episodic Ataxia Type2, FHM; Familial Hemiplegic 
HVA/ 
LVA 
Current 
type  
Alpha 
subunit  
Gene   Localization   Main function  Blocker   Human 
Disease  
 HVA  L  Cav 1.1  CACNA1S  Skeletal 
muscle  
Excitation 
contraction           
coupling 
DHP  HypoPP 
Cav1.2  CACNA1C  Cardiac           
Smooth  
muscle      
Endocrine                    
CNS 
Excitation 
contraction 
coupling  
Hormone secretion   
Plasticity (LTP) 
Timothy 
syndrome 
Cav1.3  CACNA1D  Cochlea         
Striatum          
SNPars 
Compacta        
Kidney                   
Ovary 
Sensory 
transduction        
Pacemaker activity  
Deafness 
and 
arrhythmia
… 
Ca v 1.4   CACNA1F  Retina   Sensory 
Transduction 
Congenital 
Stationary 
Night 
Blindness  
P/Q  Cav 2.1  CACNA1S  Neuronal   
(presynaptic 
terminal at 
CNS and 
NMJ)     
Purkinje cells 
Neurotransmitter 
release  
ω-aga   SCA6                     
FHM                         
EA2                      
LEMS  
N  Cav 2.2  CACNA1B  Neuronal  
(presynaptic 
terminal at 
CNS) 
Nociceptive 
sensory 
neurons  
Neurotransmitter 
release 
ω-ctx 
 
 
R  Cav2.3  CACNA1E  CNS                           
Cochlea                         
Cardiac                          
Pituitary 
Neurotransmitter 
release  
SNX-
482 
 
LVA  T  Cav 3.1  CACNA1G  Neuronal             
Cardiac 
Pacemaker activity     
Repetitive firing  
TTAP2   
Cav 3.2  CACNA1H  Neuronal           
Cardiac                      
Kidney                      
Liver  
Pacemaker            
Repetitive firing  
TTAP2   
Cav 3.3  CACNA1I  Neuronal   Pacemaker              
Repetitive firing  
TTAP2   54 
 
Migraine; HypoPP; Hypokalemic Periodic Paralysis, LTP; Long term potentiation, PC; 
Pars Compacta; SN; Substantia Nigra, SCA-6; Spinocerebellar Ataxia Type 6, SNX; 
TTA P2;  3,5-dichloro-N-[1-(2,2-dimethyl-tetrahydro-pyran-4-ylmethyl)-4-fluoro-
piperidin-4-ylmethyl]-benzamide). 
 
Different types of Ca2+ channels support neurotransmitter release at different synapses 
(Nudler et al., 2003; Catterall et al., 1998).  At mature rat, mouse and human NMJ, 
neurotransmitter release is almost completely blocked by -aga IVA indicating that P/Q 
type Ca2+ channels are the main VGCC subtype that support synaptic transmission 
(Protti and Uchitel, 1993; Uchitel et al., 1992; Katz et al., 1997).  However at the 
neonatal rat NMJ, neurotransmitter release is dependent on both P/Q- and N-type 
channels with L type VGCCs also playing a role (Rosato-Siri and Uchitel, 1999; Katz et 
al., 1996).  P/Q and N-type channels both play a role in synaptic vesicle release at the 
hippocampus (Cao and Tsien, 2010; Luebke et al., 1993; Takahashi and Momiyama 
1993; Wheeler et al., 1994) with the former playing the dominant role.   
 
1.2.4 VGCC accessory subunits  
As well as the pore forming ʱ1 subunit, there are a number of accessory subunits 
associated with VGCCs including ʱ2δ, β and γ.  These subunits have various roles in the 
trafficking of the channel to the cell membrane as well as channel kinetics.   
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1.2.4 ʱ2ʴ subunit 
Four genetically distinct ʱ2δ subunits have been described (Arikkath and Campbell, 
2003).  The subunits are the product of a single gene that is post-translationally cleaved 
into two peptides which are then linked by disulphide bridges (Arikkath and Campbell, 
2003).  The δ portion is anchored in the membrane whilst the ʱ2 portion interacts with 
the ʱ1 subunit (Gurnett et al., 1997) and is entirely extracellular (Dolphin, 2009).  The 
ʱ2δ subunit has a role in the membrane trafficking of ʱ1 and also has an effect on 
channel kinetics (Felix et al., 1997; Arrikath and Campbell, 2003).  The ducky (du/du) 
mouse has a mutation in the ʱ2δ2 gene resulting in a protein that is not anchored in the 
plasma membrane – this mutation causes a severe reduction in P-type VGCC current 
density (Brodbeck et al., 2002; Barclay et al., 2001) with a phenotype of epilepsy and 
ataxia (Barclay et al., 2001).   
 
1.2.4.2 β subunit 
Four different genes code for the β subunit and various splice forms exist (Helton and 
Horne, 2002).  It is entirely cytosolic (Arrikath and Campbell, 2003) and is composed of 
four ʱ helices.  The β subunit aids in the trafficking of the ʱ1 subunit to the plasma 
membrane (Gregg et al., 1996) and also can modulate the biophysical properties of the 
channel (Dolphin, 2003; Arrikath and Campbell, 2003).   
 
1.2.4.3 γ subunit  
The γ1 subunit is known to associate with skeletal muscle VGCCs (Arrikath and 
Campbell, 2003) but the evidence for neuronal γ subunits is much less certain (Catterall, 56 
 
2003).  γ subunits do not affect VGCC surface expression but may affect the 
biophysical properties of the channel (Arikkath and Campbell, 2003).   
 
1.2.5 Calcium Channel Toxins  
As alluded to above, a number of different peptide toxins are derived from marine snails 
(conotoxins) and spiders (such as agatoxins) are known to potently inhibit the activity of 
specific VGCCs (Adams et al., 1993).  The high selectivity of these toxins has made 
them very useful  physiological tools in studying VGCC function.  I made use of some 
of these toxins in the electrophysiology experiments in this thesis and will describe 
them briefly.   
 
1.2.5.1 P/Q-type VGCC antagonists 
1.2.5.1.1 Agatoxins  
Agatoxins are a class of peptide toxins named after the funnel web spider Agelenopsis 
aperta, which produces a venom containing toxins that can target three different types of 
ion channels including VGCCs, voltage gated sodium channels and transmitter activated 
cation channels.  The ω-agatoxins are subdivided into four classes based on their 
structure and calcium channel specificity.  ω-Aga IIIA blocks various different VGCCs 
whereas ω-Aga IVA as a high specificity for P/Q type VGCCs (Mintz et al., 1992; 
Adams, 2004) and does not affect N-, L- or R-type channels (Mintz et al., 1992).   
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1.2.5.1.2 ω-Conotoxins 
The ω-Conotoxins- MVIIC and MVIID from the C.magus snail (Hillyard et al., 1992) 
block P/Q-calcium channels but also N-type VGCCs, indicating that the ω-Conotoxin 
binding macrosites for the N and P/Q VGCCs are most likely related.  Blocking of N-
type channels is rapid and reversible whereas blocking of P-type channels is potent, 
slow and only very slowly reversible (McDonough et al., 1996).   
 
1.2.5.2 N – type VGCCs antagonists  
ω-Conotoxin GVIA from the Conus Geographus (Olivera et al., 1984) potently and 
selectively inhibits N-type VGCCs (McCleseky et al., 1987; Nowycky et al., 1985).   
 
McDonough et al. studied differences in the characteristics of inhibition of various 
toxins including voltage dependence, reversal kinetics and fractional inhibition of 
currents to study how toxins affected VGCCs function (McDonough et al., 2002).  
VGCC characterisation studies demonstrated at least two distinct binding sites on N-
type channels.  ω-CgTx-GVIA, ω-Aga-IIIA and ω-CTx MVIIC were all shown to block 
the channel pore whereas grammotoxin was found to bind to a separate region coupled 
to channel gating.  At P/Q type VGCCs ω-CTx MVIIC and ω-Aga-IIIA both had 
binding sites near the pore but ω-Aga-IVA bound to a different site associated with 
channel gating. 
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1.2.5.3 L type VGCC antagonists 
Toxins from several species of snail and snake block L-type VGCCs but 
dihydropyridines are most commonly used both in the laboratory and in medical 
practice to block L-type VGCC.  This class of drugs includes agents such as 
amlodipine, and nimodipine. 
 
1.2.5.4 R type VGCC antagonists 
SNX-482 is a 41 amino acid peptide isolated from the venom of the African tarantula 
Hystaeraocrates gigas (Newcomb et al., 1998).  It completely and irreversibly inhibits 
R-type VGCCs (Schroeder et al., 2000).   
 
1.2.5.5 T type VGCC antagonists 
TTA-P2, (3,5-dichloro-N-[1-(2,2-dimethyl-tetrahydro-pyran-4-ylmethyl)-4-fluoro-
piperidin-4-ylmethyl]-benzamide)a novel piperidine derivative was initially found to 
inhibit recombinant T-type VGCCs (Shipe et al., 2008).  Subsequently it was found to 
also potently, specifically and reversibly inhibit native T- type Calcium channels (Choe 
et al., 2011; Drefus et al., 2010)  
 
1.2.6 Calcium channel subtypes involved in synaptic transmission  
It is known that neurotransmission at both central and peripheral synapses relies on a 
combination of VGCC subtypes.  At hippocampal synapses, for example, L type 
VGCCs are not involved under normal conditions but both P/Q- and N-type and to a 
lesser extent, R-type channels are all involved in synaptic transmission (Wheeler et al., 59 
 
1994, Cao and Tsein, 2010; Takahashi and Momiyama, 1993).  Blockage of P/Q- N- 
and R-type VGCCs with specific toxins completely obliterates the EPSC in 
hippocampal neurons (Cao and Tsien, 2010).  Blockage of either P/Q- or N-type 
channels individually reduces the amplitude of the EPSC by 45% each (Cao and Tsein, 
2010).  However, P/Q-channels play the predominant role as is evidenced by the more 
rapid onset of a reduction in block after application of ω-Aga IVa and the relative 
difficulty of overcoming inhibition of P/Q-type channels through increased stimulus 
strength (Luebke et al., 1993).  P/Q-type channels are also the predominant VGCC 
involved in synaptic transmission at other central synapses including cortical and striatal 
synaptosomes (Turner et al., 1992; 1993) and at the nucleus accumbens (Horne and 
Kemp, 1991).   
 
P/Q-type VGCCs are also the predominant mediator of neurotransmitter release at the 
neuromuscular junction in both humans (Protti et al., 1996) and in rodents (Uchitel et 
al., 1992).  Mammalian neuromuscular transmission is relatively insensitive to blockage 
of N-type channels but blockage of P/Q-type channels causes an 80-90% reduction in 
neurotransmitter release (Katz et al., 1997).    
 
1.3 CACNA1A subunit  
 
The ʱ1A subunit is the pore forming subunit in P/Q-type VGCCs and is the most 
abundant ʱ1 subunit in the vertebrate brain (Ludwig et al., 1997).  It was the first 60 
 
representative of its class to be isolated by cDNA cloning (Mori et al., 1991; Starr et al., 
1991) and is encoded by the CACNA1A gene.   
 
The ʱ1A subunit is expressed densely in the cerebellum, particularly in Purkinje and 
granule cells (Kulik et al 2004; Westenbroek et al., 1995) but transcripts of ʱ1A
 are 
found throughout the human and rodent brain with immunoreactivity seen in cell 
bodies, dendrites and presynaptic terminals (Dolphin, 2009; Westenbroek et al., 1995).   
Such is the importance of the P/Q-type channel for neurotransmission, it is not 
surprising that mutation or knockout of the Cacna1a gene of this channel causes a 
severe phenotype.  Several mouse models of spontaneously occurring Cacna1a 
mutations exist including the rolling Nagoya, tottering and leaner mice (Rhyu et al., 
1999; Tstuji and Meier 1971; Plomp et al., 2009).  These mutations are recessively 
inherited and mice all display a severe ataxic phenotype.  In addition motor and absence 
seizures with spike and wave discharges on EEG and paroxysmal dyskinesias can be 
observed in the leaner and tottering strains (Nobels and Sidman, 1979; Plomp et al., 
2009, Noebels, 1984). 
 
1.3.1 Cacna1a knockout mice 
Studies of mice completely lacking the ʱ1A subunit, Canca1a-/- mice, have contributed 
greatly to our knowledge of P/Q- type VGCC function.  Embryonic development is 
initially normal in Canca1a-/- mice (Jun et al., 1999).  However, by postnatal day 10, 
they develop a severe neurological phenotype with ataxia, dystonia and weakness (Jun 
et al., 1999; Fletcher et al., 2001).  In addition as KO mice get older they develop 
prolonged episodes of sustained twisting movements of the trunk and limbs with 61 
 
extensor spasms of the hind limbs (Fletcher et al., 2001) which are thought to represent 
seizures.  Canca1a-/- mice die three to four weeks after birth despite removing 
littermates and hand-feeding (Jun et al., 1999; Fletcher et al., 2001).  Young mutant 
mice have normal brain architecture but aged mice have progressive cerebellar 
degeneration (Fletcher et al., 2001).  The NMJs of Cacna1a knockout mice are 
morphologically similar to WT animals although they are smaller in size under light 
microscopy (Urbano et al., 2003).   
 
Electrophysiological studies have shown that P/Q-type currents at central synapses are 
completely absent in Cacna1a knockout mice, thus indicating that a single gene encodes 
P/Q- channel activity (Fletcher et al., 2001).  However synaptic transmission persists 
indicating that vesicle recycling remains functional despite loss of the ʱ1 subunit (Jun et 
al., 1999).  With elimination of P/Q type currents, there is a greater reliance on Ca2+ 
entry through N- and R-type channels (Jun et al., 1999).  The frequency of spontaneous 
excitatory postsynaptic currents and inhibitory postsynaptic currenst (sEPSC and 
sIPSCs) is reduced in the soma of Purkinje cells from Cacna1a KO mice (Lonchamp et 
al., 2009).  Analysis of IPSCs in KO mice has suggested that as well as contributing to 
triggering of glutamate release in the cerebellum, P/Q-type VGCCs play a role in 
GABAergic release also (Lonchamp et al., 2009) 
 
Similar findings are seen at the neuromuscular junction of Cacna1a knockout mice 
where Ca2+ entry through both N- and R- type channels is crucial for synaptic 
transmission (Urbano et al., 2003).  MEPP amplitudes are normal but EPP amplitude is 
reduced and there is a reduction in postsynaptic AChR clusters at neuromuscular end 62 
 
plates. (Urbano et al., 2003).  Analysis of short-term plasticity has shown that there is 
little or no paired pulse facilitation (PPF) at the NMJ of KO mice (Urbano et al., 2003) 
and the synchrony of neurotransmission is altered, with increased jitter (Depetris et al., 
2008).   
 
At the KO synapse both N- and R-type channels become involved in neurotransmission.  
N-type channels are more abundant but R type channels are located closer to the release 
machinery (Urbano et al., 2003).  It is possible that a smaller number of R-type channels 
which have closer but less optimal interaction with the presynaptic release machinery 
mediate a more asynchronous form of synaptic transmission than would be seen with 
the more distant but more abundant N-type channels (Depretris et al., 2008).   
 
Mutations in CACNA1A in humans are associated with three different dominantly 
inherited disease; Episodic Ataxia Type 2, Familial Hemiplegic Migraine and 
Spinocerebellar Ataxia Type 6. 
 
1.3.2 Human diseases associated with CACNA1A mutations 
1.3.2.1 Episodic Ataxia Type 2 
Episodic Ataxia Type 2 (EA2) typically presents in the second decade with episodes of 
ataxia that last hours to days.  These symptoms may be accompanied by vertigo, 
vomiting and oscillopsia (Gancher and Nutt, 1986).  Episodes may be triggered by 
stress, alcohol, infection and exertion (Jen et al., 2007).  Patients are typically 
asymptomatic in between episodes but approximately 30-50% of patients develop a 63 
 
mild progressive cerebellar ataxia and more than half report migrainous symptoms (Jen 
et al., 2007; Spacey et al., 2005).  EA2 is caused by mutations in the CACNA1A gene 
(Ophoff et al., 1996) - over 80 different mutations including nonsense, frame shift, 
splice site and missense mutations have been described (Denier et al., 2001; Denier et 
al., 1999).  Functional analysis has revealed that mutations causing EA2 can have 
different effects; including altered channel function with reduced calcium current, as 
well as effects on protein folding and trafficking which can reduce channel expression 
and alter channel function (Guida et al., 2001; Spacey et al., 2004; Wan et al., 2005).  It 
remains unclear why P/Q- channel dysfunction causes paroxysmal cerebellar 
dysfunction.  It has been proposed that mutations causing EA2 exert their effect through 
the interaction of P/Q-type channels with inositol 1,4,5-triphosphate receptor type 1 
(ITRP1) (Schorge et al., 2010).  It is likely that there is complete loss of P/Q channel 
function in EA2 (Guida et al., 2001).  Given that an autosomal dominant mutation in 
CACNA1A leading to haploinsufficiency of one allele causes disease in humans, it 
would be expected that heterozygous Cacna1a knockout mice (Cacna1a +/-) would 
provide a mouse model of EA2.  However, these mice are not overtly ataxic although 
they do have impairment of motor learning (Katoh et al., 2007).   
 
The ataxia in EA2 is treated with acetazolamide- a carbonic anhydrase inhibitor (Baloh, 
2012).  Patients display variable responses to treatment, likely due to the characteristics 
of the individual mutation (Jen et al., 2007; Strupp et al., 2007).  Magnetic resonance 
spectroscopy in patients with EA2 has revealed some evidence for cerebellar alkalosis, 
which may be reversed by acetazolamide (Bain et al., 1992; Sappey-Marinier et al., 
1999).  The drug 4-aminopyridine has also been reported to have a prophylactic effect 
on ataxia in EA2 (Strupp et al., 2011).   64 
 
 
A higher proportion of patients with EA2 have epilepsy than expected in the general 
public (Rajkulendran et al., 2010; Tomlinson et al., 2009).  This has led to speculation 
that P/Q-type channel mutations may be linked to human epilepsy (Jouvenceau et al., 
2001; Imbrici et al., 2005; Jen et al., 2007), which is supported by the observation of 
spike and wave discharges and epilepsy in Cacna1a mutant mice (Noebels and Sidman, 
1979).   
 
1.3.2.2 Spinocerebellar Ataxia Type 6  
Spinocerebellar Ataxia Type 6 (SCA 6) is allelic with EA2 and is caused by expansions 
of the CAG repeat sequence in the 3’ terminus of the CACNA1A gene (Zhuchenko et al., 
1997).  SCA6 presents as a late onset slowly progressive cerebellar syndrome that is 
characterised by dysarthria, limb incoordination, poor balance and cerebellar atrophy.  
Occasionally there can be extra-cerebellar features such as opthalmoplegia, spasticity 
and peripheral neuropathy although these are usually less prominent than in other forms 
of SCA (Schols et al., 1998).  Pathological studies have shown evidence of Purkinje cell 
loss in the cerebellum consistent with a toxic gain of function (Pietrobon, 2010).  Mouse 
models develop progressive motor impairment and aggregation of mutant Cav2.1 
channels.  The disease is thought to be due to dysregulation of the ITPR1 signalling 
caused by a polyglutamine repeat (Durr, 2010).  Alterations in the voltage sensitivity of 
activation/inactivation and differences in surface expression of the channel have also 
been suggested as mechanisms (Matsuyama et al., 1997; Restituito et al., 2000; 
Kullmann et al., 2010; Piedras-Renteria et al., 2001).  Some patients with EA2 have also 65 
 
been found to have small CAG expansions in CACNA1A thus leading to suggestions 
that SCA6 and EA2 are a clinical continuum (Jodice et al., 1997).   
 
1.3.2.3 Familial Hemiplegic Migraine  
Migraine is an episodic disorder that affects approximately 10% of the general 
population (Pietrobon, 2005; Goadsby, 2009).  Familial Hemiplegic Migraine (FHM) is 
a subtype of severe migraine that is inherited in an autosomal dominant fashion.  
Patients have severe auras that include unilateral weakness, as well as visual, 
somatosensory or dysphasic symptoms, typically followed or accompanied by 
migrainous headache.  Most patients do not have additional neurological findings but a 
progressive cerebellar ataxia can occur in up to 20% of patients (Terwindt et al., 1996; 
Ducros, 2002).  FHM is genetically heterogeneous and is classified into three types that 
are genetically distinct but cannot be distinguished clinically (Pelzer et al., 2013).  
FHM1 accounts for 75% of cases and is caused by missense mutations in CACNA1A 
(Ophoff et al., 1996).  Eighteen different missense mutations have been described, most 
of which substitute conserved amino acids in the voltage sensor (S4) or pore lining 
(S5and S6 and the S5-6 linker) regions of the channels (Pietrobon, 2007; Barrett et al., 
2005; van den Maagenberg et al., 2004).  Functional expression studies in Xenopus 
oocytes, Human Embryonic Kidney (HEK) 293 cells and transgenic mouse studies 
including two knock-in mouse models have been used to argue that FHM1 mutations 
result in various gain of function effects including increased Cav2.1 current density in 
cerebellar neurons and enhanced neurotransmitter release (van den Maagdenberg et al., 
2004).  Knock-in mice also show a reduced threshold and increased velocity of cortical 66 
 
spreading depression which is thought to underlie the aura of migraine (van den 
Maagdenberg et al., 2004).    
 
LEMS is associated with antibodies against the P/Q-type VGCC. Perhaps surprisingly, 
patients with the inherited mutations described above are not well known to have a 
neuromuscular phenotype although some patients may have occasional episodes of 
weakness (Tomlinson et al., 2009).  However electrophysiological studies have revealed 
subtle abnormalities in single fibre electromyography in patients with EA2 and FHM 
(Ambrosini et al., 2001; Jen et al., 2001; Maselli 2003; Tomlinson et al., 2009 
suggesting that evidence of neuromuscular instability may have a role in supporting the 
clinical diagnosis of these disorders (Tomlinson et al., 2009).   
 
1.4 Structure of the Neuromuscular Junction  
 
The NMJ is a highly specialised synapse that has evolved to ensure efficient 
transmission of the motor nerve action potential into a muscle depolarization (Hoch et 
al., 2001).  It has a complex structural and functional organisation involving many 
structural and signalling proteins, several of which are involved in acquired and 
inherited diseases of neuromuscular transmission.  
 
The presynaptic nerve terminal contains a large number of synaptic vesicles which 
contain ACh.  The vesicles are concentrated in the nerve terminal in an area known as 
the active zone.  Freeze fracture microscopy has shown that the active zones consist of 67 
 
ordered arrays of particles 10-12 nm in diameter arranged in double parallel lines 
known as active zone particles (Fukuoka et al., 1987 Engel et al., 1991).  These particles 
are thought to correspond to VGCCs (Fukuoka et al., 1987).  As discussed above, the 
VGCCs are closely involved with proteins such as the SNARE proteins that are 
essential for the Ca2+ induced exocytosis of synaptic vesicles.   
 
The basal lamina between the nerve and the post synaptic membrane contains several 
important proteins that are essential for synaptic transmission.  Proteins such as 
collagens, lamins, fibronectin and perlecan anchor some of the proteins involved in 
NMJ development and function.  Acetylcholinesterase (AChE) is tethered to the basal 
lamina via a covalent interaction with ColQ.  Agrin and other nerve secreted proteins 
interact with postsynaptic proteins and help regulate gene expression (Hall and Sanes, 
1993; Hoch. 1999)  
 
The postsynaptic membrane is organised into a series of deep folds, with the AChRs 
found densely clustered at the top of the folds and the voltage gated sodium channels 
concentrated in the troughs and peri-junctional membranes (Flucher and Daniels, 1989; 
Vincent, 2008).  Several neuromuscular junction specific cytoskeletal proteins co-
localise with AChRs- rapsyn in particular is essential for AChR clustering.  Rapsyn is 
immobilised by Muscle Specific Tyrosine Kinase (MuSK) linked proteins and 
contributes to MuSK-induced phosphorylation of AChR subunits (Lee et al., 2009).  
MuSK is expressed by skeletal muscle and is essential for the formation and 
maintenance of neuromuscular synapses (Burden et al., 2013).  It is stimulated by an 
adaptor protein, Dok7 (Downstream of Tyrosine Kinase) from inside the muscle cell 68 
 
(Yamanashi et al., 2012; Hallock et al., 2010) and by lipoprotein receptor related protein 
4 (Lrp4), a receptor for the nerve secreted protein agrin, from outside the cell 
(Weatherbee et al., 2006; Zhang et al., 2008; Kim et al., 2008).  MuSK contributes to 
AChR stabilisation and clustering through various intracellular kinase cascades (Wu et 
al., 2010) and phosphorylation of the AChR β subunit (Finn et al., 2003) 
 
MuSK also has the receptor for Wnts, a family of secretory glycoproteins (Wu et al., 
2010; Koles and Budnik, 2012).  Wnt proteins are best known for roles in cell 
patterning and are essential in embryonic development (Koles and Budnik, 2012) but 
also contribute to AChR clustering.    
 
 
 
 
Figure 1.4 Structure of the neuromuscular junction  69 
 
 
1.5 Disorders of Neuromuscular Transmission  
 
Under normal conditions the end plate potential (EPP) that occurs at the neuromuscular 
junction in response to the binding of ACh and the subsequent opening of voltage gated 
Na+ channels is more than sufficient to trigger an action potential – the extent to which 
the EPP exceeds that necessary to initiate the action potential is called the “safety 
factor” of neuromuscular transmission (Wood and Slater, 2001).  Usually the degree of 
depolarisation exceeds the threshold by a factor of at least three (Finlayson et al., 2013).  
Under conditions of impaired neuromuscular transmission due to insufficient 
presynaptic ACh release or due to a defect of postsynaptic receptors, the EPP can 
become sub-threshold leading to failure of the EPP to generate an action potential and 
muscle weakness.  Both inherited and acquired disorders can affect neuromuscular 
transmission.   
 
1.6 Inherited disorders of Neuromuscular Transmission – the 
congenital myasthenic syndromes 
 
A heterogeneous group of rare genetic disorders can affect neuromuscular transmission 
and these are termed the congenital myasthenic syndromes (CMS).  Mutations have 
been identified in several of the genes encoding key proteins involved in development 
and maintenance of the neuromuscular junction and signal transmission.  These 
disorders are typically inherited in an autosomal recessive fashion and can be classified 70 
 
on the basis of the site of defective neuromuscular transmission – presynaptic, synaptic 
and postsynaptic.  They are rare, with a prevalence of genetically confirmed cases in the 
UK of 3.8 per million (Finlayson et al., 2013).   
 
Most patients with CMS present with symptoms early in life but some subtypes, such as 
DOK7 may present in childhood with walking difficulties (Finlayson et al., 2013).  
Symptoms of CMS include oculofacial weakness, limb weakness and bulbar and 
respiratory muscle weakness.   
 
1.6.1 Presynaptic CMS 
ChAT deficiency  
Choline Acetyltransferase (ChaT) deficiency is due to impaired ACh synthesis at the 
presynaptic nerve terminal.  It is characterised by sudden episodes of respiratory distress 
and apnoea (Ohno et al., 2001) and may also be associated with more generalised 
weakness (Finlayson et al., 2013).   
 
1.6.2 Synaptic CMS  
COLQ 
Mutations in the gene encoding for the acetylcholinesterase (AChE) collagenic tail 
peptide, COLQ result in a loss of AChE- resulting in a prolonged lifetime of ACh in the 
synaptic cleft which in turn leads to prolonged EPPs, AChR desensitisation and an 
excitotoxic end plate myopathy (Ohno et al., 1998; Donger et al., 1998).  Patients 
typically present with severe weakness from early infancy with frequent respiratory 71 
 
involvement but some later onset milder phenotypes have also been described 
(Mihaylova et al., 2008).  Acetylcholiesterases and 3,4 diaminopyridine can worsen 
symptoms and treatment is with salbutamol or ephedrine (Finlayson et al., 2013)  
 
1.6.3 Post-Synaptic CMS 
Postsynaptic mutations can affect the AChR subunits, leading to reduced channel 
expression or abnormal channel gating, or the proteins involved in AChR clustering 
such as rapsyn and DOK7.   
 
1.6.3.1 AChR deficiency   
AChR deficiency syndromes are the most common type of CMS (Finlayson et al., 2013) 
and are most frequently due to mutations in the gene encoding the ε subunit.  The ε 
subunit of the AChR replaces the foetal subunit late in gestation; a continued low level 
of expression of the foetal γ subunit explains why null mutations of the ε subunit are 
compatible with life and often not very severe (Finlayson et al., 2013).  Patients 
invariably have ophthalmoplegia and their neuromuscular weakness can worsen with 
intercurrent infection.  The clinical severity can vary greatly, even within families 
(Barisic et al., 2011).  Treatment is typically with pyridosgimine with 3,4 
Diaminopyridine.  
 
1.6.3.2 Escobar Syndrome 
Escobar syndrome is an antenatal CMS due to a mutation in the CHRNG gene that 
codes for the foetal γ subunit.  As it is a foetal syndrome myasthenic symptoms do not 72 
 
persist after birth but it can cause a variety of developmental effects such as 
arthrogyroposis multiplex congenita with joint contractures (Hoffman et al., 2006; 
Barisic et al., 2011).   
 
1.6.3.3 Slow channel syndrome  
This is the only dominantly inherited CMS and is due to gain of function mutations that 
can involve any of the AChR subunits (Bairisc et al., 2011).  Prolonged AChR opening 
leads to desensitisation block of the receptor and an excitotoxic endplate myopathy 
(Chaouch et al., 2012).  It presents in childhood with evidence of delayed motor 
milestones and ocular muscle weakness (Barisic et al., 2011).  Treatment is based on the 
use of open channel blockers such as fluoxetine or quinine (Harper and Engel 1998; 
Harper et al., 2003) as, similar to AChE deficiency syndromes, pyridostigmine and 3,4 
Diaminipyridine can worsen symptoms.   
 
1.6.3.4 Fast channel syndrome 
Fast channel syndrome is a very severe form of CMS frequently causing acute crises on 
a background of severe weakness (Palace et al., 2012).  There is an abnormally fast 
decay of the synaptic response to nerve impulses (Engel and Sine, 2005).  This can be 
due to an abnormally rapid closing of the ion channel or a reduced probability of the 
channel opening or a combination of the two (Palace et al., 2012; Engel and Sine, 
2005). 
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1.6.3.5 RAPSYN deficiency  
Mutations in the rapsyn gene cause a deficiency of AChRs at the motor end plate. Both 
early and late onset cases have been reported (Burke et al., 2003).  Early onset cases can 
be associated with respiratory and feeding difficulties but symptoms often improve in 
adult life.  The late onset subtype may mimic autoimmune MG (Burke et al., 2003).   
 
1.6.3.6 DOK 7 
As mentioned above, DOK-7 binds to MuSK and amplifies the MuSK signal to 
downstream pathways that are important for AChR clustering and maintenance of the 
NMJ.  DOK 7 associated CMS presents with a limb girdle pattern of weakness- 
typically as a deterioration in a child who has previously achieved normal motor 
milestones (Beeson et al., 2006; Palace et al., 2007).  DOK 7 is a slowly progressive 
syndrome – likely because of a secondary myopathy (Finlayson et al., 2013).  
Ephedrine, given for many months, can have a longstanding beneficial effect in DOK7 
CMS, most likely due to a downsteam effect from the stimulation of β2 adrenergic 
receptors (Lashley et al., 2010).   
 
1.6.3.7 MuSK deficiency  
As discussed above, MuSK lays a key role in the organisation of the postsynaptic 
cytoskeleton and AChR clustering.  MuSK deficiency is a rare form of CMS with three 
different kinships described to date (Chevessier et al 2004; Mihaylova et al., 2009; 
Maselli et al., 2010) 
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1.6.3.8 GFPT1 and DPAGT1 mutations 
Two recently described subtypes of CMS result from mutations in genes that encode 
glycosylation pathway enzymes – GPT1 and DPAGT1 – which encode gluocosamine-
fructose-6-phosphate aminotransferase1 and UDP-N-acetylglucosamine-dolichyl-
phosphate N-acetylglucosaminephosphotransferase respectively (Guergueltcheva et al., 
2012; Belaya et al 2012).  These disorders are associated with limb girdle weakness and 
often have tubular aggregates on muscle biopsy (Guergueltcheva et al., 2012; Belaya et 
al., 2012).   
 
Other rarer CMS syndromes include those caused by mutations in SCN4A, the post 
synaptic sodium channel and other post synaptic proteins such as LAMB2 and PLEC1 
(Maselli et al., 2009; Maselli et al., 2010 Barnwell et al., 1999).  Rarely mutations in the 
gene encoding Agrin have been described in CMS (Maselli et al., 2012).   
The CMS subtypes, the genes involved, their pathology and treatment are summarised 
in Table 1.2.   
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Site  Syndrome   Gene   Main pathology   Treatment  
Presynaptic 
   ChAT 
deficiency  
CHAT  Reduced ACh synthesis   Pyridostigmine,       
3,4 DAP 
Synaptic 
  AChE 
deficiency./ 
COLQ 
COLQ  Paucity of AChE – increased 
lifetime of ACh in the synaptic 
cleft with AChR desensitisation 
and an end plate myopathy  
Salbutamol/  
Ephedrine  
Pyridostigmine can 
worsen symptoms 
Postsynaptic  
Receptor 
deficiencies 
or abnormal 
synapse 
formation 
Receptor 
deficiency  
CHRNE 
CHRNA 
CHRNB 
CHRND  
Reduced AChR expression   Pyridostigmine,        
3,4 DAP 
Rapsyn  RAPSN  Impaired clustering of AChR  Pyridostigmine,        
3,4 DAP 
DOK7  DOK7  Synaptopathy – small and 
simplified pre and post synaptic 
structure  
Ephedrine and 
salbutamol 
GFPT1  GFPT1  Not ascertained, abnormal 
glycosylation of synaptic 
components  
Pyridostigmine  
DPAGT1  DPAGT1 
Escobar 
syndrome 
CHRNG   Loss of foetal AChR  -   
Abnormal 
kinetics 
Slow 
channel  
CHRNE 
CHRNA 
CHRNB 
CHRND 
Prolonged AChR channel 
opening. Excitotoxic end plate 
myopathy 
Fluoxetine,  
Quinidine  
Fast channel   CHRNE, 
CHRNA 
CHRND 
Abnormally brief channel opening   Pyridostigmine        
3,4 DAP 
Rare subtypes  LAMB2  Reduced β2 laminin,- contributes 
to alignment of nerve terminal 
with postsynaptic regions 
Ephedrine 
PLEC1  Reduced plectin, cytoskeletal 
linking protein  
3,4DAP 
MuSK  Impaired MuSK – important for 
synapse formation and AChR 
clustering  
Pyridostigmine       
3,4 DAP 
SCN4A  Altered postsynaptic sodium 
channel function  
Unclear 
AGRN  Agrin deficiency   Ephedrine 
Table 1.2 Congenital myasthenic syndrome subtypes, associated genes, main pathology 
and treatment. Adapted from Finlayson et al., 2013 
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1.7 Acquired Disorders of Neuromuscular Transmission  
 
The study of acquired autoimmune disorders of neuromuscular transmission is the main 
focus of this thesis.  The most common acquired disorder of neuromuscular 
transmission is Myasthenia Gravis (MG).  This is an autoimmune disorder, 
characterised in its most common form by IgG1 and IgG3 antibodies that are directed 
against the postsynaptic AChR receptor.  Antibodies against other postsynaptic proteins 
including MuSK and LRP4 are found in a variable proportion of patients who typically 
do not have AChR antibodies.  LEMS is another acquired disorder of neuromuscular 
transmission.  Unlike MG, it is a presynaptic disorder with antibodies directed against 
VGCCs. Both of these disorders are discussed in detail below.  
 
Botulism is a rare infectious disease that can also impair neuromuscular transmission. It 
is caused by exposure to neurotoxins produced by the anaerobe clostridium botulinum 
that is found in soil and aquatic sediment.  There are three toxin subtypes, A B and E 
and they all act by cleaving SNARE proteins, preventing the close apposition of 
vesicles to the presynaptic membrane leading to a failure of synaptic vesicle release 
(Sobel, 2005; Shapiro et al., 1998).  There are four types of botulism classified 
according to the mode of exposure- foodborne, wound, intestinal and iatrogenic 
(Shapiro et al., 1998, McLauchlin et al., 2006, Crowner et al., 2007, Chertow et al., 
2006).  It typically presents with descending paralysis causing ptosis, opthalmoplegia, 
bulbar weakness and proximal muscle weakness.  Management is based on supportive 
care and the early administration of antitoxin.   
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1.7.1 Synaptic transmission in LEMS and MG 
Synaptic transmission at the neuromuscular junction is abnormal in both MG and 
LEMS but the precise defect is quite different in the two disorders.  In MG, the number 
of ACh quanta released from the presynaptic nerve terminal is unaffected, however each 
package of ACh that is released causes a smaller end plate depolarisation than normal 
(Elmqvist et al., 1964).  There is also a reduction in MEPP amplitude (Elmqvist et al., 
1964) and a loss of AChR binding sites (Fambrough et al., 1973) with reduced 
sensitivity of the end plate to ACh (Cull-Candy et al., 1978; Ito et al., 1978). 
 
In contrast, in LEMs, the sensitivity of the end plate to ACh is preserved and 
cholinergic vesicle size and contents are normal as is evidenced by the normal MEPPs 
recorded in muscle samples from patients with LEMS (Elmqvist et al., 1964; Lang et 
al., 1984; Molenaar et al., 1982).  However, there is a reduction in the number ACh 
quanta released in response to a single nerve impulse (Lambert and Elmqvist, 1971).  In 
turn, the amplitude of the EPP evoked by nerve stimulation is reduced and can be sub-
threshold to elicit a muscle action potential.  Active zone particles, which represent 
VGCCs, are disorganised and fewer in number at LEMS affected NMJs (Fukuoka et al., 
1987; Flink and Atchison. 2003).   
 
1.8 LEMS  
1.8.1 History of LEMS  
The syndrome that subsequently became known as LEMS was first described in London 
in 1953 when a 47 year old man with lung carcinoma was found to have prolonged 78 
 
apnoea after receiving the depolarising paralytic agent succinylcholine during surgery 
(Anderson et al., 1953).  The patient’s weakness improved markedly after removal of 
the lung tumour.  Three years later a case series of six patients was described by 
Lambert and Eaton, after whom the disease was named (Lambert et al., 1956).  These 
patients all had an obvious defect of neuromuscular transmission in the context of a 
malignancy and all had distinctive findings on neurophysiology consistent with reduced 
quantal release of acetylcholine from the presynaptic nerve terminal.  
 
The initial case reports all described in LEMS in the context of a malignancy.  The 
largest case series have revealed that between 50 and 60% of patients with LEMS have 
an underlying malignancy, most often a small cell lung cancer (Titulaer et al., 2008; 
O’Neill et al., 1988; Wirtz et al., 2003).  The remaining patients 40-50% develop LEMS 
as an idiopathic autoimmune disease.   
 
1.8.2 Epidemiology 
LEMS is rare with a prevalence of 2.3 per million and an annual incidence of 0.5 per 
million (Wirtz et al., 2003).  The relatively low prevalence to incidence ratio partially 
reflects the poor survival of patients with the paraneoplastic form of the disease.  
Paraneoplastic LEMS is more common in males and the median age of onset in this 
group is older than in patients with the non-paraneoplastic form of the disease (Titulaer 
et al., 2008).  The age and sex distribution for non-paraneoplastic LEMS is similar to 
that in Myasthenia Gravis and there is also a genetic association with HLA-B8-DR3 in 
the two disorders (Titulaer et al., 2011).   79 
 
1.8.3 Clinical Features  
LEMS usually presents with proximal muscle weakness, affecting the legs initially in 
80% of cases but upper limb weakness usually develops soon after (Titulaer et al., 
2008).  Weakness typically spreads distally and the speed of progression tends to be 
faster in patients with a malignancy (Wirtz et al., 2005).  Although LEMS and MG are 
both autoimmune disorders of the neuromuscular junction, there are important 
distinctions that can be made clinically that help to distinguish the two diseases.  The 
fluctuation of symptoms and fatigability, so typical of MG, is not as prominent in 
patients with LEMS.  Moreover, facial and extraocular muscle weakness are not such a 
prominent feature of the disease in LEMS as they are in MG (Titulaer et al., 2011).   
 
Although ocular symptoms can and do occur in LEMS, in contrast to MG, they are 
rarely seen in isolation (Titulaer et al., 2008).  Respiratory failure in LEMS is 
uncommon but is recognised and can occasionally be the presenting symptom (Smith 
and Wald 1996).  It is more commonly seen in association with a malignancy and 
frequently has been reported to occur after administration of a neuromuscular blocking 
agent (O’Neill et al., 1988; Smith and Wald 1996; Sanders et al., 1980; Gracey and 
Southorn 1987).   
 
Autonomic dysfunction is found in 80-96% of patients with LEMS and can precede the 
onset of neuromuscular weakness (Waterman, 2001).  Dry mouth is the most common 
symptom followed by erectile dysfunction in men and constipation.  Orthostatic 
dysfunction, micturition difficulties and dry eyes are seen less frequently (Titulaer et al., 
2011).  Patients occasionally report a metallic taste (Mareska and Gutmann 2004).   80 
 
 
The clinical examination of a patient with LEMS typically reveals proximal muscle 
weakness and the patient may have depressed or absent deep tendon reflexes – a 
reappearance of previously absent reflexes after exercise can be demonstrated in 
approximately 40% of LEMS patients (Odabasi et al., 2002).   
 
  MG  LEMS 
Presenting 
symptom 
Ocular in 85%  Proximal lower limb in 85% 
Fatigability   Common   Usually not demonstrable, weakness 
may improve after exercise  
Reflexes  Normal   In 40% reflexes are absent but 
reappear after exercise 
Electrophysiology   Normal CMAPS, decremental 
response to low frequency repetitive 
nerve stimulation  
CMAPS have reduced amplitude, 
decremental response to low 
frequency stimulation but there is 
potentiation to high frequency 
stimulation or maximal voluntary 
contraction 
Serology  85% of patients are positive for anti-
acetylcholine receptor antibodies. A 
variable proportion of the remainder 
have anti-Muscle Specific Tyrosine 
Kinase antibodies (MuSK) 
85-90% are positive for antibodies 
against the P/Q-VGCC 
Association with 
malignancy/         
tumour  
15% of patients have an underlying 
thymoma 
50-60% of patients have an 
underlying malignancy, most often 
small cell lung carcinoma 
Symptomatic 
treatment 
Acetylcholinesterase inhibitors 
(pyridostigmine) 
3,4 Diaminopyridine 
Table 1.3 Clinical features of LEMS and MG 
 
1.8.4 Diagnosis of LEMS 
Given its rarity and the often quite subtle physical signs, the diagnosis of LEMs can be 
difficult – the mean delay from first symptoms to correct diagnosis ranges from four 
months for paraneoplastic LEMS to 19 months for non paraneoplastic LEMS (Titulaer 81 
 
et al., 2008).  The delay from symptom onset to diagnosis has been reported to be as 
high as 4.2 years in non-paraneoplastic LEMS in non-specialist centres (Pellkofer et al., 
2008).  The classical triad of proximal muscle weakness, areflexia and autonomic 
dysfunction should prompt a high suspicion of LEMS but not all patients will have all 
three features (O’Neill et al 1988).   
 
1.8.4.1 Neurophysiology  
Clinical neurophysiology is the cornerstone of diagnosis in LEMS with the repetitive 
nerve stimulation test (RNS) being the main test used.   
 
Compound muscle action potential (CMAP) amplitudes are typically low at rest and a 
decremental response to low frequency stimulation (2-5Hz) is observed (AAEM Quality 
Assurance Committee 2001).  A decrement of 10% is considered abnormal and the 
majority of patients with LEMS will show a substantial decrement (Oh et al., 2005; Tim 
et al., 2000).  This is not a specific feature for LEMS as it is also seen in MG.  A more 
specific finding for LEMS is a short-lived incremental response after maximal exercise 
or high frequency stimulation (50Hz) (AAEM Quality Assurance Committee, 2001). 
(Figure 1.5).  An increment of 100% has traditionally been used as the gold standard in 
LEMS and is very specific.  However a lower increment of 60% has been shown to 
have a sensitivity of 97% in diagnosing LEMS and a specificity of 100% in excluding 
disorders such as MG (Oh et al., 2005), although other disorders that affect presynaptic 
neuromuscular transmission such as botulism can cause similar findings.  This 
facilitatory response to high frequency stimulation has been postulated to be due to 
build-up of Ca2+ in the nerve terminal (Flink and Atchison 2003).  Single fibre EMG is 82 
 
usually abnormal in LEMS with increased jitter and block – however, this finding is not 
specific and does not help distinguish LEMS from MG.  In mild cases of LEMS, the 
findings on neurophysiology can resemble those in MG, with normal CMAP amplitude, 
decrement at low frequency stimulation and little facilitation (Sanders, 2003).   
 
 
Figure 1.5 Electrophysiological features of LEMS taken from a patient seen at the 
National Hospital for Neurology and Neurosurgery. Stimulation of nerves supplying 
either the Abductor pollicis brevis (A) or abductor digiti minimi (B) was performed 
before (upper panel) and after 10 s of exercise (lower panel). Note the amplitude 
increased significantly after exercise indicating presynaptic dysfunction.  
 
1.8.4.2 Serological Tests in LEMS 
As was briefly mentioned in the introduction, antibodies to presynaptic voltage gated 
calcium channels are detected in approximately 90% of patients with LEMS and in 
almost 100% of patients with LEMS and SCLC (Lennon et al., 1995; Motomura et al., 
1997).  These antibodies are predominantly of the P/Q- subtype although antibodies to 
N-type VGCCs are also found in up to 33% of patients with LEMS (Motomura et al., 
1997) and are detected by a radioimmunoprecipitation assay (Motomura et al., 1997).  83 
 
Up to 3-5% of patients with SCLC that do not have clinical or electrophysiological 
features of LEMS may also have antibodies to presynaptic VGCCs (Titulaer et al., 
2009).  In particular patients with paraneoplastic cerebellar degeneration in association 
with small cell lung cancer may have positive LEMS serology in the absence of clinical 
evidence of neuromuscular dysfunction and VGCC antibodies have also occasionally 
been described in pure cerebellar ataxia (Gillhus, 2011).   
 
Approximately 10-15% of patients with LEMS have no antibodies detectable against 
presynaptic VGCCs and are thus defined as “seronegative”.  However these patients 
also appear to have an antibody mediated disease as the clinical features of the disease 
and the response to immunomodulation are similar to seropositive patients (Nakao et 
al., 2002).  Furthermore, passive transfer of “seronegative” LEMS IgG can transfer the 
electrophysiological features of the disease to mice (Burges et al., 1994).  Antibodies 
against various other proteins at the neuromuscular junction have been found in a small 
proportion of seronegative LEMS patients (see below).   
 
1.8.5 Screening for malignancy in LEMS 
Given the strong association with malignancy, a diagnosis of LEMS should spark a 
thorough and systematic search for an underlying neoplasm.  LEMS represents the most 
common paraneoplastic manifestation of SCLC and occurs in 1-3% of patients with this 
tumour (Titulaer et al., 2008).  However, other tumours including non-small cell lung 
cancers, as well breast, bladder, renal and lymphoproliferative malignancies, have all 
been reported in association with LEMS.  The neurological disorder typically presents 84 
 
before the underlying malignancy, which may not be detectable initially- meaning that 
repeated screening for malignancy is required once a diagnosis of LEMS is made.   
 
Screening by chest radiograph is insufficient and patients require CT and FDG PET 
scans and often also require bronchoscopy.  If the initial search is negative, 
investigations should be repeated.  Most malignancies are, however detected within 12 
months and discovery of a tumour after 24 months is very unusual (Titulaer et al., 
2008).  Certain clinical clues can make the presence of an underlying tumour more 
likely; these include an associated cerebellar ataxia, a rapid speed of progression of 
neurological symptoms and the presence of other paraneoplastic antibodies (Titulaer et 
al., 2008).  Antibodies against SOX-1 proteins (Sry like high mobility group box 1) 
have been shown to be a serological marker of SCLC in LEMS patients with a 95% 
specificity and 65% sensitivity (Sabater et al., 2008).  Data from two national cohorts of 
LEMS patients was recently used to develop and validate a screening tool for predicting 
the presence of an underlying SCLC in LEMS patients.  The Dutch English LEMS 
Tumour Association Predictor (DELTA-P) score is calculated as a sum score according 
to different categories as listed in Table 1.4, depending on certain clinical features at the 
onset of the disease including the presence of bulbar features, weight loss, erectile 
dysfunction, smoking history at onset and performance score.  The Karnofsky 
performance score is used which calculated the extent to which people need assistance 
with the activities of daily living.  The DELTA-P score is a sum score and ranges from 
0-6.  A score of 0-1 corresponds to a chance of underlying SCLC below 3% whereas a 
score of four or more corresponds to a greater than 90% chance of underlying SCLC 
(Titulaer et al., 2011).  It is recommended that all newly diagnosed patients with LEMS 
undergo a thoracic CT followed by a FDG PET if the CT is normal.  If this is also 85 
 
normal, the DELTA-P score is calculated and the urgency and duration of further 
screening is determined by this (Fig 1.6).  
 
  < 3months since symptom onset  Score 
D  Dysarthria, dysphagia, bulbar and neck weakness  1 
E  Erectile dysfunction  1 
L  Loss of weight > 5%  1 
T  Tobacco use at onset   1 
A  Age of onset > 50 yrs.   
P  Karnofsky performance score < 60 (patients need at least some assistance 
with activities of daily living)  
1 
Table 1.4. DELTA P-score – (from Titulaer et al., 2011) 
 
 
Figure 1.6 Screening for malignancy in LEMS (from Titulaer et al., 2011) 
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1.8.6 Treatment of LEMS  
The treatment of LEMS depends on the presence of an underlying tumour. If a SCLC is 
present, treatment must be directed towards this.  The neurological symptoms typically 
improve if the underlying tumour that is “driving” the immune process is removed 
(Chalk et al., 1990).  SCLC treatment typically involves combination chemotherapy 
such as cisplatin and etoposide rather than surgery.  Anthracycline based regiments with 
cyclophosphamide, doxorubicin and vincristine have also been widely used 
(Verschuuren et al., 2006).  Occasionally, patients are also treated with radiotherapy.   
 
Interestingly there are reports that patients with paraneoplastic LEMS have an improved 
tumour prognosis compared to patients with a malignancy but without the neurological 
deficit.  Preliminary results of an ongoing prospective study showed that antibody 
positive SCLC patients with LEMS have a longer median survival than patients without 
LEMS (Maddison and Lang, 2008).  However, larger numbers of patients are required 
to corroborate this finding. 
 
Symptomatic treatment for LEMS includes drugs that prolong the nerve terminal action 
potential, allowing more acetylcholine to be released at the neuromuscular junction.   
 
1.8.6.1. 3,4 Diaminopyridine  
4-Aminopyridine has been used in LEMs but as it crosses the blood brain barrier, it can 
have unwanted CNS side effects (Keogh et al., 2011).  3,4 Diaminopyridine (3,4-DAP) 
is used more widely and is recommended by the Task Force of the European Federation 87 
 
of Neurological Societies (EFNS) for the symptomatic treatment of both paraneoplastic 
and non-paraneoplastic LEMS (Titulaer et al., 2011).  There have been four double 
blind randomized controlled trials investigating the effectiveness of 3,4 DAP in LEMS 
in 54 patients in total (McEvoy et al., 1989; Sanders et al., 2000; Wirtz et al., 2009; Oh 
et al., 2009) and the evidence was recently reviewed in a Cochrane systematic review 
(Keogh et al 2011).  3,4 Diaminopyridine was shown to result in a significant 
improvement in muscle strength, CMAP amplitude, Quantitative Myasthenia Score 
(QMG), LEMS classification and subjective symptom score in comparison to placebo.  
Perioral paraesthesia is a frequent but often transient side effect.  At higher doses, 3,4-
DAP can cause seizures and it is contraindicated in patients with epilepsy.  Prolongation 
of the QT interval on ECG is also occasionally mentioned as a side effect and clinical 
and ECG monitoring is recommended at initiation of the drug and yearly thereafter 
(Lindquist et al., 2011).   
 
1.8.6.2 Guanidine Hydrochloride  
Guanidine hydrochloride also blocks potassium channels and has  been used for the 
symptomatic treatment of LEMS (Verschuuren et al., 2006).  Severe side effects 
including bone marrow suppression and renal tubular acidosis, chronic interstitial 
nephritis, cardiac arrhythmias and liver toxicity have precluded its widespread use 
(Sanders 2003).  A small open label study outlined the use of low dose guanidine in 
combination with pyridostigmine in nine LEMS patients (Oh et al., 1997).  Although 
guanidine was effective in controlling neurological symptoms, one third of the patients 
discontinued it because of severe gastrointestinal side effects and it is generally not used 
in LEMS unless 3,4-DAP is unavailable or contraindicated.   88 
 
1.8.6.3 Immunomodulatory treatment  
If, 3,4-DAP satisfactorily controls symptoms, no further treatment may be needed.  
However, immunomodulatory therapy may be required if symptoms do not respond to 
symptomatic therapy.  Prednisolone and azathioprine are the most frequently used 
immunomodulatory agents and were prescribed in combination in 70% of patients with 
autoimmune LEMS in one series (Newsom-Davis and Murray 1984).  Although this 
combination was effective in a retrospective study, these agents have not been tested in 
prospective randomised controlled clinical trials (Newsom-Davis and Murray 1984; 
Titulaer et al., 2001).  The rationale for use of azathioprine as a steroid-sparing agent is 
extrapolated from evidence in MG, where it reduces the number of treatment failures 
and allows lower steroid doses to be used than treatment with prednisolone alone 
(Palace et al., 1998).  Successful use of rituximab has also been reported in a small 
number of LEMS patients with severe weakness (Maddison et al., 2011; Pellkofer et al., 
2009).  There is one case report describing the use of cyclosporin A in LEMS that was 
associated in a resolution of symptoms (Yuste et al., 1996).   
 
Plasma exchange and IVIG are reserved for acute treatment of severe weakness in 
LEMS.  Plasma exchange showed a short-term clinical and electromyographic benefit in 
a small group of paraneoplastic and autoimmune LEMS patients (Newsom Davis and 
Murray 1984).  The clinical benefits may not be seen for up to 10 days, longer than is 
typical in MG (Newsom-Davis 1998).  A randomized double-blind placebo-controlled 
crossover trial showed that IVIG resulted in significant improvement in muscle strength 
and a decline in VGCC antibody titres (Bain et al., 1996).  The benefit peaked at 2-4 
weeks and declined by 8 weeks. Other data regarding the benefit of IVIG are scant but 89 
 
case reports have suggested that IVIG may be beneficial (Bird, 1992; Takano et al., 
1994).   
 
1.8.7 Pathomechanisms of LEMS 
Studies of muscle biopsy samples from patients with LEMS provided some of the initial 
insights into the pathomechanisms of the disease.  Electrophysiological studies showed 
findings consistent with those found using EMG; EPP amplitudes are small but increase 
in size following high frequency stimulation (Cull-Candy et al., 1980; Lambert and 
Elmqvist 1971) whereas MEPP amplitudes are not reduced (Elmqvist and Lambert 
1968; Lambert and Elmqvist 1971; Cull-Candy et al., 1980). 
  
Light microscopy analysis of tissue biopsies from LEMS patients does not reveal any 
gross abnormalities of the motor nerve terminal (Engel and Santa, 1971).  There are 
conflicting reports of abnormalities of the postsynaptic membrane on electron 
microscopy in LEMS patients (Flink and Atchison 2003) with some reports suggesting 
hypertrophy of the postsynaptic region (Engel and Santa 1971) and others suggesting 
decreased areas and lengths of postsynaptic membrane folds (Hesselmans et al., 1992; 
Tsujihata et al., 1987).  This discrepancy may reflect differences in the duration of 
LEMS in the patients studied (Flink and Athchison, 2003) – hypertrophy of the 
postsynaptic membrane may reflect a response to chronic impairment of neuromuscular 
transmission.  Freeze-fracture studies show a paucity and disorganisation of presynaptic 
membrane active zones in biopsy samples from LEMS patients (Engel et al., 1991).  As 
active zones are topographically related to the sites of synaptic vesicle exocytosis and 
are thought to represent the VGCCs on the presynaptic membrane (Fukuoka et al., 90 
 
1987; Engel et al., 1991), these findings originally suggested that the pathology in 
LEMS is due to dysfunction of presynaptic VGCCs.  
 
The pathomechanisms of LEMS have been further elucidated by careful clinical 
observation of patients with the disease and by the study of the action of LEMS IgG on 
a variety of model systems in the laboratory.  One of the first indications that LEMS 
was an autoimmune disease came from observations that patients with LEMS also had 
other autoimmune disorders such as pernicious anaemia, coeliac disease and Type I 
Diabetes Mellitus and that up to 45% of patients have other organ specific antibodies 
detectable on serological assay (Gutmann et al., 1972; Takamori et al., 1972; Lennon et 
al., 1982; O Neill et al., 1988).  The favourable response of LEMS patients to 
immunomodulatory therapy also provided evidence regarding the autoimmune nature of 
the disease (Lang et al., 1981; Newsom-Davis et al., 1984).   
 
1.8.7.1 Passive transfer experiments  
It was passive transfer experiments that provided definitive proof that LEMS was 
autoimmune in nature.  The electrophysiological features of LEMS; namely reduced end 
plate potentials and facilitation at high frequency stimulation can be transferred to mice 
in a dose-dependent fashion by injecting them with IgG from LEMS patients (Lang et 
al., 1981; Lang et al., 1983; Kim et al., 1986).  The passive transfer of LEMS IgG is 
equally effective in C5 deficient mice, indicating that late complement components are 
not required for LEMS activity (Prior et al., 1985; Lambert and Lennon 1988).    
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Passive transfer also results in morphological changes to the presynaptic end plate with 
selective depletion of active zones and active zone particles seen on freeze fracture 
microscopy (Fukunaga et al., 1983).  These findings are similar to those seen in biopsies 
from LEMS patients (Engel et al., 1989; Engel et al., 1991).   
 
As mentioned above, autonomic symptoms are a significant feature in LEMS patients.  
Synaptic vesicle release from both parasympathetic and sympathetic neurons is also 
reduced by passive transfer of LEMS IgG to mice (Waterman et al., 1997).  
 
1.8.7.2 Antigenic targets in LEMS – the Voltage Gated Calcium Channel  
Initially the target of autoantibodies in LEMS was unknown.  An effect on presynaptic 
Ca2+ entry or function was first thought to be a feature of LEMS when it was found that 
the amplitude of end plate potentials (EPP) of intercostal muscle preparations from 
LEMS patients increased during repetitive nerve stimulation and with an increase in 
external calcium concentration (Lambert et al., 1971).  The rate of spontaneous release 
from LEMS motor terminals in the setting of reduced Ca2+ concentration is normal 
(Lang et al., 1987), suggesting that intraterminal processes involving Ca2+ are preserved 
and that it is the entry of Ca2+ into the presynaptic VGCCs that is affected by LEMS 
IgG (Flink and Atchison, 2003).  The finding that calcium currents in nerve preparations 
from animals passively treated with LEMS IgG were reduced gave further weight to the 
theory that LEMS antibodies targeted presynaptic VGCCs (Xu et al., 1998; Smith et al., 
1995).   
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A number of studies involving the incubation of LEMS IgG in a variety of cell types 
gave more direct evidence that the current through VGCCs is reduced by LEMS IgG.  
Approximately 50% of LEMS patients have an associated SCLC (O’Neill et al., 1988; 
Titulaer et al., 2011) and SCLC cells contain functional VGCCs (Roberts et al., 1985).  
Incubation with LEMS IgG has been shown to inhibit K+ induced 45Ca2+ flux through 
SCLC channels (Roberts et al 1985; de Aizpurura et al., 1988).  Moreover, 
electrophysiological studies of SCLC cell lines have shown that LEMS IgG can reduce 
the amplitude of currents through VGCCs by 58-70 % in a dose dependent manner 
(Meriney et al., 1996; Viglione et al., 1995).   
 
Calcium channel currents in other model systems including anterior pituitary cells, 
adrenal chromaffin cells and neuroblastoma cells have also been shown to be reduced 
after incubation with LEMS IgG (Login et al., 1987; Kim and Neher 1988; Grassi et al., 
1994;) as has VGCC-mediated currents in motor neurones and cerebellar neurones 
(Garcia et al., 1996; Pinto et al., 1998).  Ca2+ currents seem to be preferentially affected 
by LEMS IgG – current through other channels is not reduced (Garcia and Beam, 1996)   
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Figure 1.7 Schematic diagram highlighting antibody binding sites in LEMS  
 
1.8.7.3 VGCC specificity in LEMS 
The specific VGCC antibodies affected by LEMS IgG have been elucidated by 
analysing the effects of different neurotoxins that are specific for individual VGCC in 
cells treated with LEMS IgG.  In general, it is thought that LEMS IgG predominantly 
reduces currents through P/Q- type VGCCs but there have been conflicting results in the 
literature.   
 
In SCLC cells, ω-AgaIVA was much less effective in reducing currents mediated by 
P/Q-type channels after incubation with LEMS IgG, suggesting that current through 
these channels was reduced by LEMS antibodies (Viglione et al., 1995).  Similar 94 
 
findings have been seen in bovine adrenal chromaffin cells (Kim et al., 1998).  Other 
studies have examined the effect of LEMS IgG on Ca2+ currents in cultured motor 
neurones (Garcia et al., 1996).  Currents in motor neurons were reduced to a greater 
extent than those in sensory neurons.  Given that the predominant type of VGCCs in 
sensory neurons is believed to be N-type channels whereas P/Q-type are believed to be 
the predominant type in motor neurones, these data were consistent with a preferential 
effect of LEMS IgG on P/Q-type channels (Garcia et al., 1996).   
 
A study using electric ray organ synaptosomes showed that LEMS IgG inhibits K+ 
evoked release of ACh, and the same IgG samples reduced P/Q- but not N-type currents 
in bovine adrenal chromaffin cells (Satoh et al., 1998).  Furthermore, neurotransmitter 
release from autonomic nerves subserved by P/Q- but not by N-type VGCCs are 
reduced following exposure to LEMS IgG (Houzen et al., 1998).   
 
More compelling evidence that LEMS IgG is directed against P/Q-type VGCCs came 
from the work of Pinto et al.  This group examined the effect of overnight incubation of 
LEMs IgG on cell lines that were stably transfected with cDNAs encoding P/Q-or N-
type channels (Pinto et al., 1998).  Currents mediated by P/Q-type VGCCs (the 10-13 
cell line) were reduced by LEMS IgG but there was no reduction in current through the 
N-type VGCCs (G1A1 cell line) even though some of the patient sera contained 
antibodies that precipitated N-type VGCCs.  The same group examined the effect of 
LEMS IgG on calcium currents in cultured cerebellar neurones.  The magnitude of the 
whole-cell calcium current was not significantly different in neurones incubated with 
LEMS IgG.  However, pharmacological analysis with ω-Aga IVA and conotoxin GVIA, 95 
 
toxins revealed that there was a large reduction in P/Q type current but current through 
N-type channels was unaffected (Pinto et al., 1998).   
 
The effect of LEMS IgG on N-type VGCCs is however, far from certain with 
conflicting data in the literature.  Although the studies described above have shown that 
N type currents are not affected by LEMS IgG other studies have suggested a reduction 
in N-type currents in SCLC and neuroblastoma cell lines after incubation with LEMS 
IgG (Grassi et al., 1994; Meriney et al., 1996).   
 
The reason for these discrepancies is unknown.  It is possible that an effect of LEMS on 
N-type channels was not seen in transfected HEK cells for various reasons including 
splice variations, different subunit combinations or altered density of transfected 
channels (Flink and Atchison 2003).   
 
1.8.7.4 Upregulation of VGCCs not normally involved in neurotransmission in LEMS 
Alterations in the contribution of different VGCCs to Ca2+ in LEMS treated neurons 
have been described in the literature.  With current through P/Q-type channels 
diminished there is an increase in current through channels that are not normally 
involved in synaptic transmission.   
 
An increase in the amplitude of R-type current has been reported by Pinto et al (Pinto et 
al., 1998).  There are also reports that an L-type current is unmasked in LEMS treated 
nerve terminals (Giovannini et al., 2002; Smith et al., 1995; Xu et al., 1998).  L-type 96 
 
currents are not normally involved in neuromuscular transmission (Flink and Atchison 
2002).  Acute exposure of diaphragm phrenic nerve preparations to LEMS IgG does not 
increase the amplitude of L-type current but chronic exposure to LEMS IgG by passive 
transfer results in the emergence of a dihydropyridine sensitive L type current in nerve 
muscle preparations (Flink and Atchison 2002).   
 
The prolonged period of time necessary for L type calcium currents to become involved 
in synaptic transmission suggests that the L-type channel involvement is not merely due 
to unmasking of usually silent channels that are already present on the nerve terminal; it 
is likely that formation, assembly and/or trafficking of new channel are required.   
 
1.8.8 Immunoprecipitation assays in LEMS 
Immunoprecipitation assays have also provided evidence regarding the VGCC 
specificity of LEMS IgG and are used clinically to aid with the diagnosis of LEMS.  
Although various immunoprecipitation assays are used – they all essentially rely on the 
same technique.  Firstly, neuronal cell membranes are solubilised and crude fractions of 
membrane proteins (including VGCCs) are extracted.  Subsequently a radiolabelled 
ligand that binds to specific VGCC is used to label  the VGCC.  The radiolabelled 
VGCCs are then incubated with IgG from LEMS patients or controls and the levels of 
radioactivity are calculated; this correlates with specific antibody binding to VGCC 
(See figure 1.8.).   
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1.8.8.1. Different immunoprecipitation assays used in LEMS  
The first immunoprecipitation assay using LEMS serum described involved the use of 
ω-conotoxin – a 27 amino acid amino acid peptide derived from the marine snail Conus 
geographus that specifically blocks N-type calcium channels.  Calcium channels from 
the IMR-32 neuroblastoma cell line, which expresses N-, L-, and T- type calcium 
channels were labelled with ω-conotoxin and were incubated with LEMS IgG (Sher et 
al., 1989; Grassi et al., 1994).  This initial study showed that over 90% of IgG samples 
from LEMS patients bound to labelled 125 I- ω -Cg Tx-VGCC complexes.  However, 
there was a high false positive rate of 9% (Sher et al., 1989).  A study performed at the 
same time by a different group also used conotoxin but extracted VGCCs from human 
SCLC cells (Lennon and Lambert 1989).  Using this method, antibodies that bound to 
calcium channels were found in 52% of LEMS patients, particularly in those who had 
an associated malignancy.  A control extract of colonic carcinoma showed negative 
results, implying that LEMS antibodies targeted an antigen on SCLC cells (Lennon and 
Lambert 1989).  This method, although less sensitive seemed more specific, as 
antibodies were not detected in healthy control samples or in patients with other 
neurological diseases.  Radioimmunoprecipitation assays using 125 I- ω -Cg labelled 
VGCC from a human neuroblastoma cell lines yielded similar results with 
approximately 44% of LEMS patients, both tumour associated LEMS (T-LEMS) and 
and non tumour associated,  (NT-LEMS) testing positive (Leys et al., 1989; Leys et al., 
1991).  The test was not particularly specific, however, as a relatively high proportion of 
patients with other autoimmune diseases, such as rheumatoid arthritis and systemic 
lupus erythematous also had a positive result on the radioimmunoprecipitation assay.  
 98 
 
Toxins that are specific for P/Q- type calcium channels have been used more recently 
and have been found to have a much greater sensitivity and specificity in detecting 
antibodies in LEMS patients; --conotoxin MVIIC from the Conus magus snail inhibits 
calcium currents through P/Q-type calcium channels at micromolar concentrations 
(Wheeler et al., 1994).  
 
Lennon et al used 125 I--conotoxin MVIIC to label calcium channels extracted from 
SCLC cells and from human cerebellar and cortical tissue.  Over 90% of NT LEMS 
patients and 100% of T-LEMS patients had antibodies detected using this assay 
(Lennon et al., 1995).  In addition, approximately half of the LEMS patients also had 
antibodies that precipitated N-type channels, a finding which may reflect the homology 
that exists between different  subunits.  Patients with associated N-type antibodies 
were more likely to have an underlying malignancy (Lennon et al., 1995).  However a 
small number of patients with amyotrophic lateral sclerosis (ALS) were also found to 
have antibodies against P/Q- and N-type calcium channels.  Suenaga et al found that 
antibodies to P/Q-type channels were present in 74% of all LEMS patients and 
antibodies to N-type channels were detectable in 62% (Suenaga et al., 1996).  
Motomura et al reported the highest specificity assay for detecting antibodies to P/Q-
type channels in LEMs patients (Motomura et al., 1997).  In this study, 92% of LEMS 
patients had antibodies to P/Q – type channels.  Antibodies to N type channels were 
detected in 33% but all of these patients also had P/Q- type antibodies detectable; 
suggesting that N- type antibody positivity reflected a shared epitope binding site.  All 
controls including those with MG, RA and SLE were negative for VGCC antibodies.  99 
 
The concentration of VGCC used in this assay was low (100 pM) and therefore only 
antibodies of high avidity could be measured.   
 
 
Figure 1.8 Radioimmunoprecipitation assay for LEMS (schematic diagram). (1) 
Neuronal cell membranes (such as primate cerebellar cells) are solubilised and crude 
fractions of membrane proteins (including VGCCs) are extracted.  (2) A radiolabelled 
ligand (such as 131I-MVIIC) that binds to specific VGCC is used to purify the VGCC 
form the other membrane proteins.  (3)The radiolabelled VGCCs are then incubated 
with IgG from LEMS patients or controls and the levels of radioactivity are calculated; 
this correlates with specific antibody binding to VGCC 
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1.8.8.2 Synthetic peptides and recombinant proteins  
Synthetic peptides and recombinant proteins have been used to demonstrate that the 
extracellular S5-S6 linker domain III of the P/Q-type VGCC is a major epitope 
recognised by autoantibodies in LEMS patients (Iwasa et al., 2000).  Sera from other 
LEMS patients have shown antibodies positive for domains II and IV of the S5S6 linker 
domain (Takamori et al., 1997)  
 
A polyclonal peptide antibody generated against the S5-S6 loop of Domain III of the 
P/Q- VGCC has been shown to inhibit Ca2+ current through P/Q- and N-type channels 
in cerebellar granular cells and also in HEK 293 cells expressing either P/Q- or N- type 
VGCCs subunits (Liao et al., 2008).   
 
1.8.9 Mechanism of action of LEMS IgG  
It has been proposed that LEMS IgG causes a reduction in VGCCs by antibody 
mediated cross-linking followed by internalization.  As discussed above, LEMS IgG has 
been shown to reduce peak density of currents mediated by P/Q-type VGCCS in HEK 
cells (Pinto et al., 2002).  The maximum current at any given potential is dependent on 
several factors including the single channel conductance, the voltage dependence of 
activation and the voltage dependence of inactivation (Pinto et al., 2002).  LEMS IgG 
does not affect the voltage dependence of activation/inactivation (estimated from the 
current/voltage relationship; Pinto et al., 2002), nor is mean single channel conductance 
altered by LEMS IgG (Magnelli et al., 1996).  These findings suggest that LEMS IgG 
reduces current through VGCCs by reducing the surface expression of VGCCS (Pinto et 
al., 2002). 101 
 
 
Morphological studies of the effect of LEMS at the motor end plate have shown that the 
reduction in the number of active zone particles is preceded by a shortening of the 
distance between adjacent active zone particles as might be expected if cross linking 
occurs (Engel et al., 1989; Fukuoka et al., 1987).  Moreover, monovalent IgG does not 
result in aggregation and depletion of active zone particles- giving further support to the 
theory that antibodies in LEMs cause crosslinking which in turn causes depletion of 
VGCC (Nagel et al., 1988) 
 
1.8.10 Seronegative LEMS –other target antigens  
Approximately 10-15% of patients with LEMS do not precipitate antibodies against 
VGCCs (Nakao et al., 2002; Motomura et al., 1997, Titulaer et al., 2011).  Nevertheless, 
the pathology of “seronegative” LEMS is still thought to be autoimmune and various 
alternative antigenic targets have been suggested.  There have been rare reports of 
antibodies to the  subunit of the VGCC detected in LEMS patients (Rosenfeld et al., 
1993) but the pathogenicity of these antibodies is unknown as the  subunit is mainly 
intracellular.   
 
Antibodies to the N terminus of synaptotagmin 1 have been detected in another group of 
LEMS patients including both VGCC antibody positive and seronegative LEMS 
patients (Takamori et al., 1995).  Immunising animals against the extracellularly 
exposed segment of synaptotagmin can induce an animal model of LEMS (Takamori et 
al., 1994; 2000.  It is therefore thought that synaptotagmin could be a target antigen in a 
small proportion of patients with LEMS (Takamori et al 2008).   102 
 
 
The presynaptic muscarinic acetylcholine receptor (M1 AChR) has also been suggested 
as an alternative antigenic target in LEMS.  This is a G protein coupled receptor that 
modulates ACh release at the adult neuromuscular junction.  Stimulation of the M1 
receptor enhances P/Q-type VGCC mediated ACh release (via a cascade involving 
phospholipase C, protein kinase C and the generation of diacylglycerol from 
phosphatidyl inositol 4,5 bisphosphate) (Santafe et al., 2006).  The M1 mAChR is 
expressed in the nerve terminal and is partially exposed extracellularly (Garcia et al., 
2005).  Fourteen of 20 anti VGCC antibody positive LEMS patients and five 
“seronegative” LEMs patients were found to be positive for antibodies against the M1 
AChR in one study (Takamori et al., 2007).  IgG from patients positive for anti M1 
mAChR antibodies and negative for anti VGCC antibodies was shown to transfer the 
electrophysiological features of LEMS to mice (Nakao et al., 2002; Takamori et al., 
2007).   
 
More recently antibodies against the protein ERC1 were identified by a recombinant 
ELISA assay and a cell based assay in a single patient with non-tumour LEMS 
(Huijbers et al., 2013) who also had antibodies to VGCC.  ERC1 contributes to the 
formation of presynaptic active zones and has a supportive role in promoting ACh 
exocytosis (Hida and Ohtsuka, 2010).  Additional testing of 58 other LEMS patients as 
well as disease and healthy controls revealed no other cases suggesting that ERC1 is a 
rare antigen in LEMS (Huijbers et al., 2013).   
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1.8.11 LEMS – further questions  
Although the pathology of LEMS has been extensively investigated in the past, 
questions still remain and I intend to address a number of these in this thesis. 
Firstly, I wished to visualise the binding of LEMS IgG to neurons in culture.  As 
outlined above, a radioimmunoprecipitation assay is currently used for the detection of 
LEMS antibodies.  Cell-based assays have been increasingly used in recent years to 
specifically detect antigenic targets in a variety of autoimmune diseases including 
limbic encephalitis, NMDA receptor encephalitis and in MG.  I wanted to use 
immunohistochemical techniques to detect cell surface binding of IgG from LEMS 
patients to neurons in culture in an effort to more specifically define the antigenic target 
in LEMS.   
 
I also wanted to clarify the effect of LEMS IgG on the presynaptic nerve terminal.  
Many of the studies examining the pathophysiology of LEMS to date have been 
indirect, using post-synaptic responses as a measure of presynaptic vesicle release.  I 
decided to specifically analyse the effect of LEMS IgG on synaptic vesicle release.  To 
do this I planned to use a technique whereby synaptic vesicles in cultured neurons could 
be fluorescently labelled and the rate of spontaneous and action potential (AP) evoked 
release could be directly assessed after exposure to LEMS IgG   
 
Finally, I wished to define the VGCC specificity of LEMS IgG.  Although the studies 
reviewed above provide strong evidence that LEMS IgG acts on P/Q-type VGCCs, and 
this provides a compelling explanation for a reduction in neurotransmitter release, a 
direct causal link has not been demonstrated. That is, it remains possible that LEMS 104 
 
IgG has two separate actions, one on P/Q-type VGCCs, and another one on 
neurotransmitter release through another mechanism, mediated by another IgG species 
recognising an antigen yet to be identified. Moreover, the role of N-type antibodies in 
LEMS is incompletely understood.  Up to 33% of LEMS patients have antibodies 
against N-type channels but currents through N-type VGCCs expressed in HEK cells 
have not been shown to be affected by LEMS IgG.  There are discrepancies in the 
literature, with some studies showing a reduction in current through N-type VGCCs 
exposed to LEMS IgG.  I therefore decided to probe the effect of LEMS IgG on 
synaptic vesicle release in cultures lacking P/Q type VGCCs from a Cacna1a-/- mouse. 
This experiment had two goals: first, to test directly the requirement for IgG binding to 
P/Q-type VGCCs to decrease neurotransmission; and second, to clarify whether LEMS 
antibodies affect neurotransmitter release via N-type VGCCs.  
 
1.9 Myasthenia Gravis  
 
Myasthenia Gravis is a more common autoimmune disorder of the neuromuscular 
junction, characterised by painless, fatigable muscle weakness.  There is a large cohort 
of MG patients attending the NHNN and I wished to take advantage of this to tackle 
some of the unanswered questions regarding the clinical management of this disorder. 
 
Firstly I will outline the clinical features of Myasthenia Gravis.  
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1.9.1 Epidemiology  
The incidence of MG varies among age, gender and ethnic groups (Alshekhlee et al., 
2009). MG is the commonest disorder of the NMJ with a prevalence estimated at 15 per 
100,000 although it is still under diagnosed in the older population (Vincent et al., 
2003).  The incidence of MG is bimodal with different sex ratios in the two age groups 
in which it presents most commonly: young adults and elderly patients: a female to 
male ratio of approximately 2:1 is seen in young adults, and a reversed sex ratio in the 
older group that accounts for approximately 60% of cases (Roberston et al., 1998; 
Phillips, 2003).  An increasing frequency of MG in the elderly has been noted in the 
past decade (Pakzad et al., 2011; Matsuda et al., 2005) 
 
1.9.2 Classification of MG 
Myasthenia Gravis is classified in a number of different ways: according to antibody 
specificity (AChR antibody MuSK antibody, LRP4 antibody), thymic histology 
(thymoma, non thymomatous – hyperplastic, atrophic or normal), age of onset (< or > 
40 years) distribution of clinical symptoms (ocular or generalised), and severity. The 
Myasthenia Gravis Foundation of America (MGFA) clinical classification system 
(Jaretzki et al., 2000) classifies MG based on severity of symptoms.   
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Class   Description  Subtypes  
I  Ocular Muscle weakness  
II  Mild weakness affecting 
muscles other than ocular 
muscles (but may also have 
ocular muscle weakness of 
any severity) 
IIa 
Predominantly affects limb, 
axial muscles or both*  
IIb  
Predominantly affects 
oropharyngeal or respiratory 
muscles or both** 
III  Moderate weakness 
affecting muscles other than 
ocular muscles (but may 
also have ocular muscle 
weakness of any severity) 
IIIa  
Predominantly affects limb, 
axial muscles or both * 
IIIB 
Predominantly affects 
oropharyngeal or respiratory 
muscles or both ** 
IV  Severe weakness affecting 
muscles other than ocular 
muscles (but may also have 
ocular muscle weakness of 
any severity) 
IVb 
Predominantly affects limb, 
axial muscles or both * 
IVb 
Predominantly affects 
oropharyngeal or respiratory 
muscles or both ** 
Class 
V  
Intubation with or without mechanical ventilation except when for post-operative 
management  
The use of a feeding tube without intubation places the patient in Class IVb 
Table 1.5 MGFA classification of MG severity  
* May also have a lesser involvement of oropharyngeal muscles 
** May also have a lesser or equal involvement of limb or axial muscles 
 
1.9.3 History of MG 
The first reported cases of MG date from the 1600s.  The English physician Willis 
described a patient with “fatigable weakness” involving the ocular and bulbar muscles 
(Jayam-Trouth et al., 2012).  The first paper to deal entirely with MG was published in 
1878 by Wilhelm Erb, a German physician (Jayam-Trouth et al., 2012).   The name 
“myasthenia gravis” dates from the description by Jolly at the Berlin society meeting in 
the 1890s of two cases under the name “myasthenia gravis pseudo paralytica” (Jolly, 
1895).    
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1.9.4 Autoimmune nature of MG 
MG is one of the best characterised autoimmune diseases.  The autoimmune nature of 
the disease was proposed in the late 1950s/early 1960s (Nastuk et al., 1959) and the 
typical features of MG were successfully passively transferred by injection of IgG from 
an MG patient to mice in 1975 (Toyka et al., 1975).   
 
As is the case with LEMS, the association of other autoimmune diseases with MG 
provides further support for its autoimmune nature.  Thyroditis, rheumatoid arthritis and 
SLE are all seen more frequently in MG patients than in the general population (Sieb et 
al., 2013).  More recently neuromyelitis optica spectrum disorder (NMOSD) has been 
described to occur in association with MG at least 70 times more frequently than would 
be expected by chance (Leite et al., 2012).  There are currently four different antigenic 
targets described in MG. 
 
1.9.4.1 AChR Antibodies in MG 
Antibodies that bind to AChRs in the synaptic cleft are present in the serum of 
approximately 85% of patients (Vincent 2002; Fambrough et al., 1973; Toyka et al., 
1977) and are detected by a radioimmunoprecipitation assay using 125I-ʱ- bungarotoxin 
(Lindstrom et al., 1976).  Antibodies against the AChR are of IgG1 or IgG3 subtype and 
can activate complement which results in focal destruction of the post synaptic 
membrane by the membrane attack complex (Meriggioli and Sanders, 2009).  Anti-
AChR antibodies also cross link AChRs leading to an increase in their rate of 
destruction and may also inhibit the function of AChR directly (Vincent, 2002).   108 
 
 
1.9.4.2 MuSK MG 
Antibodies to Muscle Specific Tyrosine Kinase (MuSK) can be detected in 
approximately 15-20% of MG patients that test negative for antibodies to AChR.  
MuSK is a transmembrane postsynaptic protein essential for clustering of AChRs at the 
post synaptic receptor during development (DeChiara et al., 1996) and also for the 
maintenance of the neuromuscular junction (Kong et al., 2004).  The frequency of 
MuSK positive MG varies according to geographic location with the highest prevalence 
about 40° north of the equator (Evoli and Padua, 2013).  It is also more common in 
women than men and it typically presents below the age of 40 (Oh, 2009). 
 
MuSK antibody positive patients are more likely to have early bulbar and respiratory 
symptoms with less severe limb involvement (Evoli and Padua, 2013; Farrugia et al., 
2006).  The disease process can be rapidly progressive leading to myasthenic crisis 
(Guptill et al., 2011; Evoli and Padual, 2013).  Muscle atrophy, particularly of the facial 
and tongue muscles is a well-recognised feature of MuSK MG (Farrugia et al., 2006).   
 
Thymic pathology in MuSK positive patients usually does not show lymphocytic 
infiltrates or complement deposition and thymectomy has not been shown to be helpful 
in the treatment of the disease (Evoli and Padua, 2013).  In contrast to the IgG1 and 
IgG3 subclass antibodies that are seen in AChR positive MG, the antibody subtype in 
MuSK MG is IgG4.  This antibody subclass does not cause complement activation and 
does not crosslink antigens (Gomez et al., 2010).    109 
 
 
The pathogenicity of anti- MuSK antibodies has been confirmed by passive transfer 
experiments but remains incompletely understood.  Passive transfer of MuSK antibodies 
to mice has been shown to cause reductions in post synaptic AChR packing in a dose-
dependent fashion, associated with depletion of MuSK from the post synaptic 
membrane (Cole et al., 2008).  MuSK antibodies have also been shown to block binding 
of collagen Q to MuSK (Kawakami et al., 2011).  It has also been suggested that the 
weakness seen in MuSK MG is not only due to a reduction in post synaptic AChR 
numbers but also because of a lack of presynaptic compensatory increase in quantal 
release of ACh, something that is seen in AChR ab-positive MG (Viegas et al., 2012) 
suggesting that inhibition of retrograde signalling may be an important aspect of the 
disease (Koneczny et al., 2013).   
 
1.9.4.3 LRP 4 antibodies 
Approximately 10% of patients with MG do not have antibodies to AChR or MuSK 
(Zouvelou et al., 2013).  Recently, antibodies against Lipoprotein related protein 4 
(LRP-4) have been detected in the serum of a varying proportion of patients with 
“double-seronegative” MG (Zhang et al., 2012; Higuchi et al., 2011; Pevzner et al., 
2012, Zouvelou et al., 2013).   
 
LRP-4 is a postsynaptic protein that is a receptor for agrin and is essential for 
neuromuscular junction formation (Wu et al., 2012).  Binding of agrin to LRP4 
stimulates myotubes to form clusters of AChRs linked via rapsyn (Kim et al., 2008; 
Weatherbee et al., 2006).  Antibodies against LRP-4 are mainly of the IgG1 subtype and 110 
 
have the potential to inhibit interaction between neural agrin and the extracellular 
portion of LRP-4 (Higuchi et al., 2011).  Mice immunized with the extracellular domain 
of LRP-4 generate anti LRP4 antibodies and exhibit MG type symptoms indicating that 
these antibodies are likely to be pathogenic (Shen et al., 2013) 
 
1.9.4.4 Autoantibodies to agrin  
Very recently autoantibodies to agrin were detected in seven of a cohort of 93 patients 
with MG, including five patients who also had AChR antibodies and two who were 
negative for AChR, MuSK and LRP4 antibodies (Zhang et al., 2014).  Sera from these 
patients was shown in vitro to inhibit agrin induced MuSK phosphorylation and AChR 
clustering (Zhang et al., 2014).  The significance of antibodies to agrin is unknown and 
further, larger studies are required to determine the frequency of these antibodies in MG 
patients.   
 
1.9.5 Seronegative MG 
A small proportion of patients remain persistently negative for both AChR and MuSK 
antibodies.  These “seronegative” patients are similar to patients positive for AChR 
antibodies with regards to clinical features and thymic histology.  Many of these 
patients do in fact have antibodies detectable against AChR receptors that are expressed 
in a cell line with rapsyn which has a role in clustering of AChR (Leite et al., 2008).   
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1.9.6 Clinical presentation of MG 
MG presents with painless fatigable muscle weakness.  The pattern of muscle 
involvement varies but the ocular muscles are involved first in 85% of cases.  Up to 
20% of patients with MG have prominent bulbar symptoms early on in the disease 
(Grob et al., 1987).  Limb weakness in MG can affect any muscle group although 
proximal muscles are most often affected.  Symptoms worsen towards the end of the 
day and with exercise.  Extreme heat, emotion, infection and menstruation can all 
exacerbate myasthenia as can many drugs including aminoglycoside antibiotics and 
penicillamine.   
 
1.9.7 Course and Prognosis  
Prior to the introduction of treatment in the form of acetylcholinesterases in the mid 
1930s 70% of the recognised patients died of respiratory failure or pneumonia (Grob et 
al., 2008).  However, due to improvements in the management of MG, and in particular 
the management of acute respiratory myasthenic crises, the mortality has now fallen to 
less than 5% (Barohn, 2008).  The course of MG can be very variable between patients.  
The natural history of the disease was characterised by a large long-term follow up 
study of 1976 MG patients over 60 years (Grob et al 2008).  Typically the first 
symptoms are ocular in 85% of cases and generally 80% of these patients subsequently 
develop generalised symptoms.  If the symptoms are limited to the eyes for more than 
two years however, there is a 90% probablility that MG will not become generalised 
after this (Grob et al., 2008).  Typically the most severe weakness occurs in the first two 
years after diagnosis and 39% of patients are classified as having severe disease.  There 
is a spontaneous rate of remission of approximately 30% (Grob et al., 2008).   112 
 
 
1.9.8 Diagnosis and diagnostic tests  
1.9.8.1 History and examination  
A history of painless fatigable muscle weakness is critical to the diagnosis of MG.  
Relevant questions for the patient upon review include the pattern of muscle weakness, 
diurnal variation and any exacerbating factors.  Fatigability can be demonstrated in the 
clinic by looking for the development of ptosis during prolonged up gaze or by testing 
shoulder abduction before and after unilateral repetitive movements.   
 
1.9.8.2 Erdrophonium test  
The edrophonium (“Tensilon”) test is uncommonly performed but has a high sensitivity 
for generalised MG (Phillips and Melnick, 1990).  The acetylcholinesterase inhibitor, 
edrophonium, is administered intravenously and the clinician observes for a transient 
improvement in muscle strength (such as the resolution of ptosis).  The edrophonium 
given can cause life threatening bradycardia and atropine and resuscitation facilities 
must be available. 
 
1.9.8.3 Ice test  
A relatively sensitive and specific test for MG is the ice pack test.  It is useful in patients 
who have ptosis and is performed by placing an ice pack over the eye for 2-3 minutes 
and assessing for an improvement in ptosis – it has a sensitivity approaching 90% 
(Reddy and Backhouse, 2007) 
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1.9.8.4 Neurophysiological tests 
Neurophysiological tests are critical to the diagnosis of MG.  Routine nerve conduction 
studies (NCS) and electromyography (EMG) are usually not informative but the 
compound muscle action potential (CMAP) amplitudes can be reduced in severe cases.  
However, repetitive nerve stimulation (RNS) typically elicits a decremental response at 
3-10 Hz, with a decrement of >10% considered abnormal (Oh et al 1992; Sande).  RNS 
is a specific test for MG but is not sensitive, being frequently negative in ocular MG 
(Oh et al., 1992).  Single fibre EMG is more sensitive and is especially useful in ocular 
MG although it is less specific.  Jitter, the trial to trial variation in the latency from 
stimulus to response is increased and there may also be intermittent failure of excitation 
of muscle fibres – “block” (Howard et al., 1994).   
 
1.9.8.5 Serological tests  
Serological tests are very useful in the diagnosis of MG.  Not every patient with MG 
will have demonstrable antibodies but in those that do, these tests are highly specific.  
Approximately 85% of patients with generalised MG and almost all patients with an 
associated thymoma will have detectable circulating antibodies to AChRs and a variable 
proportion of the remainder will have antibodies to MuSK (Hoch et al., 2001).  A small 
proportion of the remainder will have antibodies to LRP-4 (Zhang et al. 2012; Higuchi 
et al 2011; Pevzner et al 2012 Zouvelou et al 2013) or agrin (Zhang et al 2014).   
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1.9.8.6 Diagnosis of MuSK MG 
The diagnosis of MuSK positive MG can be difficult.  The clinical neurophysiology in 
MuSK MG patients usually shows abnormal SFEMG in the facial muscles but can be 
normal in the limb muscles (Farrugia et al., 2006).  Moreover, clinical improvement on 
erdrophonium testing is much less common than in seropositive MG.  Thymic 
pathology in MuSK patients does not show lymphocytic infiltrates or complement 
deposition and muscle biopsy does not show reduced AChR density as it does in AChR 
antibody positive patients (Leite et al., 2005).   
 
1.9.9 Role of the thymus in MG 
The thymus has an important role in the pathogenesis of early onset MG associated with 
anti AChR antibodies.  The thymus is essential for T-cell differentiation and for the 
establishment of tolerance.  Interactions between thymic stromal cells expressing self 
antigens and developing thymocytes lead to the elimination of autoreactive T cells.  
The thymus is abnormal in a large proportion of patients with MG.  Approximately 10% 
of MG patients have a thymic epithelial tumour, a thymoma (see below).  In 65-70% of 
MG patients without a thymoma, the thymus is enlarged (hyperplastic) with 
lymphocytic infiltrates and germinal centres that contain a large amount of B cells and 
myoid cells which express AChRs (Vincent, 2002; Tsinzerling et al., 2007) – follicular 
hyperplasia which is particularly common in early onset MG.  The thymus in patients 
with MG who develop the disease later in life is usually atrophic. The immunogenic 
role here is less clear, although atrophic thymic tissue has been shown to produce AChR 
antibodies in vitro (Katzberg et al., 2001).   
 115 
 
1.9.10 Thymomatous MG  
Approximately 10-15% of MG patients will have an underlying thymoma (Tsinzerling 
et al., 2007).  Thymomas arise from tissue elements of the thymus and develop in the 
anterior mediastinum (Cowen et al., 1995).  Myasthenia gravis is present in 30-40% of 
patients (Wright and Mathisen, 2001) but thymomas can also be associated with a 
variety of other systemic and autoimmune disorders including pure red cell aplasia, 
pancytopenia, hypogammaglobulinemia and collagen vascular disease (Hon et al., 2006; 
Miyakis et al., 2006; Murakawa et al., 2002).  Thymomas are the most frequently 
encountered tumour of the anterior mediastinum but remain rare with an annual 
incidence of 0.15 cases per 100,000 (Engels and Pfeiffer, 2003).   
Thymomatous MG is usually associated with AChR antibodies, and in younger patients, 
with anti titin antibodies (Voltz et al., 1997).  
 
1.9.10.1 Classification system for thymoma  
Several classification systems for thymomas exist.  The WHO classification is one of 
the most frequently used and is based on the traditional descriptive classification and the 
corticomedullary classification.  The Masoka staging system, commonly used in tandem 
with the WHO classification system is based on the presence of invasion and the 
anatomical extent of tissue involvement.   
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WHO classification 
A  Bland spindle /oval epithelial tumour cells with few or no lymphocytes  
AB  Mixture of a lymphocyte poor A type thymoma with a more lymphocytic component  
B1  Histological appearance of normal thymus composed of areas resembling cortex with 
epithelial cells scattered in a predominant population of immature lymphocytes and areas 
of medullary differentiation  
B2  Large polygonal tumour cells arranged in a loose network , large nuclei and prominent 
nucleoli , background population of immature T cells  
B3  Medium round or polygonal cells with slight atypical. Epithelial cells mixed with minor 
component of intraepithelial lymphocytes  
C  Heterogeneous group of thymic carcinomas  
Masoka stage   
I  Macroscopically completely encapsulated and microscopically no capsular invasion  
II  Microscopic invasion into capsule (IIa) or macroscopic into surrounding fatty tissue or 
mediastinal pleura (IIb)  
III  Macroscopic invasion into neighboring organs (i.e. pericardium, great vessels or lung) 
IV  a-Pleural or pericardial dissemination  
b – lymphogenous or haematogenous metastases  
Table 1.6 WHO grading and Masoka staging of thymoma (Tomaszek et al., 2009.) 
 
1.9.10.2 Screening for thymoma  
There is controversy about the best screening method for evaluation of possible 
thymoma in myasthenic patients.  Computed tomography (CT) is often regarded as the 
first choice technique to characterize a mediastinal mass (Tomaszek et al., 2010) and 
can help in distinguishing thymomas from other mediastinal tumours (Maher and 
Shephard, 2009).  However radiological differentiation is not always straightforward 
and histological characterization is necessary for definitive characterisation (Maher and 
Shephard, 2009).  CT and MRI are thought to be equivalent for the evaluation of 
anterior mediastinal tumours with the exception of thymic carcinomas and thymic cysts, 
when CT is more reliable (Tomiyama et al., 2009).   
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1.9.10.3 Treatment of thymoma  
Surgery, as first described by Blalock in 1941 (Blalock et al., 1941) remains the 
treatment of choice for thymoma unless the patient is not fit for surgery (Lanska et al., 
1990).  There is controversy about the surgical approach with increasing reports 
regarding the efficacy of minimally invasive techniques.  However, most surgeons 
continue to opt for a transsternal surgical approach with completeness of resection the 
most important prognostic factor for survival (Kondo and Monden, 2003).  Masaoka 
stage and WHO classification are also important prognostic factors (Tomaszek et al., 
2009).   
 
No additional survival benefit has been demonstrated for post-operative radiotherapy in 
the case of completely resected Masaoka Stage 1 thymomas (Nakagawa et al., 2003).  
However, radiotherapy is frequently used in the setting of an incompletely resected 
thymoma or if the thymoma is invasive (Zhu et al., 2004).  It is controversial whether 
patients with completely resected Masaoka stage II thymomas should undergo 
radiotherapy (Tomaszek et al., 2009).   
 
Chemotherapy is reserved for patients with inoperable disease or patients with gross 
residual disease after surgical treatment (Wright et al., 2005).  No standardised regime 
exists but cisplatin based protocols are frequently used consisting of doxorubicin, 
cyclophosphamide, cisplatin vincristin or cisplatin with etoposide and ifosfamfide (Kim 
et al., 2005).  
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Myasthenic symptoms often remain after removal of a thymoma with over 80% of 
patients requiring continued immunosuppression (Evoli et al., 2002).   
 
1.9.10.4 Thymoma recurrence  
Thymomas are traditionally thought of as slow growing, rather indolent tumours but 
recurrence of a thymoma after surgery is not uncommon and has been reported in up to 
30% of patients.  Even after complete resection recurrence rates between 11% and 19% 
have been reported (Wright et al., 2005; Haniuda et al., 2001).  Prognosis following 
thymoma recurrence is poor and successful treatment is more likely if recurrence is 
detected early.  Currently there are no published guidelines as to the frequency, duration 
or mode of surveillance for thymoma recurrence.   
 
We noted that there is a small cohort of patients that develop recurrence of thymoma 
many years after their initial surgery.  We decided to describe the clinical characteristics 
of patients with late thymoma recurrence.  
 
1.9.11 Medical treatment of MG  
The treatment of MG is both symptomatic and immunomodulatory although there is a 
paucity of controlled randomised trials to provide definitive guidance.  Treatment often 
relies on institutional preferences and the experience of the prescribing clinician.   
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1.9.11.1 Acetylcholinesterase inhibitors 
Acetylcholinesterase inhibitors are usually first line therapy, providing symptomatic 
relief in ocular and generalised myasthenia.  There are no randomised controlled trials 
but clinical experience and case reports support their efficacy. Side effects of 
acetylcholinesterase inhibitors are both muscarinic (abdominal cramps, salivation and 
lacrimation) and nicotinic (muscle cramps and fasciculations).  Cholinergic crisis, 
which can mimic myasthenic crisis, can occur in high doses.  AChE inhibitors have a 
short half-life and so require regular dosing although a controlled release preparation is 
available in some countries.  Most patients will require immunosuppressive treatment as 
well but given the adverse effects associated with these drugs, it may be reasonable to 
treat with an AChE inhibitor alone initially.  Patients with MuSK positive MG tend not 
to respond so well to acetylcholinesterase inhibitors and are more sensitive to their side 
effects (Kawakami et al., 2011).  The basis of this cholinergic hypersensitivity in MuSK 
positive MG is thought to relate to the interference of MuSK binding to Col-Q which 
leads to a reduction of acetylcholinesterase at the neuromuscular junction (Kawakami et 
al., 2011).   
 
1.9.11.2 Immunosuppression  
1.9.11.2.1 Corticosteroids  
The majority of patients with generalised MG will require immunosuppression and 
patients with MuSK positive MG may require early and aggressive immunosuppression 
due to symptom severity.  Corticosteroids are generally the first line 
immunosuppressive treatment.  A Cochrane review found only limited evidence from 
randomised controlled trials, nonetheless several observational trials support their 120 
 
efficacy (Pascuzzi et al., 1984; Mann et al., 1976).  It is thought that early use of 
steroids in ocular MG may prevent generalisation (Monsul et al., 2004).  High initial 
doses of prednisolone can transiently worsen myasthenic weakness and trigger crisis 
and patients may require admission to hospital for escalation of treatment (Miller et al., 
1986).  Bone protection strategies and alternate day dosing are often used to counteract 
side effects.   
 
If longer-term immunosuppression is required, steroid sparing agents are typically used.  
Azathioprine, methotrexate and mycophenolate are among the most frequently used oral 
immunosuppressant agents. 
 
1.9.11.2.2 Azathioprine  
Azathioprine is one of the most widely used second line immunosuppressant agents.  It 
has been shown in two randomised controlled trials to have a steroid sparing effect 
(Myasthenia Gravis Clinical Study Group 1993; Palace et al., 1998).  The maximal 
efficacy of azathioprine treatment may only be achieved after two years of treatment 
(Palace et al., 1998).  Thiopurine methyl transferase levels are routinely measured 
before commencement of treatment as one in 300 people are homozygous for a variant 
of the TPMT gene that puts them at risk of developing azathioprine toxicity and bone 
marrow suppression (Relling et al., 2011). 
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1.9.11.2.3 Mycophenolate Mofetil  
On the basis of small case series and case reports, mycophenolate mofetil has been used 
widely in MG (Hauser et al., 1998; Chaudhry et al., 2001; Meriggioli et al., 2003).  Two 
randomised controlled trials suggested that it was not effective in MG or sparing 
prednisolone dose when used for 90 days or 36 weeks (Muscle Study Group. 2008; 
Sanders et al., 2008).  However, these studies were of short duration and have been 
contradicted by retrospective studies that have shown that mycophenolate use improves 
symptoms and reduces steroid dose in a large proportion of MG patients after six 
months of therapy (Hehir et al., 2010).  
 
1.9.11.2.4 Methotrexate 
Methotrexate has also been recommended in MG by the European Federation of 
Neurological Sciences (EFNS) as a second line agent.  It has been found to have a 
similar steroid sparing effect to azathioprine in a randomised controlled trial (Heckmann 
et al., 2011) and another phase II trial is currently underway (Pasnoor et al., 2012). 
 
1.9.11.2.5 Cyclosporine 
Cyclosporine has been found to be effective as monotherapy in MG in a small 
randomised trial and it has a fast onset of action compared to other steroid sparing 
agents in MG (Tindall et al., 1987).  However, concerns about nephrotoxicity have 
limited widespread use.   
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1.9.11.2.6 Tacrolimus  
Tacrolimus was shown to be effective in the treatment of MG in a pilot study (Nagane 
et al., 2005).  However, as with mycophenolate, the results of a double blind placebo 
controlled trial were disappointing (Yoshikawa et al., 2011).  The duration of the trial 
was 28 weeks, likely too short to demonstrate a steroid sparing effect, highlighting the 
importance of trial design in MG (Benatar and Sanders, 2011). 
 
1.9.11.2.7 Cyclophosphamide 
Cyclophosphamide is an alkylating agent that is rarely used due to its adverse effect 
profile and is generally reserved for truly refractory cases of MG. It has been shown to 
be of benefit, showing marked improvement in myasthenic weakness in a small group 
of myasthenic patients (Drachman et al., 2003).   
 
1.9.11.2.8 Rituximab  
More recently, the monocloncal antibody to the B cell antigen CD 20, rituximab has 
been used in MG.  A growing number of retrospective studies have demonstrated its 
efficacy in MG (Maddison et al 2011; Collongues et al., 2012) in particular it is 
effective in MuSK MG - causing a sustained reduction in MuSK antibody tires (Diaz –
Manera et al., 2012; Yi et al., 2013). 
 
1.9.11.2.9 Eculizumab  
Interest in other monoclonal antibodies has increased in recent years.  Eculizumab is a 
humanised monoclonal antibody that cleaves the complement component C5 and hence 123 
 
blocks the formation of the terminal complement complex.  A recent small RCT has 
suggested that eculizumab may have a role in treating severe refractory MG (Howard et 
al., 2013).   
 
1.9.11.2.10 Plasma Exchange and IVIG  
Plasma Exchange (PLEX) and Intravenous immunoglobulin (IVIG) are treatments with 
a rapid but transient effect and are used in certain situations such as myasthenic crisis, 
rapidly worsening myasthenia and pre operatively. PLEX directly removes AChR 
antibodies from the circulation – adverse effects include hypotension, infection, 
thrombotic complications due to venous access and coagulopathy due to removal of 
circulating clotting factors.  IVIG has been demonstrated in a placebo controlled 
randomoised controlled trial (RCT) to be effective for the treatment of worsening 
myasthenic weakness (Zinman et al., 2007), its mechanism of action is complex and 
involves inhibition of cytokine competition with autoantibodies, inhibition of 
complement deposition, interference with the binding of Fc receptor and interference 
with antigen recognition by sensitized T cells (Jayam Trouth et al., 2012).  IVIG and 
PLEX have recently been compared in a randomised controlled trial for the treatment of 
moderate to severe MG.  IVIG was found to have comparable efficacy to PLEX with 
the duration of effect of both treatments comparable (Barth et al., 2011). 
 
1.9.12 Thymectomy in the management of MG  
Removal of the thymus gland, thymectomy, is a frequently used treatment for MG.  The 
first use of thymectomy for the treatment of MG was described by Blalock in 1939 for a 
patient with thymoma (Blalock et al., 1939).  As discussed above, approximately 20% 124 
 
of cases of MG are thymomatous and thymectomy is always indicated in these cases 
unless the patient is unfit for surgery.   
 
Subsequently, Blalock performed thymectomy on MG patients without thymoma, found 
hyperplasia in the thymus glands and reported improvement in at least half the patients 
(Blalock et al., 1944).  There is a rationale for the use of thymectomy in non-
thymomatous AChR antibody positive MG as the B cell follicles and the germinal 
centres of the thymic tissue are the likely site of antibody production.  Since these early 
reports, thymectomy has become an accepted treatment for early onset MG.  However, 
there is a lack of evidence surrounding its efficacy.  Non-randomised studies suggest 
that thymectomy is associated with an improvement in myasthenic symptoms and an 
increased likelihood of remission (Gronseth and Barohn, 2002; O’Riordan et al., 1998).   
 
There is currently a randomised trial underway that will seek to answer whether 
thymectomy combined with prednisolone, compared to prednisolone alone will result in 
an improvement of myasthenic weakness, allow a lower dose of prednisolone and 
enhance quality of life by reducing symptoms and adverse events (Newsom-Davis et al., 
2008). The data from this trial will not be available for some years however and so we 
took advantage of the large cohort of myasthenic patients attending our institution to 
examine the long-term outcome of MG after thymectomy.   
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1.9.13 Myasthenic Crisis  
Myasthenic Crisis is the most serious complication of MG and is traditionally defined as 
acute respiratory failure due to worsening MG requiring admission to an intensive care 
unit (ICU) for ventilatory support (Jani-Acsadi and Lisak, 2007).  It is potentially life 
threatening and is said to occur in 15-20% of patients with MG (Ahmed et al., 2005).  
The risk of developing crisis is greater in patients with oropharyngeal weakness, 
patients with a thymoma and patients who have MuSK MG (Oostehuis, 1981, Thomas 
et al., 1997; Vincent and Leite, 2005).  The mortality of myasthenic crisis has declined 
considerably in recent years from between 50-80% in the 1960s (Thomas et al., 1997) to 
less than 5% nowadays (Thomas et al., 1997; Cohen and Younger 1981; Alshekhlee et 
al., 2009), due largely to improvements in the respiratory management of these patients 
in the ICU.  Aside from the respiratory care, the treatment of MC rests on quick acting 
immunomodulation- namely plasma exchange and intravenous immunoglobulin (IVIG) 
(Newsom-Davis et al 1978; Gajdos et al., 2005; Qureshi et al and Suri, 2000; Vedeler et 
al., 2006).  A randomised controlled trial of 84 patients with moderate to severe MG 
recently has shown that IVIG and PLEX have comparable efficacy (Barth et al., 2011).  
As the recognition of MG in the elderly has increased (Vincent and Drachman, 2002) so 
too has the recognition of MC in the older population.  Some studies suggest that MC is 
actually more common in older myasthenics whereas others report it across the whole 
age spectrum of MG (Lacomis, 2005).  There is little evidence regarding the long-term 
prognosis of MC, particularly in the older age group.  We wished to describe the current 
management of patients admitted to a neurological intensive care unit (N-ICU) with 
severe exacerbations of MG and to examine their long-term outcome.  
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1.10 Questions to answer in this thesis  
 
In summary, although there has been extensive research as detailed in both LEMS and 
MG, unanswered questions remain.  I decided to focus on a number of important areas 
in these disorders.   
 
Firstly in relation to LEMS I wished to gain a more in-depth understanding of the 
pathomechanisms of the disesase. In particular, I had the following aims: 
 
1)  To visualise the binding of LEMS IgG to surface antigens in neuronal cultures in 
an attempt to clarify the antigenic target of LEMS antibodies and with a view to 
developing a cell-based assay for LEMS.   
2)  To define the pathomechanism of LEMS IgG by measuring the effect of LEMS 
IgG on synaptic vesicle release  
3)  To test the causal role of antibodies to P/Q-type VGCCs, and ascertain the role 
of antibodies to N-type VGCCs, by probing the effect of LEMS IgG on synaptic 
vesicle release in synapses lacking P/Q-type VGCCs from a Cacna1a-/- knockout 
mouse. 
 
With regard to MG, I decided to take advantage of the large cohort of patients attending 
the NHNN for management of their MG.  I was particularly interested in the long term 
outcomes of MG.  The aims were as follows: 
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1)  To assess the current policy toward thymectomy for MG patients and to examine 
the long term outcome of patients with thymomatous and non thymomatous MG 
after thymectomy 
2)  To describe the clinical characteristics of patients with late recurrent thymoma 
and to discuss post-operative surveillance for detection of recurrence.  
3)  To describe the current management of patients with severe exacerbations of 
MG and myasthenic crisis in the ITU and to assess their long term outcome.   
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2 Methods  
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This chapter describes the methods that were used for the laboratory based experiments 
in this thesis.   It is subdivided into the following sections: 
  Animal husbandry  
  Preparation and maintenance of neuronal cultures 
  Preparation of LEMS IgG 
  Immunohistochemistry 
  Synaptic vesicle imaging with FM dyes 
  Electrophysiological recordings of excitatory post synaptic currents  
 
2.1 Animal husbandry  
 
All animal procedures were carried out in accordance with Home Office regulations 
under the UK Animal (Scientific Procedures) Act 1986.  Animals were housed under 
controlled environmental conditions (24-25°C, 50-60% humidity, 12 h light/dark cycles 
and free access to food and water).  For cortical glial cultures and rat hippocampal 
cultures, new-born (P0) Sprague Dawley rats were obtained from the Central Biological 
Unit, UCL.  Cacna1a knockout mice were a kind gift of Arn van den Maagdenberg 
(Leiden University).  The Cacna1a+/- breeding pairs were housed in the Biological 
Services Unit, Institute of Neurology.  Transgenic mice were bred on a C57BL 
background for at least eight generations before being used in experiments and the 
strain was propagated by breeding heterozygous Cacna1a +/- animals with C57 mice.  
One pair was kept per cage.  Breeding pairs were replaced if a litter was not produced 130 
 
for 3 months.  Litters were weaned at 21 days and were ear-tagged to ascertain 
genotype.  The PCR based genotyping was carried out by Dr Stuart Martin, Huxley 
Building, UCL.   
 
Pairs of heterozygous Cacna1a +/- animals were set up for the experiments where 
homozygous Cacna1a-/- and Cacna1a+/+ pups were required.  New-born pups were used 
for preparation of cultures at P0-P1.  Pups that were not used for culture were culled 
before weaning to ensure that homozygous knockout pups did not reach maturity.  Tail 
clips for PCR based genotyping were taken from pups used for neuronal cultures 
immediately after sacrifice.    
 
2.2 Preparation and maintenance of neuronal cultures  
 
This is the protocol that was used for the preparation of hippocampal neuronal cultures 
from rats and mice used in all our experiments.  The method had been optimised 
previously in our laboratory as described in the thesis of F. Alder (2012) and was 
originally based on a modified version if the protocol described by Kaech and 
Banker,2007).   
 
2.2.1 Materials consumables and timeline for hippocampal cell culture preparation.  
Table 2.1 describes the equipment used for cell culture.  Table 2.2 logs the laboratory 
consumables used.  Table 2.3 describes the cell culture media and reagents. Table 2.4 
describes the timetable for preparation of dissociated hippocampal cultures.   131 
 
 
Cell culture equipment  Type  Source  
Laminar flow hood  Gelaire BSB4  Labcaire 
Tissue culture incubator 37 °C 5% 
CO 2 atmosphere 
Galaxy S, Galaxy S +   Wolf laboratories 
Water bath   JB Series  Grant 
Dissection microscope    Zeiss 
Dissection tools  2 x Dumont #5 
2 x Dumont #55 
Scissors 
WPI  
WPI 
WPI  
Centrifuge  Universal 32R  Hettich 
Haemocytometer  Bright-line  Sigma  
Ceramic coverslip racks    Thomas Scientific  
Pipetters  Powerpette and 
Labmate pipetters 
Jencons Scientific 
Oven  Autoclave oven   Binder  
Table 2.1 Cell culture equipment  
 
Cell culture materials  Type   Source 
Plasticware  Centrifuge tubes (15 ml and 50 ml)  Sigma 
Culture dishes (30, 60, 90 mm)  Sigma 
Pasteurpipettes ( 5, 10 and 25 ml)  Sigma 
Freezing vials  Sigma 
T25 and T75 flasks  Sigma 
12 well culture plates  Sigma 
Sterile eppendorf tubes  Sigma 
Glass pipettes  Pasteur pipettes (plugged and 
unplugged) 
Sigma 
Filters   70 μm , 0,2μM  vWR 
Glass coverslips  18 mm diameter  Fisher Scientific  
Table 2.2 Cell culture materials  
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Media and other 
reagents 
Component   Source   Amount  
Nitric Acid 70%  Nitric Acid  Sigma   
Water   Sigma   
PDL-Laminin   Laminin   Sigma  9 ml  
Poly-D-Lysine  Sigma  1ml  
CMF-HBSS  Tissue culture grade H20  Sigma  900 ml 
10x Hanks BSS  Invitrogen  100 ml 
1M HEPES buffer pH7.3  Invitrogen  10 ml 
Trypsin  Trypsin 2.5%  Sigma    
Glial Medium (GM)  MEM  Sigma   450 ml 
D-Glucose  Sigma 45% solution   6.7 ml 
Penicillin-streptomycin  Invitrogen 100x  5 ml 
Horse Serum  Invitrogen   50 ml  
L-Glutamine 200 mM  Sigma  5 ml  
2 x cell freezing 
medium 
FBS  Invitrogen  40 ml 
DMSO  Sigma  10 ml 
Digestion solution 
(filtered and frozen in 
10 ml aliquots) 
137 mM NaCl (MW 58.44)  Sigma  1.6 g 
5 mM KCL (2M stock)  Sigma  0.5 ml  
10 M NaOH to pH to 7.2  Sigma   
7 mM Na2HPO4 (MW 
141.96) 
Sigma  0.2 g 
25 mM HEPES (MW 238.31)  Sigma  1.19 g 
Wash solution stock 
(store at 4 °C) 
HBSS  Sigma  500 ml  
5 mM HEPES   Invitrogen  2.5 ml 
Dissociation solution 
(filtered and frozen in 
10 ml aliquots)  
Wash solution   Stock (as above)  200 ml 
12 MM Mg S04 (MW 120.37_  Sigma  0.288 g 
Dissection solution   Wash solution   Stock (as above)  40 ml 
FBS 20%  Invitrogen  10 ml 
DNAse stock solution 
(frozen in 25μl 
aliquots)  
DNAse 75u/μl  Sigma  150 KU 
Tissue culture grade H20  Sigma  2ml 
Digestion mix  Trypsin   Sigma  25 mg 
Digestion solution   Stock (as above)  2.5 ml 
DNAse   Stock (as above)  10 μl 
Dissociation mix 
(filter) 
Dissociation solution   Stock (as above)  2.5 ml 
DNse  Stock   12.5 μl 
Complete Neurobasal 
A 
Neurobasal A medium  Invitrogen  500 ml 
B27 serum free supplement  Invitrogen  10 ml 
Glutamax (25 μM glutamine)  Invitrogen  1.25 ml 
AraC    Sigma   1 μM (1 ml 
stock ) 
Trypan Blue (0.4%)    Sigma    
Table 2.3 Cell culture media and reagents  
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Day  Glial Cells  Coverslips  Neurons 
Prior  Prepare and freeze glial cells     
-14   Defrost and plate glial cells into T75 flasks     
-13  Feed with GM     
-10  Feed with GM  Soak coverslips in 70% 
nitric acid 
 
-7  Feed with GM  Rinse and bake 
coverslips  
 
-6    Coat coverslips with 
PLL 
 
-5  Dislodge glial cells and plate on coverslips     
-4  Feed with GM     
0  Feed with Complete Neurobasal A    Prepare and 
plate neurons 
onto glial cells  
1      Add araC 
7      Feed with 
Complete 
Neurobasal A 
14-21      Use neurons for 
experiments  
Table 2.4 Cell culture time -table  
 
2.2.2 Preparation of cortical astroglial cells 
Postnatal (P0) Sprague Dawley rats were sacrificed and decapitated.  The heads were 
rinsed with 70% ethanol and were washed four times in 30 ml of wash solution.  The 
heads were then placed in a 10 cm dissection plate that was filled with wash solution.  
The skin of the head was removed using a Dumont #5 forceps.  The skull was pierced 
with the tip of a scissors and the parietal bones of the skull were peeled back to expose 
the brain.  The brain was scooped out and placed onto a 60 mm dissection dish filled 
with dissection solution, ensuring that the brain remained submerged at all times.  The 
dish was placed under the dissection microscope.  The cerebral hemispheres were 
separated from the brain stem and all the meninges were removed using the fine 
forceps.  Each hemisphere was then finely chopped using a small dissection scissors.  
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All steps up to trypsinisation were performed using ice cold solutions.  The pieces of 
chopped cerebral hemisphere were transferred to a 50 ml tube containing 9.5ml of 
CMFH-HBSS, 1.5 ml of 2.5% trypsin and 1.5 ml of DNAse (10mg/ml).  This was 
incubated for 5 minutes at 37°C in a water bath and swirled occasionally.  The tissue 
was triturated through a 10 ml pipette ten times until large clumps were broken down 
before being returned to the water bath for another 10 minutes.  A 5 ml pipette was then 
used to triturate the tissue again until remaining clumps of tissue were broken down.  
The suspension of cells was passed through a 70 μm cell filter and was collected in a 50 
ml tube containing 15 ml of Glial Medium (GM).  The suspension of cells in GM was 
centrifuged for 10 minutes at 2000 RPM to remove enzymes and lysed cells.  The 
supernatant was discarded and the pellet was broken and re-suspended in 20 ml of GM.  
The cells were counted using the haemocytometer and cell viability was assessed using 
0.4% trypan blue.  A typical yield was around 10 million cells per pup.   
 
The cells were plated at a density of 7-10 x 106 per T75 flask and topped up to a final 
volume of 12 ml with GM.  The flasks were transferred to an incubator at 37°C, 5% 
C02.  The following day, the media was exchanged.  The flask was first tapped to 
remove loosely attached cells, the medium was then aspirated off and was replaced with 
fresh (warmed to 37 °C) medium.  Media were exchanged every 3 days until the cells 
reached 90-95% confluence.   
 
When the glial cells had reached confluence, they were split.  Each T75 flask was 
divided into eight in order to amplify the colony.  The cells were rinsed with 10 ml of 
warm CMF-HBSS and were then treated with 2 ml of trypsin/EDTA until the cells had 135 
 
dislodged.  The side of the flask was gently tapped to aid dislodgment of the cells.  
Once the majority of the cells were seen to dislodge, 8 ml of warmed glial medium was 
added to each flask to inactivate the trypsin/EDTA.  The cells were transferred using a 
10 ml pipette to a 15 ml tube.  The cells were then centrifuged for 10 minutes at 2000 
RPM.  The supernatant was discarded and the pellet was re-suspended in GM and 
divided between eight flasks.  This process was repeated in order to obtain a large batch 
of cells (approximately 150 flasks).   
 
Glial cells were frozen in liquid nitrogen in order to create a stock of cells that could be 
defrosted at weekly intervals for neuronal cell preparation.  The cells were dislodged 
from the T75 flasks with trypsin/EDTA as described above but were re-suspended in 
0.5 ml GM and 0.5 ml 2 x freezing medium.  The cells were then transferred to 
individual 1.8 ml cryotubes with the cells from two T75 flasks being transferred to one 
cryotube.  They were frozen for 2 hours at -20 °C, and at -80°C before being placed in 
liquid nitrogen for long term storage. 
 
The glial cells were defrosted two weeks before planned neuronal culture preparation.  
A cryotube was defrosted and the cells were re-suspended in ice cold GM.  The cells 
were then centrifuged for 10 minutes at 2000 RPM to remove DMSO.  The supernatant 
was discarded and the pellet was re-suspended in warmed GM.  Cells from one cryotube 
were plated into nine T75 flasks.  As described above, the media was changed the 
following day and cells were grown to 90% confluence with the medium changed every 
2-3 days.  
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2.2.3 Preparation of coverslips 
Using  forceps, 19 mm glass coverslips were placed into ceramic racks and submerged 
in 70% nitric acid for 3-4 days.  The coverslips in the racks were then rinsed four times 
for 2 hours each time in ddH20 before being baked overnight at 225°C.  Once cooled, 
the coverslips were placed in 12 well plates (6 coverslips per plate) and were coated 
with 150 μL PLL.  The coverslips were incubated with PLL overnight and were then 
rinsed twice for two hours with 3ml tissue culture grade H20 per well.  Coverslips were 
allowed to dry in the tissue culture hood.   
 
Glial cells in T75 flasks were dislodged with trypsin/EDTA as described above and 
were re-suspended in GM.  The cells were plated onto the treated coverslips at a density 
of 60K per cm2.  The GM was replaced the following day and the cells were left to form 
a monolayer. 
 
2.2.4 Preparation of rat neuronal cultures  
The rats were culled, decapitated and the heads were rinsed in ethanol and washed in 
wash buffer as described above.  The skin and skull bones were removed and the brain 
was scooped out and placed in a 60 mm dish containing ice cold dissection buffer.  The 
hippocampus was dissected out in the following fashion.  First, the brain was divided in 
the midline by gently cutting the midline sagittal section.  The hemispheres were then 
flipped outwards and the meninges were removed.  Care was taken to completely 
remove all the meninges.  The hippocampus  became visible on the inner surface of the 
cerebral hemisphere and was removed carefully using a forceps.  The same was done 137 
 
for the other cerebral hemisphere and the process was repeated for all the brains that 
were to be used. 
 
The dissected hippocampi were  transferred to a new dish with dissection buffer and 
then to a 15 ml tube were washed 5 times in 5 mlof wash buffer.  The pieces of 
hippocampus were  transferred to a tube containing the digestion mix and were 
incubated in the water bath for ten minutes at 37°C.  After ten minutes the trypsin was 
inhibited with 5 ml of dissection buffer.  The cells were rinsed twice with 5 ml of 
dissection buffer and twice with 5 ml of wash buffer.   
 
The tissue was triturated 5 times in 2 ml dissociation mix using a half diameter fire 
polished cotton-plugged Pasteur pipette.  The triturated pieces were allowed to settle 
and the suspended cells were transferred to a new 15 ml tube.  The remainder of the 
cells were triturated with a 1/3 diameter fire polished Pasteur pipette.  Remaining 
clumps were allowed to settle before the solution was transferred to a new 15 ml tube.  
10 ml dissection solution was added and the cells were centrifuged for 5 minutes at 
2000 RPM.   
 
The supernatant was discarded; the pellet was broken and was re-suspended in 
Complete Neurobasal A.  The cells were counted using the haemocytometer and cell 
viability was assessed using trypan blue.  The GM was removed from the glial cell 
coated coverslips and 1 ml warmed complete Neurobasal A was added to each well.  
The cell solution was diluted to a concentration of 30,000 cells per well with complete 
Neurobasal A and 1 ml was added to each well.  The cells were returned to the 138 
 
incubator and the following day were fed with 1ml per well of warmed complete 
Neurobasal A containing 3 μM araC, giving a final concentration of 1 μM.  Seven days 
later, the cells were fed; 1 ml of medium was removed from each well and was replaced 
with 1 ml warmed Neurobasal A. 
 
Cells were used for experiments from day 14 after plating to day 20.   
 
 
Figure 2.1 Neuronal cultures 14 days in vitro (63x)  
 
2.2.5 Modifications for Cacna1a knockout cultures 
A number of modifications were made when culturing cells from mouse pups.  The 
genotype of each pup was determined after the culture preparation by PCR based 
genotyping carried out on tail clippings that were taken immediately after sacrifice.  As 
mouse litters could be large (6-12 pups per litter), typically 3-4 pups would be dissected 
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at a time.  The whole culture process was completed before the next 3-4 pups were 
culled and dissected.  Surgical instruments were cleaned with 70% ethanol between 
each pup.  The volumes of media and reagents were reduced according to the physical 
size of the tissue.  Cells from each mouse were plated onto 3-5 coverslips depending on 
the cell count on the haemocytometer.  Coverslips from heterozygous mice were 
subsequently discarded after genotyping.  All other steps were carried out as for 
hippocampal cultures.   
 
2.3 Preparation of LEMS IgG 
 
IgG samples from patients diagnosed with LEMS were provided by Dr Bethan Lang, 
Weatherall Institute of Molecular Medicine, Oxford.  Samples generally came from 
plasma exchange procedures which form part of the treatment of LEMS (Newsom-
Davis et al 1984).  Control samples were pooled from healthy controls.  Samples from 
patients with clinically and electrophysiologically confirmed LEMS were chosen for the 
functional studies that were carried out.  Samples from four of these patients 
precipitated high levels of anti-voltage gated calcium channel antibodies in the 
diagnostic 125 I MVIIC radioimmunoprecipitation assay.  A fifth patient did not have 
detectable anti VGCCs antibodies and was used as a “seronegative LEMS” sample.  
LEMS sample collection was approved by the Oxfordshire Regional Ethical Committee 
A (07/Q1604/28). Each patient provided written informed consent 
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Sample 
number 
Age at 
disease 
onset 
Gender   Tumor 
status 
Electrophysiology   P/Q ab titer 
(pM) 
N- ab titer 
(pM)  
CMAP 
amplitude 
(mV) 
% Increment   
1  48  M  Nil  6.1 mV 
 
146  261  Neg  
2  68  M  Anaplastic 
large cell 
lung 
carcinoma  
2.2 mV 
 
145  575  60 
3  44  F  SCLC  1.2 mV 
 
1,233  10,755  127 
4  58  M  Nil  4.2 mV  281  362  Neg  
Table 2.5 VGCCs positive LEMS samples used in experiments  
Plasma samples were routinely stored at -20 °C in the host laboratory.   
 
The IgG was extracted from plasma samples using the ethacridine lactate-ammonium 
sulfate method.  This was performed by Dr B. Lang.  Samples were transported from 
Oxford to London on dry ice.  The samples were allowed to defrost and were aliquoted 
into 0.5ml eppendorfs before being refrozen at -20 °C.  The number of freeze-thaw 
cycles was kept to a minimum   
 
Samples to be examined for antibody binding to cells by means of 
immunofluorrescence were not dialysed before use.  Samples to be examined for effects 
on cultures cells were dialysed before use.  Two days before the planned experiment, 
the IgG samples were defrosted.  The samples were diluted with complete Neurobasal A 
to a ratio of 1mg IgG /0.5 ml Neurobasal.  The IgG/NeurobasalA samples were dialysed 
overnight against complete Neurobasal at 4° C using Slide-A-Lyzer dialysis cassettes 
(Fisher).  The diluted IgG sample was added to dialysis cassette that had been 141 
 
prehydrated with Neurobasal A.  The dialysis cassette fixed into a buoy was submerged 
in a 1000ml plastic beaker containing Neurobasal A.  A magnetic stirrer was used to 
continuously agitate the sample which was kept in cold room storage at 4°C overnight.  
The next day, the IgG sample was removed from the dialysis cassette and was warmed 
to 37°C.  The sample was then filtered using a 0.2 μm SFCA (surfactant free cellular 
acetate) filter (Fisher) to ensure low protein binding.  Warm filtered IgG was added to 
each well for a final concentration of 1mg/1ml IgG.  An equivalent amount of 
Neurobasal A was removed from each well before the IgG was added to ensure that the 
volume remained constant.  The cells were returned to the incubator and the samples 
were left overnight.  Control IgG samples were treated in tandem with LEMS IgG 
samples in exactly the same way.   
 
2.4 Immunohistochemistry using LEMS IgG 
 
Immunofluorescence techniques were used to visualise binding of LEMS antibodies to 
hippocampal neuronal cultures.   
Equipment  Source    Usage  
LSM 500 confocal 
microscope 
Zeiss  Used for confocal microscopy imaging including 
various objectives, condenser and photmultiplier tube  
Luckham Rotatest R100 
shaker 
vWR  To agitate coverslip during antibody incubation  
Table 2.6. Equipment used for immunohistochemistry experiments  
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Material   Type   Source  
Corning 6 well culture dish   6 well plate   SigmaAldrich 
Plastic Pasteur pipette (for 
washing cells) 
  vWR 
Bakefoil (to exclude light from 
fluorescent secondary antibodies) 
   
Slides   76 x 26 mm  Thermoscientific  
Coverslips   19 mm glass coverslips  ThermoScientific  
Nailpolish      
Table 2.7 Labware used in immunohistochemistry experiments   
 
Reagent/Antibody  Source  Use 
Phosphate Buffered Saline  Sigma   Wash cells  
4% PFA   Sigma   Fix cells  
BSA (5% BSA in PBS)  Sigma  Block cells (to reduce 
non specific binding)  
Anti Human IgA 594  Invitrogen (A11014)  Secondary antibody – to 
human IgG primary 
Permeabalization solution  5% BSA 
and 1% triton in PBS) 
Sigma    
Anti GFP antibody   Abcam    Antibody to GFP 
(Transfected voltage 
gated calcium channels 
were tagged with GFP) 
Anti Rabbit 488  Invitrogen  Secondary antibody to 
anti GFP primary  
Anti-Synapsin antibody  Invitrogen  Antibody to synapsin 
Zenon antibody detection kit   Invitrogen   Secondary antibody 
detection system for 
human IgG 
Vectashield mounting medium  Vector Labs   Mount cells  
Table 2.8 Antibodies and reagents used in immunohistochemistry experiments  
 
Various methods were used to attempt to visualise the binding of LEMS IgG to 
neuronal cells using immunofluorescence techniques.  The methods will be explained in 
more detail in Chapter 3.  The method is described here in brief; the medium from the 
tissue culture well containing mature hippocampal neurons (14-21 days in vitro) was 143 
 
aspirated.  Cells were washed four times in PBS for five minutes each time.  The cells 
were then fixed in 4% paraformaldehyde (PFA) in PBS for 30 minutes at room 
temperature before being washed in PBS (four times for two minutes each time).  
Coverslips were  incubated in 5% BSA in PBS as a blocking agent for 30 minutes.  
They were washed in PBS (3 times) and incubated with the primary antibody –LEMS 
IgG in 1% BSA (1.500 or 1.1000) in PBS for 2 hours at room temperature or overnight 
at 4°C.  The coverslips were  washed with PBS (five times- 1-2 minutes per wash) and 
were  incubated with the secondary antibody, anti human IgG A594 in PBS (1:1000) for 
one hour at room temperature.  Following incubation with secondary antibodies, the 
coverslips were washed again in PBS (5 times, 2 minutes per wash) and were finally 
washed in water to remove excess salts.  Excess fluid was removed and the coverslips 
were mounted onto slides cell side down using Vectashield Hardset Mounting Media.  
Once the mounting medium had set the coverslips were sealed with nail varnish.  The 
cells were imaged the following day using a confocal fluorescent microscope.  
Alexa594 was excited using the 543 nm line of the He-Ne laser and its emission was 
recorded using a band pass 560-615 nm filter.  Alexa 488 was excited by the 488 nm 
line of an argon laser and its emission was recorded using a band pass 505-530 filter.  
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Figure 2.2 Schematic diagram of immunostaining for LEMS IgG with anti human IgG 
(Alexa 594) and co-staining for synapsin with anti rabbit synapsin and anti rabbit Alexa 
488 as the secondary antibody. 
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2.5 Synaptic vesicle imaging with FM dyes 
2.5.1 Equipment and apparatus used for synaptic vesicle imaging  
Equipment   Source   Usage  
Air Table  TMC  Isolates vibration for steady imaging.  Microscope, recording 
chamber and, for electrophysiology experiments, 
micromanipulators were all placed on the air table 
Faraday Cage  Custom made  Reduces electrical noise.  Microscope and electrophysiology 
equipment within the Faraday cage are electrically grounded 
Perfusion System  Custom Made  Gravity perfusion system. Cells were continually perfused with 
fresh extracellular buffer.   
Perfusion pump  Masterflex: 
Easyload II 
Pump used to drive perfusion  
QuantEM 512 SC   Photmetrics   Live cell fluorescent imaging  
Axiovert 135 
microscope  
Zeiss   
High Power LED 
Driver DC2100 
ThorLabs  Excitation with 488nm LED 
500nm dichoric filter 
Emission fluorescence collected with 510 Long Pass filter 
Master8  A.M.P.I  Programmed to apply difficult electrical stimulation paradigms to 
the recording chamber.  The Master8 was connected to the 
chamber via two constant voltage isolated stimulators 
Constant voltage 
isolated 
simulators 
Digitimer  
DS21-MKII 
Two isolated constant voltage simulators were connected in 
series to apply voltage across the chamber.   
Oscilloscope  Tektromix 
TDS1002 
The oscilloscope was used to visualise the voltage of the 
stimulation applied to the chamber  
Recording 
Chamber 
Custom made  The recording chamber held the coverslip in place during the 
experiments. It had an inflow and outflow for perfusion and 
parallel platinum stimulation wires that were connected to the 
voltage stimulators  
Table 2.9 Lab equipment for synaptic vesicle imaging  146 
 
 
2.5.2. Extracellular solutions used for synaptic vesicle imaging  
The following extracellular solution was used in all experiments 
Extracellular solution    Composition (mM)  Source 
pH 7.4 adjusted with 1M 
NaOH (Sigma) 
 
Osm 305-310 
 
Made on day of 
experiments  
NaCl 125mM  Sigma  
KCl 2.5mM  Sigma 
CaCl2 2 mM  Sigma 
MgCl2 2mM  Sigma 
Glucose 30 mM  Sigma 
HEPES 25 mM  Sigma  
Table 2.10 Composition of experimental extracellular buffer 
 
Several software programmes were used for the acquisition and analysis of data from 
FM experiments  
 
2.5.3 Software used for data acquisition and analysis  
Software  Source  Usage 
Capture Pro     Viewing images  
Image J  Wayne Rasband, National 
Institute of Health USA 
Viewing and analysing images off 
line 
SigmaPlot  Systat Software Inc  Data analysis and manipulation 
Mathcad  PTC  Data fitting and modelling  
SigmaPlot 11.0  Systat software  Data analysis 
Excel 2007  Microsoft Office  Data analysis  
Table 2.11 Software used in acquisition and analysis of data for FM experiments  
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2.5.4 Protocol for imaging of vesicular recycling with FM dyes 
All experiments were performed at room temperature.  For the FM experiments the 
following neurotransmitter antagonists were added to the extracellular solution in order 
to inhibit recurrent activity.  
 
Drug  Target  Stock 
Concentration 
Final 
Concentration 
Source 
NBQX (2,3 
dihydroxy-6-nitro-7-
sulfamoyl-
benxol[f]quiniozaline-
2-3,-dione) 
AMPA receptor 
antagonist 
25mM 
(stored at -20 °C) 
10μM  Ascent 
Scientific  
DL-AP5 (DL-2-
Amino-5-
phosphonopentalnoic 
acid) 
NMDA receptor 
antagonist 
100mM 
(stored at -20 °C) 
50μM  Ascent 
Scientific  
Table 2.12 Neurotransmitter blockers used in FM experiments 
 
The styryl FM dye used to label recycling vesicles was SynpatoRedC1 (SRC1), which 
was obtained from Biotium USA.  The excitation and emission wave lengths for SRC1 
are 558 and 734 nm respectively.  The dye was made up with MilliQ water and stored at 
20 °C at a concentration of 20 mM.  The final concentration used was 200 μM.   
 
All imaging experiments were carried out using a 63X oil immersion microscope.  
Cultures were imaged at a resolution of 512 x 512 pixels, an area which typically 
contained several hundred boutons.  Each pixel was 0.254 μM. 
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The following stimulation protocols were programmed into the Master 8.  The Master 8 
was connected to the stimulators to allow loading of synaptic vesicles, low frequency 
stimulation and complete destaining.   
 
Paradigm  Frequency (Hz)  Number of pulses  Number of 
rounds 
Delay between 
rounds (seconds) 
Loading  30  120  4  20 
Low frequency 
stimulation 
0.5  450  1  - 
Complete 
destaining 
10  300  3  120 
Table 2.13 Master 8 stimulation protocols  
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Figure 2.3 Rig for FM experiments   
 
Before the experiment began, the perfusion system was washed with MilliQ water and 
was then perfused with extracellular buffer at room temperature.  A coverslip was 
placed in the chamber, which was connected to the gravity perfusion system and the 
stimulation electrodes.  The flow rate of the perfusion system was adjusted to 1 
ml/minute.  The perfusion was then stopped and buffer was allowed to drain until 
approximately 400 μl of buffer remained in the chamber.  Action potentials were 150 
 
evoked by field stimulation via platinum electrode separated by 1 cm.   The stimulation 
intensity was adjusted to 15V by adjusting the amplitude on the stimulators.  This 
stimulus intensity was chosen because it was previously shown to trigger all the action 
potentials on an invidual coverslip (Ermolyuk et al., 2012; F Alder PhD thesis 2012).  
The SRC1 dye was added to the extracellular solution and was gently mixed using 
expelled air from a 1ml pipette.  The loading paradigm (see above) was applied.  
Approximately 30 seconds after the last pulse, the dye was removed from the bath with 
fresh extracellular solution (5 x 1 ml washes) and the perfusion system was restarted for 
15 minutes.  During this washing time, the cells were focused on using the transmitted 
light function on the camera.  An appropriate region of interest (ROI) was chosen by 
viewing the area using transmitted light.  The focus was then adjusted using 
epifluorescence imaging and a reference image was taken.  When it was confirmed that 
the ROI was in focus, a corresponding image was taken with transmitted light.  This 
provided the reference image for refocusing of the microscope during the experiment. 
The microscope was focused using transmitted light before a snapshot image with a fast 
exposure time was taken with epifluorescence. 151 
 
 
Figure 2.4 Imaging equipment for FM  152 
 
 
Figure 2.5 The recording chamber for FM experiments.  The cells were plated onto 
glass coverslips and secured in a custom-made recording chamber for the duration of 
the experiment.  A rubber O-ring was used to prevent leakage of the extracellular 
solution.  Two parallel platinum electrodes were used to evoke field stimulation across 
the coverslip.  The coverslip was perfused with fresh extracellular solution during 
experiments via the in- and outflow.  
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Figure 2.6 Custom made chamber for FM destaining experiments in place on rig  
 
Each fluorescent snap shot took a z stack of ten images which were then combined 
using a prewritten macros to give one high quality combined image.  After 15 minutes 
of washing the imaging was started.  Images were first taken in the absence of any 
stimulation to obtain measurements for spontaneous destaining (kSP) for ten minutes.  
The region was imaged every 40 seconds approximately with refocusing using 
transmitted light between each image.  After ten minutes, the low frequency stimulation 
paradigm was applied for 15 minutes while images were taken every 40 s to measure 
evoked synaptic vesicle release (kEV).  The cells were then subjected to the complete 
destaining paradigm after which the region was imaged five times to determine the 
background fluorescence.  The perfusion system was rinsed with Milli-Q water between 
each experiment and 30% ethanol at the end of each day.  
Coverslip 
Platinum   field stimulation  electrodes
(connected to constant voltage isolated
stimulator)   
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2.5.5 Analysis 
The images from these experiments were analysed in the following way.  Time stacks of 
fluorescence images were run through macros in Image J to time sort, z project and x-y 
align the images.  A mask file was created by subtracting the average of the last five 
images (which accounted for background fluorescence) from the average for the first 
five images to allow identification of active boutons.  Boutons were selected using the 
look up tables (LUT) red hot” assay for easy visualisation  This showed dim areas as 
red, brighter areas as yellow and the brightest areas as white in a graded fashion so areas 
of high intensity corresponding to boutons could be readily identified.  The drawing tool 
was used to draw around and so to select areas corresponding to individual boutons.  
Boutons in areas of high background fluorescence, overlapping boutons and boutons 
that were obscured by a large amount of movement artefact were discarded.  Once all 
potential boutons were identified, the selected regions of interest (ROIs) were applied to 
the time stack image.  The area and mean grey value at each time point for each 
individual bouton were extracted to a Sigma plot file.  
 
The data were split into three stages: spontaneous destaining before starting low-
frequency stimulation, during 0.5 Hz stimulation, and after full destaining by 10 Hz 
stimulation.  The start and end times and corresponding frame numbers were specified 
for each stage.  The data were imported to a Mathcad program, and the fluorescence 
intensity profiles for each putative bouton were fitted with mono-exponential fits after 
subtracting the final residual fluorescence.  For the initial stage of the experiment, 
before stimulation, the exponential fit gave an estimate for the rate of spontaneous 
destaining, kSP.  During low frequency stimulation, the monoexponential fit gave an 156 
 
estimate for evoked destaining kEV.  Boutons with high spontaneous destaining rates 
(kSP >0.001 s-1) were discarded, as were boutons with low signal to noise ratios as 
defined by a goodness of fit criterion χ 2 larger than 0.1.  The values for kSP and kEV for 
the remaining boutons were transferred back to SigmaPlot. The specific action-potential 
evoked destaining rate was then calculated by subtracting the spontaneous destaining 
rate from the evoked destaining rate (kAP = kEV –kSP).  All selected boutons from a 
particular set of experiments were combined and were plotted in SigmaPlot.  
 
2.6 Electrophysiological recording of excitatory post synaptic currents  
 
The same extracellular buffer as described for the FM destaining experiments was also 
used for the electrophysiology experiments although without glutamate receptor 
blockers.  A Caesium chloride based intracellular solution was used for whole cell patch 
clamp electrophysiology experiments.   
 
Cesium Chloride intracellular 
solution 
pH was adjusted to 7.4 with 
cesium hydroxide 
Osmolality 290  
Stored at -20 °C 
Compound (concentration)  Sources 
CsCl 120 mM  Sigma  
HEPES 10mM  Sigma 
EGTA 2 mM  Sigma 
NaCl 8 mM  Sigma 
MgCl2 0.2 mM  Sigma 
MgATP 2mM  Sigma 
Na2GTP 0.3 mM  Sigma 
Qx 314 Br 5 mM  Sigma 
Phosphocreatinine 10 mM  Sigma 
Table 2.14 Intracellular recording solution used in electrophysiology experiments 
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Equipment  Source  Usage  
Scientifica Slice-
scope 
Scientifica  Imaging cells 
Air table   TMC  Isolated vibrations for steady recording  
Faraday Cage   Custom Made  Reduced electrical noise.  The Faraday cage confined the 
microscope and electrophysiological recording equipment 
XCite Series 120 
Q 
Olympus   Used to visualise cells in transmitted light.  Image acquired 
was observed using Patch Vision software run on computer 
2.  
Perfusion System   Custom Made  2 way pump perfusion system used to continually perfuse 
cells with fresh extracellular buffer  
Perfusion pump  Masterflex  Used to drive perfusion  
Constant voltage 
isolated stimulator 
Digiterm DS2A- 
MkII 
Connected to the field stimulating electrode to apply voltage 
adjacent to a cell  
Oscilloscope   Tektronix TDS 
1002  
Visualising voltage stimulation applied to the chamber and 
visualising EPSC recorded  
Micro 
manipulators 
Scientifica  Used to direct recording pipettes during electrophysiological 
recording  
Headstage  Axon instruments  Contains voltage clamp and voltage follower circuutis for 
voltage and current clamp recordings.  Connected to the 
mircromanipulator  
Pipette holder  Custom made  Connected to the headstage.  Used to securely hold pipettes.  
Multiclamp 700B 
amplifier 
Axon instruments  Amplifier used for electrophysiological recordings.  Run on 
computer 1 
PCI-6221 and 
BNC-2090 
National 
Instruments 
Analogue to digital signal converter and interface.  Used to 
communicate between the computer and amplifier and 
stimulator.   
Recording 
chamber 
Custom Made  Holds coverslip during an experiment.  Chamber included an 
inflow and outflow for perfusion and a ground pellet  
P97 
Flaming/brown 
micropipette 
puller 
Sutter Instruments 
company  
Used to pull recording pipettes 
Filamented 
borosilicate glass 
pipettes  
Warner 
Instruments 
Pipettes were pulled to a resistance of 3.5-5 MΩ.  
Concentric 
Bipolar 
stimulating 
electrode (1.0mm, 
impedance 10nA  
FHC  Used to simulate the presynaptic cell  
Table 2.15 Equipment for electrophysiology experiments 
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Figure 2.8 Electrophysiology rig I 
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Figure 2.9 .Electrophysiology rig II micromanipulators and headstage  
Software  Source  Use 
Multiclamp     
Labview   National Instruments 
and custom written  
Acquisition software for electrophysiology 
experiments.  Used to record output from the 
amplifier.  Software run on Computer 1 
LinLab    Used to record position of chosen cell  
Patch vision     Used to image cells  
Excel     Used for analysis of raw data  
Table 2.16 Software used for data acquisition and analysis in electrophysiology 
experiments  160 
 
 
The contribution of VGCC subtypes to the amplitude of the excitatory post synaptic 
potential (EPSC) was assessed using the specific blockers ω-conotoxin GVIA (ω-ctx), ω 
agatoxin IVA (ω-aga) and SNX 482.  These experiments were performed in Cacna1a 
knockout mice and their heterozygous and wildtype littermates.  DL-APV and NBQX 
were used in the extracelluar solution to prevent recurrent excitability.   
 
Drug  Target  Stock 
Concentration  
Final 
Concentration 
Storage  Provider  
ω-ctx  N type 
Calcium 
channel 
antagonist 
500 µM  5 µM  -20°C  Ascent Scientific   
ω-aga  P/Q-type 
calcium 
channel 
antagonist 
25 µM  250nM  -20°C  Ascent Scientific  
SNX -
482 
R type 
calcium 
channel 
antagonist  
20 µM  200 nM  -20°C  Ascent Scientific  
Table 2.17 VGCCS toxins used in electrophysiology experiments  
 
2.6.1. Protocol for electrophysiological recording of EPSCs 
Cells were patched in the somatic whole cell voltage clamp configuration at room 
temperature.  Excitatory post synaptic currents (EPSCs) were recorded via a 
MultiClamp 700B amplifier, filtered at 4 Hz and digitized at 10 kHz.  Filamented 
borosilicate glass pipettes were pulled to a resistance of 3.5-5 MΩ.  The glass coverslip 
was placed in the recording chamber and was constantly perfused with extracellular 
buffer at a rate of 1ml/minute throughout the experiment.   161 
 
The cells on the coverslip were visualised with the 10x objective and a suitable cell was 
located.  The position of the cell was recorded using the LinLab software.  The 
stimulating electrode was brought to the area of the coverslip adjacent to the cell of 
interest using the coarse micromanipulator.  The recording pipettes were filled with 
intracellular solution and were placed in the pipette holder of the Ag/AgCl2 electrode 
which was attached to the headstage.  The chloride of the silver wire was regularly 
replaced by electroplating to avoid electrical drift.  Positive pressure was applied to the 
glass pipette before it was lowered into the bath using the coarse manipulators.  The 
pipette resistance was calculated using the seal test and the pipette offset was zeroed.  
The pipette was manoeuvred to just above the cell using the coarse manipulator.  
LinLab software was used to locate the chosen cell.  The objective was changed from 
10x to the 63x and the pipette was brought closer to the cell using the fine 
micromanipulator.  Just before the cell was patched, the pipette offset was zeroed again 
and the pipette was gently moved in a diagonal fashion until it was brought in contact 
with the cell surface.  This was observed as a slight dimpling of the cell surface.  The 
pressure was released and a gentle suction was applied to achieve a gigaseal between 
the membrane and the pipette.  If a gigaseal was not obtained the cell was discarded.  
The pipette potential was switched a holding potential of -70mV and the capacitance 
transients were neutralised using the amplifier control software.   
 
Once the gigaseal was stable, a short sharp suction was applied to rupture the membrane 
and enter the whole cell configuration.  The access was monitored and a small pressure 
was applied to the pipette in order to stabilise it below 25 MΩ if this was required.  The 
access resistance was monitored throughout the experiment and the cell was discarded if 
the access resistance drifted by more than 25%.  The patch was held for 5 minutes 162 
 
before recording to allow for equilibration of the intracellular solution between the cell 
and the pipette.  An extracellular bipolar electrode was positioned nearby to stimulate 
one or more axons at a frequency of 2 pulses 50 milliseconds apart every 5 seconds.  
The amplitude of the stimulating pulse was adusted for each experiment – the lowest 
amplitude that achevied a post synaptic response was chosen. The EPSCs evoked were 
recorded using LabView software. 
 
Fig 2.10 Hippocampal cell culture 14 days in vitro with concentric bipolar stimulation 
(right) and electrode and pipette for whole cell patch clamp (left) 
 
In order to isolate the contribution of each type of presynaptic VGCC, the amplitude of 
the EPSCs were measured at baseline and after sequential application of toxins to block 
P/Q, N and R type VGCCs.  After 15 minutes of baseline recording, ω –Aga (250 nm) 
was added to the perfusion solution.  After 30 minutes, ω- ctx (5 μM) was added and 
after 45 minutes, SNX-482 (200nM) was added.   163 
 
 
2.6.2 Analysis of EPSCS  
The average EPSC peak for each experiment was calculated in LabView 8.0.  As 
demonstrated in the figure 2.11, baseline start and end constraints (see cursors on figure 
2.11) were placed roughly 20 ms apart 10 ms before the beginning of the EPSC.  The 
start find (blue cursor) was placed at the start of the EPSC to initiate the search for the 
EPSC.  The maximum of the peak was calculated to be the maximal point between the 
peak start and peak end (green cursors).  The position of the cursors was applied to 
individual EPSC traces and the maximal amplitude of each EPSC was calculated.  Once 
the peak of each EPSC trace was found, the data were extracted and exported to Excel. 
 
 
Figure 2.11 Analysis of EPSCs.  The average EPSC peak for each experiment was 
calculated in LabView in order to calculate where to place the baseline (Bl) and peak 
(Pk) cursors.  The “Bl start” (red) and “Bl end” (yellow) cursors were placed roughly 
20 ms apart, 10 ms before the start of the EPSC. The “Start find” cursor (blue) was 164 
 
placed at the start of the EPSC.  The peak of the EPSC was calculated as the maximal 
point between the “Pk start” and “Pk end” cursors (green).   
 
2.7 Statistical Methods 
 
All electrophysiology and synaptic vesicle imaging data were described by the mean 
and the standard error of the mean.  The 2 tailed unpaired t test was used for statistical 
analysis to assess significance.   
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3. Immunostaining for LEMS IgG  
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3.1 Background 
 
As was discussed in Chapter 1, it has long been accepted that the pathology of LEMS is 
autoimmune.  Initial clues about this came from clinical observations, including the 
association of LEMS with other autoimmune diseases and the improvement of LEMS 
symptoms after immunomodulatory treatment.  The definitive evidence however, came 
from passive transfer studies (Lang et al., 1981; Lang et al., 1984, Fukunaga et al., 
1983; Kim et al., 1986) whereby the electrophysiological and morphological features of 
the disease were transferred to rodents.   
 
3.1.1 Antigenic target in LEMS 
The presumed antigenic target in LEMS is the presynaptic voltage gated calcium 
channel (VGCC).  Antibodies directed against P/Q-type VGCCs can be detected by 
radioimmunoprecipitation assay in the vast majority of LEMS patients (Motomura et 
al., 1997) and Ca2+ currents are reduced in a wide variety of cell types after incubation 
in LEMS IgG (Garcia and Beam, 1996; Hewett and Atchison,1991; Kim and Neher, 
1988; Roberts et al., 1985; Grassi et al., 1994; Viglione et al., 1995; Meriney et al. 
1996; Pinto et al., 1998; Johnston et al 1994). 
 
Ambiguity remains however,regarding the exact target of antibodies in LEMS patients; 
not least because 10-15% of patients have no detectable P/Q- or N-type antibodies 
(Motomura et al., 1997; Nakao et al., 2002).  Moreover, Western blots and 
immunoprecipitation assays rely on the use of detergents to solubilize proteins from 167 
 
cells which may result in the detection of antibodies that are not necessarily pathogenic.  
The results of immunoprecipitation assays can also be affected by the particular 
protocol used; for example, mouse anti-synaptotagmin monoclonal antibodies can 
detect radiolabelled VGCC from rat brain precipitated in 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) detergent but not 
from VGCC precipitated in digitonin, (Lennon et al., 1995). 
 
There is previous literature regarding how immunoprecipitation assays can be 
misleading.  Antibodies that react against a different ion channel; the voltage gated 
potassium channel (VGKC) have been detected in association with three different 
clinical syndromes- neuromyotonia, Morvan’s Syndrome and limbic encephalitis (Irani 
et al., 2010).  These antibodies are detected in a similar fashion to the 
immunoprecipitation assay described above for detection of antibodies in LEMS 
syndrome.  VGKCs from homogenized mammalian brain, solubilized with digitonin, 
are labelled with iodinated - dendrotoxin (125I--DTX) and a 
radioimmunoprecipitation assay with serum from patients is performed.  A recent study, 
however, revealed that IgG from most patients with these conditions fails to bind to 
VGKCs expressed on HEK 293 cells (Irani et al., 2010).  This was a surprising finding 
and further investigation subsequently revealed that patient antibodies actually bind to 
various proteins that are complexed with 125I--DTX labelled VGKC in brain extracts – 
namely contactin associated protein-2, leucine-rich glioma inactivated 1 protein and 
Tag-1/contactin-2 that associates with contactin associated protein- 2.   
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The aim of this study was to visualise the binding of antibodies from LEMS patients to 
cultured neuronal cells using high resolution microscopy.  LEMS antibody binding to 
neuronal cells has not been visualized in this way before but if successful, 
immunohistochemistry techniques could be used to develop a cell-based assay which 
would help to  clarify further the exact antigenic target in LEMS.  This could have 
important implications for the diagnosis of LEMS and could help develop more specific 
therapies for patients with LEMS.  
 
3.1.2 Previous attempts to visualise binding of LEMs IgG using 
immunohistochemistry  
Previous studies have attempted to detect binding of IgG at the motor end plate in mice 
passively treated with LEMS IgG (Fukuoka et al., 1987b).  Hitherto, this has been a 
difficult task due in part, to the relatively low density of active zone particles which are 
the morphological representation of VGCCs (Fukuoka et al., 1987).  The density may 
be even lower in LEMS as LEMS antibodies are thought to cross link and internalize 
VGCCs (Nagel et al., 1988).  In these experiments, there has also traditionally been a lot 
of non-specific background staining as passive transfer of IgG means that the end plates 
are exposed to high concentrations of IgG.  Moreover, the reaction product can diffuse 
and be reabsorbed onto cell membranes making it difficult to distinguish between pre 
and post synaptic staining (Engel et al., 1987).  Fukuoka et al. used the avidin-biotin 
detection system to increase sensitivity of immunolocalization and found significant 
immunostaining of presynaptic mouse active zones in mice treated with LEMS IgG 
(Fukuoaka et al., 1987).  However this method resulted in a significant amount of non-
specific staining and the resolution of the microscopy was limited.   169 
 
 
In another experiment, Polizzi et al. tested sera from 20 patients with LEMS for binding 
to frozen sections of adult rat brain using standard immunohistochemistry techniques.  
However, only five of the 20 patients sera showed binding to neuronal antigens (Polizzi 
et al., 1998).  Moreover, the immunostaining seen in this study was not specific and was 
not consistent with antibody binding to cell surface antigens.   
 
3.2 Specific aims of this chapter  
 
With improvements in imaging technology and increasing sophistication and quality of 
fluorescent secondary antibodies, I hoped that I would be able to specifically detect 
binding of LEMS IgG to cell surface antigenic targets using immunohistochemistry.  I 
also wished to assess whether any immunostaining seen could be specifically co-
localized to presynaptic sites.   
 
3.3 Methods  
 
The reagents and equipment used and methods are outlined in more detail in chapter 2.  
Briefly, non permeabilized hippocampal neuronal cultures were used to detect the 
binding of LEMS IgG with anti human IgG Alexa 594 as a fluorescent secondary 
antibody.  I chose to use hippocampal neuronal cultures for our experiments as they 
have been well validated in other immunohistochemistry experiments in the past (Irani 170 
 
et al., 2010b).  Furthermore, the main aim was to detect binding of LEMs IgG to 
extracellular epitopes of VGCCs.  As there is a high degree of sequence homology 
between mouse, rat and human CACNA1A gene products (figure 3.1),an antibody that 
binds to an extracellular epitope of the human P/Q-type VGCC is likely to bind to the 
corresponding region of the rat P/Q-type VGCC.   
 
 
Figure 3.1 Amino acid sequences of the extracellular elements of the alpha1 subunit of 
the P/Q VGCCs demonstrating a high degree of amino acid sequence homology 
between the species. Sequences in grey highlight areas where there is some uncertainty 
Species Position Sequence
Human 118-136 EQHLPDDDKTPMSERLDDT
Rat 120-138 EQHLPDDDKTPMSERLDDT
Mouse 120-138 EQHLPDDDKTPMSERLDDT
Human 183-190 ATVGTEFD
Rat 185-192 ATVGTEFD
Mouse 185-192 ATVGTEFD 
Human 249-335 MGKFHTTCFEEGTDDIQGESPAPCGTEEPARTCPNGTKCQPYWEGPNNGITQFDNILFAVLTVFQCITMEGWTDLLYNSNDASGNTW 
Rat 251-337 MGKFHTTCFEEGTDDIQGESPAPCGTEEPARTCPNGTKCQPYWEGPNNGITQFDNILFAVLTVFQCITMEGWTDLLYNSNDASGNTW
Mouse 251-337 MGKFHTTCFEEGTDDIQGESPAPCGTEEPARTCPNGTKCQPYWEGPNNGITQFDNILFAVLTVFQCITMEGWTDLLYNSNDASGNTW
Human 507-521 VHYNQPEWLSDFLYY 
Rat 509-523 VHYNQPEWLSDFLYY 
Mouse 509-523 VHYNQPEWLSDFLYY 
Human 569-578 AVIKPGTSFG
Rat 571-580 AVIKPGTSFG 
Mouse 571-580 AVIKPGTSFG 
Human 637-689 GGQFNFDEGTPPTNFDTFPAAIMTVFQILTGEDWNEVMYDGIKSQGGVQGGMV
Rat 639-691 GGQFNFDEGTPPTNFDTFPAAIMTVFQILTGEDWNEVMYDEIKSQGGVQGGMV
Mouse 639-691 GGQFNFDEGTPPTNFDTFPAAIMTVFQILTGEDWNEVMYDGIKSQGGVQGGMV 
Human 1262-1280 AAEDPVQPNAPRNNVLRYF
Rat 1213-1231 AAEDPVQPNAPRNNVLRYF 
Mouse 1215-1231 AAEDPVQPNAPRNNVLRYF
Human 1329-1339 AFTGNSKGKDINTI
Rat 1283-1293 AFTGNSKGKDINTI
Mouse 1283-1293 AFTGNSKGKDINTI
Human 1398-1486 LFKGKFFHCTDESKEFEKDCRGKYLLYEKNEVKARDREWKKYEFHYDNVLWALLTLFTVSTGEGWPQVLKHSVDATFENQGPSPGYRME
Rat 1349-1437 LFKGKFFHCTDESKEFERDCRGKYLLYEKNEVKARDREWKKYDFHYDNVLWALLTLFTVSTGEGWPQVLKHSVDATFENQGPSPGYRME
Mouse 1349-1437 LFKGKFFHCTDESKEFERDCRGKYLLYEKNEVKARDREWKKYEFHYDNVLWALLTLFTVSTGEGWPQVLKHSVDATFENQGPSPGYRME
Human 1587-1598 FYGASVAYENALRV
Rat 1538-1552 FYGASVAYENALRV
Mouse 1538-1552 FYGASVAYENALRV
Human 1646-1656 LVTEFGNNFIN
Rat 1597-1607 LVTEFGNNFIN
Mouse 1597-1607 LVTEFGNNFIN
Human 1711-1786 MQVFGNIGIDVEDEDSDEDEFQITEHNNFRTFFQALMLLFRSATGEAWHNIMLSCLSGKPCDKNSGILTRECGNEF
Rat 1666-1737 MQVFGNIGIDGEDEDSDEDEFQITEHNNFRTFFQALMLLFRSATGEAWHNIMLSCLSGKPCDKNSGIQKPECGNEF
Mouse  1666-1737 MQVFGNIGIDGEDEDSDEDEFQITEHNNFRTFFQALMLLFRSATGEAWHNIMLSCLSGKPCDKNSGILTADCGNEF171 
 
about the exact start and end of the extracellular regions. (Sequences taken from 
uniprot.org) 
 
Both fixed and live neuronal cultures were used.  Medium was aspirated from the 
neuronal cultures and the cells were washed thoroughly with PBS.  If the cells were to 
be fixed, they were incubated with 4% PFA for 10 minutes.  Following fixation, the 
cells were washed with PBS.  When live cells were used, the cells were gently washed 
with PBS after removal of the culture medium.  In both cases, non specific epitopes 
were then blocked in 5% BSA in PBS for 30-60 minutes after which they were washed 
in PBS.  The cells were incubated with the primary antibody (either a LEMS or control 
sample, typically in a concentration of 1:1000 of 1% BSA in PBS) for 60 minutes at 
room temperature.  The IgG samples were of varying concentrations ranging from 
5mg/ml to 22 mg/ml and the concentration required for dilution was adjusted for each 
sample.  The primary antibody was then removed and the cells were washed with PBS.  
When the primary antibody had been incubated with live cells, they were fixed with 4% 
PFA at this point.  The cells were then incubated with the secondary antibody (typically 
anti human IgG Alexa 594 at a concentration of 1:1,000 for one hour at room 
temperature followed by washing with PBS.   
 
Another antibody was used for co-localisation in some experiments, typically this was 
rabbit anti-synapsin but anti-Green Fluorescent Protein (GFP) was used to localise GFP 
tagged VGCCs and the synaptic vesicle FM dye, SRC-1 was also used in some 
experiments.  In these experiments, the cells were fixed once again with 4% PFA and 
were then washed with PBS.  The cells were permeabilized by incubating them with 5% 172 
 
BSA in 0.1% Triton in PBS for 30 minutes.  After permeabilization the cells were PBS 
washed and blocked in 5% BSA in PBS.  The cells were incubated with the primary and 
secondary antibodies (for example, rabbit anti-synapsin and anti-rabbit Alexa 488) in 
the same fashion as was described for LEMS IgG outlined above. 
At the end of the experiment, the cells were washed thoroughly and the coverslips were 
mounted on glass slides using Vectashield mounting medium.  The cells were imaged 
using an LSM 500 confocal microsope.  Alexa 594 was excited using the 543nm line of 
He-Ne laser and its emission was recorded using a band-pass 560-615nm filter.  Alexa 
488 was excited by the 488nm line of an argon laser and its emission was recorded 
using a band pass 505-530 filter.  I am grateful to Dr Y. Ermolyuk for his help with the 
use of the confocal microscope.  There were a number of changes made to this protocol 
depending on the exact aim of the experiment being carried out and these are outlined 
below.  The figures shown are representative of 10 different images taken from each 
coverslip.   
 
3.4. Results 
 
3.4.1. Immunostaining of one LEMS sample in fixed unpermeabilized rat 
hippocampal cultures using anti-human IgG Alexa 594 as a secondary antibody 
The first experiment was designed to test whether our secondary antibody – anti human 
IgG Alexa 594 – was specific for human IgG.  Fixed, non-permeabilized rat 
hippocampal neuronal cultures were incubated with (a) LEMS IgG at a concentration of 173 
 
1:100 in 1% BSA in PBS, or (b) no primary antibody in 1% BSA in PBS followed by 
incubation with anti-human IgG Alexa 594 as the secondary antibody (figure 3.2).   
 
In the cells incubated with LEMS IgG from one patient,immunostaining of cell bodies 
and neurites was detected (Figure 3.3.a).  There was no immunostaining of cells that 
were not incubated with a primary antibody (figure 3.3.b), suggesting that the LEMS 
IgG bound to some antigenic target on the surface of neuronal cells and that the 
secondary antibody was specific for human IgG.  On high resolution images it was 
observed that LEMS stained both cell bodies and neurites of some but not all cells 
(figures 3.4 and 3.5).  The cells were not permeabilized and so, only cell surface binding 
was observed.  No significant glial cell staining was observed.  The images shown are 
representative of experiments from two different cultures and ten images were taken 
from each coverslip. 
 
Figure 3.2 Schematic diagram showing binding of anti human IgG A594 to LEMS IgG 
in hippocampal neurons (a), compared to hippocampal neurons that were not incubated 
with a primary antibody (b).   
 
(a)  (b) 174 
 
 
 
Figure 3.3 Fluorescence images (right panels) showing (a) immunostaining of LEMS 
IgG with anti human IgG 594 on cell bodies and neurites of hippocampal neurons.  The 
cultures that were not incubated with a primary antibody did not exhibit any 
immunostaining (b) implying that the secondary antibody was specific for human IgG 
DIC images are shown for comparison (left panels). Scale bar =100 µm 
 
(a)
(b)
DIC
DIC
LEMS/A594
No primary /A594175 
 
 
Figure 3.4 A section of hippocampal neurons showing that LEMS IgG immunostained 
neurites and cell bodies of hippocampal neurons (a-d). DIC image is shown for 
comparison (f). Scale bar = 10 µm. The thickness of each slice was 1 um and the 
distance between sections was 2.5 µm 
 
 
Figure 3.5 High resolution fluorescence image superimposed on DIC showing that 
LEMS IgG immunostains soma and neurites of hippocampal neurons in culture. Scale 
bar = 5 µm 
(a) (b) (c)
(d) (e) (f)
(a) (b)
 176 
 
3.4.2 Immunostaining of LEMS IgG compared to control IgG in fixed 
unpermeabilised rat hippocampal cultures using anti human IgG Alexa 594 as a 
secondary antibody 
Having confirmed that the secondary antibody was specific and having detected LEMS 
IgG binding to hippocampal cell bodies and neurites as outlined above, the next step 
was to compare the immunostaining of LEMS IgG to control IgG.  
 
The experiments were carried out in the same manner as described above.  Binding of 
one LEMS sample was compared to a pooled sample of control IgG from healthy 
volunteers (figure 3.6).  It was once again confirmed that LEMS IgG can be detected 
binding to fixed non permeabilised cells (figure 3.7a) but the degree of this staining and 
its specificity was difficult to quantify.  Moreover, there was a high degree of non-
specific staining with control IgG (figure 3.7b).  The images shown are representative of 
experiments from three different cultures and ten images were taken from each 
coverslip. 
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Figure 3.6 Schematic diagram showing (a) immunostaining of LEMS IgG in fixed non-
permeabilised hippocampal neurons compared to (b) immunostaining with control IgG  
 
 
 
Figure 3.7 (a) Fluorescence images showing immunostaining of LEMS IgG (a) 
compared to control IgG (b). Scale bar = 100 µm.   
 
(a) (b)
LEMS/A594 Control/A594
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3.4.3 Immunostaining of LEMS IgG compared to control IgG in neurons transfected 
with GFP tagged VGCCS  
The previously described experiment was disappointing because there was a high 
degree of non-specific binding detected in cultures incubated with control IgG and the 
immunostaining detected with LEMs IgG was difficult to quantify.  The next step was 
to attempt to specifically localise the binding of LEMS IgG to VGCCs using neurons 
that were transfected with green fluorescent protein (GFP) tagged human P/Q-type 
VGCCs.  The enhanced GFP-Cav2.1 fusion plasmid was previously used by a group in 
our laboratory (Imbrici et al., 2004).  As the cDNA used was human, it would also allay 
any concerns that difference in antigens between the species was the reason why 
binding was not detected.   
 
3.4.3.1 Methods 
The experiments were conducted in the same way as outlined above.  After completion 
of staining for LEMS with primary and secondary antibodies the cells were washed with 
PBS, fixed with 4% PFA and then permeabilised with 5% BSA in 0.1% Triton in PBS 
for 30 minutes.  The cells were then washed with PBS and incubated with rabbit anti-
GFP primary antibody at a concentration of 1:1,000.  The remainder of the experiment 
was carried out in the same way as outlined above for the incubation with LEMS 
antibodies except the secondary antibody used was anti rabbit-IgG Alexa 588 at a 
concentration of 1:1,000 (Figure 3.8.)   
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3.4.3.2 Results 
Some LEMS IgG binding to surface antigens in neuronal culture was detected (3.9b) 
but the LEMS IgG binding was not co-localised to the GFP tagged VGCCs (figure 
3.9a).  The images shown are representative of experiments from two different cultures 
and ten images were taken from each coverslip. 
 
 
Figure 3.8 Schematic diagram showing the immunostatining of LEMS IgG with anti 
human IgG A594 in neurons transfected with GFP-tagged VGCCs.   
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Figure 3.9 Fluorescence images showing immunostaining of LEMS IgG with anti-
human IgG 594 (red) in neurons transfected with GFP- tagged VGCCs (green) (a) 
overlay of green and red channels (b) LEMS IgG (c) GF- tagged VGCCs.  Scale bar = 
5 µm.   
 
3.4.4 Immunostaining of LEMS IgG compared to control IgG in neurons transfected 
with GFP tagged VGCCS in permeablized hippocampal neurons 
The above experiment was repeated in neurons that had been permeabilised before 
incubation with LEMS antibodies.  LEMS IgG could be immunolocalised to some cell 
bodies and neurites but was not definitively confirmed to bind to transfected VGCCs 
(Figure 3.10).  The images shown are representative of experiments from two different 
cultures and ten images were taken from each coverslip. 
 
(a) (c) (b)
Overlay LEMS/A594 GFP/A488181 
 
 
Figure 3.10 Immunostaining of LEMS IgG (red) in permeabilised neurons transfected 
with GFP tagged P/Q- VGCCS (green). (a) DIC image (b) Overlay of green and red 
channels (c) LEMS IgG immunostaining with anti-human IgG A594 (d) immunostaining 
of GFP tagged VGCCs with A488   Scale bar = 10 µm.   
 
3.4.5 Immunostaining of live neurons with zenon labelled LEMS IgG after preblock 
with control IgG.   
So far, the success with immunostaining for LEMS IgG was limited by a high degree of 
non–specific staining.  There was a concern that fixation of neuronal cultures could 
cause a conformational change in the epitope which could affect antibody binding.  It 
was also postulated that the LEMS IgG may have a low avidity and that if binding were 
unstable, it may impede the immunolocalisation experiments.  Alternatively, it was 
(a) (b)
(c) (d)
DIC
LEMS IgG/A594 GFP /488
Overlay182 
 
possible that LEMs IgG did not specially bind to VGCCs. Thus a different approach 
was taken for the next experiment.   
 
3.4.5.1 Aim and background 
The aim was to image the binding of LEMS IgG labelled with anti human IgG Zenon® 
Fab fragments in live neuronal cultures and to attempt to localise IgG binding to 
synapses using synaptic vesicle imaging with the FM dye, SRC-1.   
 
The Zenon® labelling reagents used in this experiment contain a fluorophore, labelled, 
Fc specific anti Human IgG Fab fragment.  This labelled Fab fragment binds to the Fc 
portion of an antibody (such as LEMS IgG) with high affinity and selectivity.  Non 
specific IgG is used to complex unbound Fab fragments and to ensure that any 
fluorescence seen is due to specific binding of the Zenon® Fab fragments to human 
IgG.  Using live cultures would ensure no conformational changes in epitopes occurred 
and could also allow a divalent IgG to bind to two epitopes through cross linking, thus 
increasing the affinity of antibody binding. 
 
Synapses were stained using the synaptic vesicle dye SRC1 after incubation with 
Zenon® labelled LEMS IgG.  Synaptic vesicle imaging with SRC-1 is discussed in 
detail in Chapter 2 and in Chapter 4.  SRC-1 is an FM dye that is fluorescent when 
incorporated to the lipid bilayer of a cell membrane.  It can be specifically used to label 
recycling synaptic vesicles and in this experiment was used to attempt to co-localise 
LEMS IgG binding to the site of synapses.   183 
 
 
3.4.5.2 Methods 
Live neuronal cultures were incubated in Neurobasal containing control IgG (at a 
concentration of 250L per 1ml ) to preblock non-specific binding of IgG.  The solution 
also contained NBQX (10 M) and DL APV (50 M) to prevent recurrent electrical 
activity in the live cells.  After 15 minutes the coverslip was incubated with LEMS IgG 
at a concentration of 1:100 that was labelled with human IgG Zenon fragments® 
(Invitrogen). (Figure 3.11).  The coverslip was then transferred to the imaging rig where 
recycling synaptic vesicles were labelled with the fluorescent styryl dye, SRC-1 (See 
Chapter 2 and Chapter 4 for methods).   
 
3.4.5.3 Results  
Zenon ® labelled LEMS IgG stained neurites and some cell bodies but binding could 
not be reliably localised to the sites of recycling synaptic vesicles labelled with SRC-1 
(figure 3.12).  The images shown are representative of experiments from two different 
cultures and ten images were taken from each coverslip. 184 
 
 
 
Figure 3.11 Schematic diagram demonstrating labelling of primary IgG with Zenon® 
Fab fragments 
 
 
Unlabelled IgG 
antibody  Zenon labelled 
Fab fragments +
Non specific IgG to 
complex unbound 
Fab Fragments
Zenon labelled IgG185 
 
 
Figure 3.12 Fluorescence images demonstrating Zenon® antibody labelling (green 
channel) and labelling of synaptic vesicles with SRC-1 (red channel) in live neuronal 
cultures. (a) DIC image) (b) Fluorescence images superimposed on DIC (c) LEMS IgG 
lablelling with Zenon fragments (d) Labelling of synaptic vesicles with SRC-1. Scale bar 
= 10 µm.   
 
3.4.6 Immunostaining of LEMS IgG in fixed neuronal cultures with co-localisation 
with synapsin  
3.4.6.1 Aim 
As there was limited success with the methods described thus far, the next step was to 
attempt to detect specific binding of LEMS IgG to neuronal cultures using co-
localisation with the synaptic membrane protein synapsin.  It was also decided to use 
(a) (b)
(c) (d)
DIC
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multiple different LEMS samples as hitherto, just one LEMS sample had been used.  A 
uniform concentration of 1,1000 was used for each sample.  
 
3.4.6.2 Methods 
Four different LEMS samples were used – each of these samples had a different 
concentration and the amount of IgG used in each experiment was adjusted to achieve a 
concentration of 1:1,000.  A pooled control sample was used for comparison and the 
concentration was also adjusted to achieve a final concentration of 1:1,000.   
 
The experiments were conducted in a similar way as described for fixed neuronal 
cultures above.  The cells were washed, fixed in PFA and blocked with 5% BSA in 
PBS.  They were then incubated with LEMS or Control IgG and washed before 
application of the secondary antibody.  After incubation with anti-human IgG Alexa 
594, the cells were fixed, permeabilised, blocked and were then incubated with rabbit 
anti synapsin antibody (Invitrogen).  The cells were washed in the usual way and then 
anti-rabbit IgG A 488 was used as the secondary antibody (figure 3.13). 
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Figure 3.13 Schematic diagram showing immunolocalization of LEMSs IgG and co-
staining with synapsin  
 
3.4.6.3 Results 
Control IgG caused non-specific immunostaining (figure 3.14e).  However, LEMS IgG 
from the four patients used did show variable patterns of immunostaining of cell surface 
antigens.  As was seen before, LEMS IgG bound to both cell bodies and neurites (figure 
3.14 a-d).  However the pattern and degree of binding was not the same in each LEMs 
sample.  Furthermore, the binding of LEMS IgG could not be specifically localised to 
synapses as identified by synapsin immunofluorescence (figure 3.14 (a-d)).  The images 
shown are representative of experiments from four different cultures and ten images 
were taken from each coverslip. 
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Figure 3.14 Immunostaining of fixed non permeabilized hippocampal cultures with 
LEMS IgG and co-staining with anti-synapsin (a-d) (a: LEMS Sample 1; b: LEMS 
Sample 2; c: LEMS Sample 3; d: LEMS Sample 4) and Control IgG (e).  Scale bar = 20 
μM 
 
3.4.7 Immunostaining of LEMS IgG in live neuronal cultures with co-localisation 
with synapsin  
3.4.7.1 Aim 
As described above, there was a concern that fixation could cause a conformational 
change in the epitope that could affect LEMS IgG binding.  Therefore it was decided to 
repeat the above experiment (3.4.6) in live neuronal cultures.   
 
DIC
Control IgG/ A594 Synapsin/A488
(e) Control 191 
 
3.4.7.2 Methods 
The experiments were carried out in the same way as described in 3.4.6 except that live 
neuronal cultures were gently washed in PBS before blocking in 5% BSA in PBS.  The 
live cells were incubated with the primary antibody (LEMS or control IgG)  The cells 
were then washed and fixed in 4% PFA and the rest of the steps were carried out in the 
same way as described above.  
 
3.4.7.3 Results  
A similar pattern of immunostaining as was observed for the fixed cells was seen in the 
live cells.  LEMS samples showed a variable degree and pattern of immunostaining 
(figure 3.15 a-d).  However it was difficult to quantify this or to determine its specificity 
and there was no reliable co-localisation with synapsin staining.  Control IgG did not 
cause significant immunostaining (figure 3.15 e).  The images shown are representative 
of experiments from three different cultures and ten images were taken from each 
coverslip. 
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Figure 3.15 Immunostaining of live non permeablized hippocampal cultures with LEMS 
IgG (a-d) and co-staining with anti-synapsin (a: LEMS Sample 1; b: LEMS Sample 2; 
c: LEMS Sample 3; d: LEMS Sample 4) and Control IgG (e).  Scale bar = 20 μM 
 
3.4.8 Immunostaining of LEMS IgG in live Cacna1a WT and KO cultures  
As described above, although, some immunostaining of LEMS IgG was detected in 
both fixed and live neuronal cultures, the pattern and the intensity of staining varied 
significantly amongst different LEMS samples and it was difficult to assess the 
specificity of this staining.  Therefore it was decided to use hippocampal neurons that 
were lacking P/Q- type VGCCs from Cacna1a knockout mice.  The aim was to 
compare immunostaining of LEMS IgG and Control IgG in WT and KO cultures to see 
if LEMS IgG immunostaining was specific for P/Q- type VGCCs.   
 
Control IgG/ A594 Synapsin/A488
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DIC195 
 
3.4.8.1 Methods 
The experiments were performed in the same way as outlined in the experiments 
described in section 3.4.7.  WT and Cacna1a knockout cultures were used.  LEMS 
Sample 3 was used and was compared to pooled control.   
 
3.4.8.2 Results  
LEMS immunostaining was seen in WT samples in a similar way to described above.  
However, LEMS immunostaining was also seen in the KO sample implying that the 
immunostaining that was observed was not specific for P/Q-type VGCCs in this 
particular sample (figure 3.16 a and b).  There was minimal immunostaining seen with 
control IgG in the WT culture (figure 3.16c).  There was large degree of non-specific 
staining, most likely due to technical issues seen in KO sample stained with control IgG 
(figure 3.16 d).  The images shown are representative of experiments from two different 
cultures and ten images were taken from each coverslip. 
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Figure 3.16  Immunostaining of LEMS IgG in WT (a) and Cacna1a KO cultures (b) 
compared to control IgG in WT (c) and KO (d) cultures. Scale bar = 20 μM 
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3.5 Discussion  
 
These experiments showed LEMS IgG from five different patients binding to cell 
surface antigens in live and fixed hippocampal neurons.  However, a high degree of 
non-specific immunostaining was seen with control IgG,although this improved slightly 
when experiments were repeated with an adjusted uniform concentration of IgG.   
 
The immunostaining seen with LEMS IgG varied between samples and could not be 
localised to synaptic sites labelled with synapsin or the synaptic vesicle dye SRC-1.  
Moreover, the immunostaining was not specific for human VGCCs that were 
overexpressed and tagged with GFP.  One LEMS sample tested in Cacna1a KO 
cultures showed a similar pattern of binding to that seen in WT cultures, meaning that 
the immunostaining observed was not specific for P/Q-type VGCCs in the sample 
tested.  
 
There could be many reasons for the non-specificity of labelling observed in these 
experiments, including large volumes of IgG leading to non-specific binding, 
conformational changes in cell proteins that result in changes to cell surface antigens 
after fixation and a low density of the surface target antigen of LEMS IgG.  Moreover, 
the Kd of the LEMS IgG may be high meaning that it was not possible to visualise 
binding of LEMS IgG.  An alternative explanation in live cultures could be that the IgG 
cross links and internalizes LEMS IgG meaning that I was not able to visualise 
immunostaining in non-permeabilised cells.  198 
 
 
A further alternative explanation is that the immunostaining that we were seeing was 
due to IgG binding to alternative antigens, unrelated to LEMS.  Our collaborators in 
Oxford had performed similar experiments in cerebellar neuronal cultures.  They had 
found that only a small proportion of LEMS samples reliably immunostained neuronal 
cultures (personal communication).  Furthermore, many of the samples that did 
immunostain neurons were subsequently found to be positive for additional antibodies.  
In particular, LEMS patients who have an underlying malignancy may have antibodies 
to a wide variety of antigens other than VGCCs including GABA(B) receptors (Boronat 
et al., 2011) and antibodies against the VGKC complex (Kalra et al., 2014).  It is 
possible that the immunostaining that was detected in these experiments could be due to 
IgG binding to antigenic targets other than the VGCC.  Further experiments with 
additional secondary antibodies are required to investigate this.   
 
Very recently, antibodies from three LEMS patients were found to bind to HEK293 
cells expressing specific individual recombinant subunits of human neuronal VGCCs 
(Hajela et al., 2014).  All three LEMS IgG samples were found to bind to HEK 293 
cells expressing ʱ1A, ʱ1B, ʱ1C, or ʱ1E, subunits in combination with ʱ2δ and β subunits – 
indicating that, in these experiments, LEMS IgG recognised multiple different types of 
HVA VGCCs - P/Q-, N-, L and R-type.  LEMS IgG was also found to bind to HEK 293 
cells expressing a single ʱ1A, ʱ1B, ʱ1C, or ʱ1E subunit without accessory subunits.  
Furthermore, LEMS IgG bound to HEK 293 cells expressing the β3 subunit alone but 
not cells expressing ʱ2δ alone (Hajela et al., 2014).  These data suggest that LEMS IgG 
probably binds to a conserved region of the VGCC ʱ and β subunits and that LEMS 199 
 
antibodies recognise multiple types of VGCCs.  These experiments were done in fixed 
permeabilised cells so it is difficult to be sure of the pathogenicity of the antibodies.  In 
particular, as the β subunit is intracellular, it would seem likely that development of anti 
β antibodies is a secondary response rather than a primary pathogenic process.  This 
group did not use a control IgG from a healthy patient but did use IgG from a patient 
with Myasthenia Gravis that did not demonstrate any immunoreactivity.  This study is 
therefore open to alternative interpretations and further studies on nonpermeabilised 
cells are required to detect specific binding of pathogenic LEMS antibodies.    
 
Having had disappointing results with immunohistochemistry experiments, the next step 
was to examine the functional effects of LEMS antibodies on synaptic vesicle release.   
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4. Effect of LEMS IgG on synaptic vesicle release 
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4.1 Background  
 
As mentioned previously, the pathophysiology of LEMS is firmly established as 
autoimmune.  This was long suspected by the clinical association of LEMS with 
autoimmune disease (Lennon et al., 1982; O’Neill et al., 1988) and the response of 
LEMS patients to immunomodulatory treatment (Lang et al., 1981; O’Neill et al., 
1988).  The definitive evidence came from passive transfer experiments where the 
functional effects of LEMS antibodies were first shown.  Mice injected with IgG from 
LEMS patients had electrophysiological features resembling LEMS - reduced quantal 
release with a reduction in the end plate potential (EPP) amplitude in nerve muscle 
preparations, and facilitation in response to high frequency stimulation (Lang et al. 
1981; Lang et al. 1983; Lang et al., 1987; Prior et al., 1985; Giovannini et al., 2002; 
Lambert et al., 1988).  Facilitation is an increase in the amplitude of the compound 
muscle action potential/EPP after maximal exercise or high frequency stimulation.  This 
phenomenon arises because action potential trains that occur during high frequency 
stimulation lead to a gradual temporary increase in presynaptic Ca2+ concentration and 
hence an increase in Ca 2+ dependant exocytosis, thus suggesting that VGCCs may 
involved in the pathogenesis of LEMS.  Acute exposure of muscle nerve preparations to 
LEMS IgG results in reduced quantal content in vitro (Flink and Atchison, 2002; 
Buchwald et al., 2005).  These in vivo and in vitro experiments provide strong evidence 
that antibodies in patients with LEMS are directly pathogenic. 
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4.1.1 Antigenic targets in LEMS  
As mentioned in the previous chapter, antibodies against P/Q-type VGCCs can be 
detected by immunoprecipitation of MVIIC-labelled VGCCs from solubilised cerebellar 
homogenates in 85-90% of patients with LEMS (Motomura et al,. 1995, Takamori et 
al., 2000; Nakao et al., 2002).  Additional antibodies against N-type channels can be 
similarly detected by immunoprecipitation with conotoxin GV1A labelled VGCCS 
labelling in approximately one third of patients (Motomura et al., 1995).  P/Q-type 
VGCCs and, to a lesser extent, N-type VGCCs are responsible for the majority of the 
Ca2+ influx that triggers release of ACh at the mammalian neuromuscular junction and 
at central synapses (Uchitel et al., 1992, Cao and Tsien, 2010).  It has therefore been 
proposed that failure of neuromuscular transmission that occurs in LEMS results from a 
decrease in action potential dependent Ca2+ influx due to antibodies binding to 
presynaptic P/Q- and possibly N- type VGCCs.  This hypothesis is consistent with the 
characteristic neurophysiological finding of facilitation both in LEMS patients and in 
synaptic preparations in vitro from animals treated with LEMS IgG.   
 
4.1.2 Functional effects of LEMS antibodies 
The finding that calcium currents are reduced following exposure to LEMS IgG in a 
wide variety of cell types, including SCLC cell lines (de Aizpurua et al., 1988; Johnston 
et al. 1994; Lang et al., 1989; Meriney et al., 1996; Viglione et al., 1995), cultured 
motor neurones (Garcia et al., 1996a; Garcia et al., 1996b), cortical synaptosomes 
(Hewett et al., 1991), bovine adrenal chromaffin cells (Kim et al., 1988), anterior 
pituitary cells (Login et al., 1987), insulinoma cell lines (Magnelli et al., 1996) and 203 
 
neuroblastoma cells (Peers et al., 1990) is further supporting evidence for the hypothesis 
that LEMS IgG affects presynaptic VGCC function.  
 
However, it remains unproven whether the effect of LEMS IgG on EPP amplitude is 
caused by a decrease in action potential dependent ACh exocytosis due to blocking of 
presynaptic voltage gated calcium channels.  Studies of the effect of LEMS antibodies 
on synaptic transmission have focused almost exclusively on the postsynaptic effects of 
LEMS IgG.  Postsynaptic responses are not always a direct read-out of presynaptic 
neurotransmitter release (Atwood and Wojtowicz, 1999) as synapses are subject to 
extensive plasticity meaning that alternative mechanisms could theoretically explain the 
impaired synaptic transmission in LEMS.  
 
There have been some studies that have examined the effect of LEMS IgG on 
presynaptic neurotransmitter release.  Studies on biopsied intercostal muscle from 
patients with LEMS showed that the rates of spontaneous and evoked release of 
acetylcholine are reduced compared to healthy human muscle (Molenaar et al., 1982).  
Decreased rates of resting and evoked release of acetylcholine were also found in 
diaphragmatic muscles of mice passively treated with LEMS IgG in vitro whereas the 
actual ACh, choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) content 
of homogenised gastrocnemius muscles was normal  (Lang et al., 1984).  Moreover, 
incubation of LEMS IgG with electric ray synaptosomes has been found to reduce 
depolarisation evoked ACh release (as measured using a chemiluminescence reaction) 
by 39-45% (Satoh et al., 1998).   
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Synaptic vesicle release has also been estimated in bovine adrenal chromaffin cells 
using increases in membrane capacitance (Cm) during perforated patch whole cell 
voltage clamp as a measure of membrane area, and therefore, exoctytosis.  Treatment 
with LEMS IgG resulted in a smaller exocytotic response to a single depolarising pulse 
compared to control IgG.  Furthermore, the magnitude of the reduction in exocytosis 
was proportional to the reduction in Ca2+ current caused by the individual LEMS 
samples (Engisch et al., 1999).  LEMS IgG was not found to change the basal Ca2+ -
exocytosis relationship observed during single step depolarisations (Engisch et al., 
1999).  A similar reduction in the exocytic response to stimulation was seen when 
membrane capacitance was measured in SCLC cells exposed to LEMS IgG (Viglione et 
al., 1995).  Although these studies suggest that the abnormal synaptic transmission that 
occurs in LEMS is due to an effect on stimulus-evoked ACh release, a direct effect of 
LEMS IgG on synaptic vesicle release at the presynaptic membrane has not been 
shown.   
 
4.1.3 Seronegative LEMS  
Approximately 10-15% of patients with LEMS do not have antibodies against P/Q-type 
VGCCs demonstrable byradioimmunoprecipitation assay (Nakao et al. 2002).  The 
clinical features of LEMS are similar in these “seronegative” patients to classic 
“seropositive” LEMS with two exceptions; the incidence of small cell lung cancer is 
lower and the electrophysiological abnormalities are less pronounced (Nako et al, 2002; 
Oh et al., 2007).  Passive transfer of seronegative IgG transfers the electrophysiological 
features of LEMS suggesting that seronegative LEMS is also an antibody mediated 
disorder (Nako et al., 2002).  It may be that so called “seronegative” LEMS is caused by 205 
 
the same antibodies as seropositive LEMS but at a concentration that it not detectable 
by immunoprecipitation, or perhaps the antibodies are directed against an epitope that is 
not recognised by the current assay (Titulaer et al,. 2011).  Alternatively, the antibodies 
in “seronegative” LEMS may be directed against a completely different protein, 
disruption of which causes a similar phenotype.  Various alternative antigenic targets 
have been suggested.  Synaptotagmin was found to cause an immune mediated model of 
LEMS in rats (Takamori et al., 1994) and antibodies to recombinant synaptotagmin 
were identified in a small number of LEMS patients using immunoblot assays 
(Takamori et al., 1995, 2007).  Immunoblotting against the solubilized muscarinic ACh 
receptor has resulted in the detection of autoantibodies against the M1 receptor in 
seropositive and seronegative LEMS patients (Takamori et al., 2007).  More recently 
autoantibodies to a neuromuscular junction protein ERC 1 (ELKS/RAB6-
interacting/CAST family member 1) were found in one LEMS patient using a 
recombinant ELISA assay and a cell expression assay (Huijbers et al., 2013).  However, 
it is not known whether these are disease-causing antibodies or how antibodies against 
these targets might result in a LEMS phenotype.  
 
4.2 Fluorescent labelling techniques to investigate synaptic 
transmission 
 
Fluorescent markers which accumulate at the synaptic terminal of neurons during 
endocytosis and are released during exocytosis of synaptic vesicles have proved useful 
tools in the investigation of synaptic transmission for many years.  Horse radish 
peroxidase (HRP) was one of the first such markers and has been used since the 1960s.  206 
 
It is endocytosed by nerve terminals and can mark recycled synaptic vesicles in fixed 
and frozen preparations (Graham and Karnovsky, 1966; Heuser and Reese, 1973; 
Ceccarelli et al., 1972).  The subsequent discovery of hydrophilic fluorescent dyes such 
as 3,3’ –diethyloxadicarbocyanine iodide (DiOC2) that stain live nerve terminal 
preparations from mouse frog and Drosophila was an important development in this 
field (Yoshikami and Okun,. 1984).  The first description of staining and subsequent 
destaining of live nerve terminals came from the work of Lichtman et al. (Lichtman et 
al., 1985; Lichtman and Wilkinson, 1987) who showed that certain fluorescent dyes 
(e.g. sulforhodamine,8-hydroxypyrene trisulfonic acid) were internalized by nerve 
terminals of snake neuromuscular preparations in an activity-dependent fashion.  
However, for unknown reasons, these dyes did not work in mammalian preparations 
(Betz et al., 1996).  
 
The development of the fluorescent styryl FM dyes in the early 1990s (Betz et al. 1992), 
allowed the visualisation of synaptic vesicle recycling in living mammalian and reptile 
cells in real time (Cousin, 2008).  FM dyes are a family of modified styryl dyes 
originally synthesized by Fei Mao (hence “FM”).  All FM dyes have a similar structure 
(see figures 4.1 and 4.2) with a lipophilic tail linked to a charged head via a multiple 
double bond bridge (Betz et al., 1996).  The lipophilic tail region allows the dye to 
reversibly partition into hydrophobic domains, including the lipid cell membrane 
(Cousin, 2008) whereas the positively charged hydrophilic head group stops the dye 
from passing through cell membrane.  The speed at which the dye departitions from 
lipid membrane is determined by the tail region; the longer the hydrocarbon tail, the 
slower the departition rate (Cousin, 2008).  The fluorescence spectrum of the dye is 
determined by the fluorophore nucleus formed by the aromatic rings and the double 207 
 
bond bridge; the more double bonds present in the flurophore, the longer the excitation 
and emission wavelength (Betz et al. 1996; Gaffield and Betz, 2006).   
 
The fluorescent properties of a styryl dye are dependent on whether the dye is in 
solution or partitioned into a lipid membrane.  In polar solvents, such as aqueous 
solutions, styryl dyes do not fluoresce.  However, the quantum yield increases by over 
two orders of magnitude when the dye is incorporated into a non-polar substance such 
as a lipid bilayer (Gaffield and Betz, 2006).  Hence almost the entire fluorescent signal 
emitted from a styryl dye is from the proportion that is buried within cell membranes.   
 
 
Figure 4.1 FM dye chemical structure (from Gaffield and Betz, 2007) 
 
 
Figure 4.2 Structure of SRC-1 (from biotium.com) 
 
FM dyes can be used to specifically label and monitor the release of synaptic vesicles 
(Fig 4.3).  When an FM dye is incubated with neurons, the dye molecules initially 208 
 
partition into the outer leaflet of the plasma membrane of the cells.  If the neurones are 
stimulated, exocytosis of synaptic vesicles occurs, followed by endocytosis which 
internalizes the membrane bound dye.  Excess dye that has not been internalized can be 
washed off, leaving fluorescently labelled synaptic vesicles inside the nerve terminals.  
Recycling synaptic vesicles are labelled specifically by this procedure (Cousin, 2008).  
A second stimulation of neurons can then unload the labelled synaptic vesicles.  This is 
visualized as a decrease in fluorescence as the dye enters the extracellular medium; in 
theory the loss of fluorescence reflects of the extent of synaptic vesicle exocytosis.   
 
 
Figure 4.3 Schematic diagram for FM destaining experiments (a) Baseline (b) FM 
fluorescence of cell membrane (c) Specific labelling of synaptic vesicles after high 
frequency stimulation and wash out of excess dye (d) Spontaneous synaptic vesicle 
release (e) Action potential evoked synaptic vesicle release during low frequency 
stimulation (f) Complete destaining   
 
FM dyes were first used in frog muscle nerve preparations (Betz et al., 1992; Richards 
et al., 2003).  However, since then, they have been used in a wide variety of other 
synaptic preparations including the Drosophila larval neuromuscular junction 
(Ramaswami et al., 1994), crayfish neuromuscular junction (Wang and Zucker, 1998), 209 
 
snake neuromuscular junction (Teng et al., 1999) and goldfish bipolar cells (Lagnado et 
al., 1996).  FM dyes have also been used on studies in synaptic transmission in brain 
slices (Kay et al., 1999; Pyle et al., 1999; Winterer et al., 2006) and with relevance to 
this current project, in hippocampal neuronal cultures (Darcy et al., 2006; Harata et al., 
2001; Hopf et al., 2002; Klingauf et al., 1998; Ermolyuk et al., 2013).    
 
A number of different FM dyes exist, and are suited to different applications (Gaffield 
and Betz, 2006).  Although FM-143 is the most commonly used dye (Cochilla et al., 
1999; Harata et al 2001), FM dyes that have fast departition rates due to a shorter 
lipophilic tail, such as SynaptoRed C1 (SRC1), are particularly useful in experiments 
when fast recycling events are examined.  SRC1 has a red shifted emission spectrum 
compared to FM-143 (the peak excitation and emission spectra are 734 and 558 nm 
respectively) and was shown in our laboratory to specifically label synaptic vesicles in 
hippocampal neuronal culture with a high signal-to-noise ratio (F. Alder 2012).  As 
SRC-1 had been validated in our laboratory, has a known Kd and has a fast departition 
rate, this particular styryl dye was the most appropriate choice in our experiments.   
 
4.3 Specific aims of this chapter  
 
The aim of these experiments was to quantify the effects of IgG from LEMS patients on 
action potential evoked synaptic vesicle exocytosis in hippocampal neuronal cultures 
using the membrane specific fluorescent marker, SRC1.  A protocol was used that 
would allow estimation of several key properties of neurotransmission at the level of 210 
 
individual boutons in the presence of LEMS IgG or control IgG. These properties were: 
the size of the recycling pool of vesicles (RP) and the rates of spontaneous (kSP), 
evoked, (kEV) and action potential dependent (kAP) synaptic vesicle release.  A futher 
aim was to assess the functional effects of LEMS IgG from a LEMS patient without 
detectable anti-VGCC antibodies (“seronegative” LEMS).   
 
 
4.4 Methods  
4.4.1 Choice of hippocampal neuronal cultures  
Hippocampal neuronal cultures from rodents were chosen as a model system for these 
experiments.  These synapses have been extensively used to study the coupling of Ca2+ 
to synaptic transmission (Cao and Tsien, 2010) and show similar roles for N- and P/Q-
type VGCCs as have been described at the neuromuscular junction.  There is a high 
degree of conservation of the extracellular part of the P/Q-type channel between 
species, where epitopes for pathogenic antibodies are presumably located (see figure 
3.1).  Additionally there are many examples of functional effects of human LEMS IgG 
in passive transfer to rodents and in rodent in vitro experiments (Pinto et al., 1998; 
Garcia et al., 1996; Lang et al., 1981).  Therefore it is highly likely that antibodies from 
LEMS patients would cross-react with P/Q-type VGCCs native to rat hippocampal 
cultures.  Cells 14-19 days in vitro were used to ensure that the effect of LEMS IgG was 
being tested in relatively mature synapses (Grabrucker et al., 2009). 
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4.4.2 IgG samples used  
IgG from four individual patients with confirmed LEMS was studied and was compared 
to IgG from healthy human controls.  All patients had antibodies that 
immunoprecipitated 125I-ω-MVIIC labeled VGCCs (See table 4.1).  Samples were 
considered to be positive if the anti-VGCC antibody titre was greater than 50 pM.  The 
titres ranged from 261-10,755pM.  Experiments were performed and analysed blind to 
the disease status of each IgG sample.  Two patients also had N-type antibodies.   
 
Sample 
number 
Age at 
disease 
onset 
Gender   Tumor 
status 
Electrophysiology   P/Q ab 
titer 
(pM) 
N- ab titer 
(pM)  
CMAP 
amplitude 
(mV) 
% Increment   
1  48  M  Nil  6.1 mV  146  261  Neg  
2  68  M  Anaplastic 
large cell 
lung 
carcinoma  
2.2 mV  145  575  60 
3  44  F  SCLC  1.2 mV  1,233  10,755  127 
4  58  M  Nil  4.2 mV  281  362  Neg  
Table 4.1 LEMS IgG used in FM expermients 
 
4.4.3 Concentration of IgG Samples  
The neuronal cultures were incubated in Neurobasal A medium supplemented with IgG 
(control or LEMS) at a concentration of 1mg/ml overnight before each experiment.  As 
IgG concentration of individual samples varied from 5-22 mg/ml, the dilutional volume 
for each sample was chosen individually.  This concentration of 1mg/ml was chosen 
based on previous work in which LEMs IgG was incubated with a wide variety of cell 
types including cerebellar neuronal cultures, HEK cells, bovine adrenal chromaffin 212 
 
cells, anterior pituitary cells small cell lung cancer rat cortical synaptosmes, atrial 
myocytes and neuroblastoma cell lines (Pinto et al., 1998; Pinto et al., 2002 ; Hewett 
and Atchison, 1991; Hewett and Atchison, 1992; Houzen et al., 1998; Kim et al., 1988; 
Roberts et al., 1985; Login et al., 1987; Grassi et al., 1994; Viglione et al., 1995; 
Meriney et al., 1996; Johnston et al., 1994).  In these experiments a range of 
concentrations of LEMS IgG from 0.1 to 4 mg/ml was used.  In the cell type most 
similar to ours, cerebellar neuronal cultures, 2 mg/ml LEMS IgG was used (Pinto et al., 
1998), but concentrations as low as 0.4 mg/ml were shown to be effective in anterior 
pituitary cells (Login et al., 1987).  It was decided to use a concentration of 1mg/ml IgG 
in Neurobasal A medium, since this concentration was adequate for examining 
functional effects in many previous studies and because only small samples of LEMS 
IgG were available, precluding the use of higher concentrations.   
 
4.4.4 Duration of exposure to LEMS IgG  
The duration of incubation of neurons with IgG was also considered.  The dissociation 
constant (kd) for antibodies depends on a number of variables, namely the concentration 
of the reactants, the temperature and pH of the solution.  The affinity constants for 
antibodies usually lie in the range 10-6 -10-10 M.  It was decided that with the 
concentrations present, it was likely that several hours would be needed for steady state 
equilibration.  Furthermore, as LEMS antibodies may cause cross-linking and 
internalization of VGCCs, the effects may take some time to develop (Engel et al., 
1988).  In general, when functional effects of antibodies are examined in cultures, the 
IgG is allowed to incubate with the cells for 12-24 hours.  In the system that was most 
similar to ours, Pinto et al., incubated cerebellar neurons with LEMS IgG for 15-22 213 
 
hours (Pinto et al., 1998).  However, there are examples of experimental protocols 
where the acute application of LEMS IgG was shown to have an effect.  Buchwald et 
al., applied LEMS IgG directly to motor nerve terminals by macropatch clamp and an 
acute effect of LEMS IgG on evoked quantal release was demonstrated (Buchwald et 
al., 2005).  Treatment of in vitro hemidiaphragm preparations with LEMS IgG for just 2 
hours can reduce end plate potentials and cause facilitation at high frequency 
stimulation (Flink and Atchison, 2002).  One hour incubation with LEMs IgG is 
sufficient to reduce calcium uptake in rat cortical synaptosomes (Hewett and Atchison, 
1991).  However, the vast majority of experiments in which IgG is incubated with a 
cultured cell system allow for chronic exposure of cell. As arguably this is also the most 
clinically relevant approach, our cultured neruons were incubated with IgG overnight.  
The range of exposure time of neurons to IgG in our experiments was 16-22 hours.   
 
4.4.5 Experimental protocol  
The full experimental protocol is described in Chapter 2 but briefly; experiments were 
performed at room temperature (23-26 °C) 15-19 days after plating.  The imaging 
solution contained (in mM) 125 NaCl. 2.5 KCl, 2 MgCl2, 2 CaCl2, 30 glucose and 25 
HEPES (pH 7.4).  The solution was supplemented with (in μM) 10 2,3-dihydroxy-6-
nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX) and 50 DL-2-amino-5-
phosphonopentanoic acid (DL-AP5) to prevent recurrent activity from synaptically 
connected neurons.   
 
Fluorescence imaging experiments were performed on an inverted epifluorescence 
microscope (Axiovert 135 Zeiss) using a 1.3 NA 63X oil immersion objective and a 214 
 
QuantEM 512 SC EM-CCD camera.  Recycling synaptic vesicles were fluorescently 
labelled using several rounds of saturating field stimulation (4 trains of 120 action 
potentials at 30 Hz) delivered via platinum bath electrodes in the presence of the 
amphiphilic dye SRC1 (SynaptoRed C1) at a bath concentration of 200 μM).  These 
settings were previously calibrated to achieve complete labelling of recycling vesicles 
(Ermolyuk et al., 2012).  Excess dye was subsequently washed out for 15 minutes 
leaving synaptic vesicles specifically labelled.  The SRC1 fluorescence decay was 
monitored.  Images were taken every 40 seconds, first in the absence of stimulation and 
subsequently during low frequency stimulation (0.5 Hz) (450 APs in total).  SRC1 was 
excited with the 488 nm LED.  The light passed through a 500 nm dichroic filter and 
emission fluorescence was collected with a long pass (LP) 510 nm filter.  At the end of 
the experiment, the neurons were subjected to high frequency stimulation (four rounds 
of 300 AP at 10 Hz) to evoke exocytosis of all recycling vesicles at which point, five 
further images were taken.   
 
The methods used in the analysis of these experiments are described in detail in Chapter 
2.  Briefly, images were analysed using Image J (NIH).  Following X-Y alignment of 
consecutive images, active boutons were identified by subtracting the five-frame 
background average acquired after complete destaining from a five-frame average that 
was acquired immediately after SRC1 washout.  Regions of interest (ROIs) 
corresponding to presynaptic boutons were outlined by hand in each frame to 
compensate for small degrees of drift.  For each ROI, the mean pixel intensity integrated 
over the ROI was normalized by the initial maximal level, after subtraction of the image 
after full destaining.  215 
 
 
The TRP (total size of the recycling pool) was calculated by measuring the fluorescence 
signal at the start of imaging (t=0), having subtracted the background fluorescence. The 
spontaneous (kSP) and evoked (kEV) destaining rates were calculated by fitting 
monoexponential functions to the fluorescence time course in each selected ROI, in 
unstimulated or stimulated conditions respectively.  The specific AP-evoked SRC1 
destaining rate was calculated as kAP = kEV–kSP.  Boutons with high spontaneous 
destaining rates (kSP >10-3 s-1) and boutons with low signal-to-noise ratios (χ2 >0.1) were 
excluded from the analysis as it was not possible to fit the monoexponential functions to 
noisy signals accurately.  Noisy signals were sometimes caused by movement of 
fluorescence during the experiment which could be due to mobile vesicles leaving or 
entering a synapse, movement of the synapse itself or particles of dirt in the perfusion 
system.  Cells with high spontaneous destaining rates were generally not healthy and so 
were not included in the analysis.   
 
4.5 Results: Effect of LEMS IgG on synaptic transmission 
 
4.5.1 Estimation of kEV, kSP, kAP and TRP 
The average destaining trace for a single bouton normalised to the fluorescence at  t= 0 
is shown in figure 4.4.  A slow fluorescence decrease in the absence of stimulation 
occurred (blue trace) corresponds to the spontaneous release of synaptic vesicles (kSP).  
Applying low frequency stimulation (0.5 Hz) to the culture led to a faster decrease in 
fluorescence (red trace), giving an estimate of kEV.  The specific rate of of AP evoked 216 
 
fluorescence, kAP, which is proportional to the rate of AP-dependent synaptic vesicle 
exocytosis was estimated (Ermolyuk et al., 2012).  The rate of action potential evoked 
synaptic vesicle exocytosis (kAP) was calculated as kAP= kEV-kSP.  The background 
fluorescence was estimated after complete destaining (three rounds 300 APs at 10 Hz).  
This value was subtracted from the initial fluorescence to get an estimate for the Total 
Recycling Pool size (TRP) in each bouton (before normalisation).   
 
The data were shown in two formats; bar chart and cumulative distributions.  The means 
were best displayed as a bar chart.  Cumulative figures were used as each data point 
represented one experiment, allowing every experiment to be shown.  To acquire the 
cumulative graphs, the data were ranked in ascending order and the normalied 
cumulative distribution (Y axis) was then plotted against each value (X axis).   
 
The time course and a typical destaining trace of a single bouton is illustrated in Figure 
4.4. 217 
 
 
 
 
Figure 4.4 Time course and example trace from a typical experiment.  The fluorescence 
trace was fitted with mono-exponential functions to determine kSP (blue trace) and kEV 
(red trace).  The background fluorescence was measured after high frequency 
stimulation at the end of the experiment (green).  An average of five images taken at the 
end of the experiment was subtracted from an average of five images at the beginning of 
the experiment to estimate RP.  
 
Fluorescence images for a typical control and a typical LEMS treated experiment are 
shown in Figure 4.5.  The destaining profiles for two representative boutons for each 
treatment (LEMS or control) are also shown.  The profiles were fitted with 
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monoexponential functions to denote spontaneous (blue line) and evoked (red line) 
synaptic vesicle release.   
 
Figure 4.5 Fluorescence images and destaining profiles for a typical (a) control and (b) 
LEMS treated hippocampal culture.  Scale bar = 5μm 
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4.5.2 Estimation of TRP size in LEMS treated neurons compared to controls  
The Total Recyling Pool (TRP) was measured by taking the fluorescence signal at t=0 
(the fluorescence signal at the start of imaging having taken the background 
fluorescence into account).  There was no significant difference in the size of the TRP in 
neurons treated overnight with LEMS IgG compared to neurons treated with control 
IgG (p=0.49). (Table 4.2, Figure 4.6) 
 
  Control   LEMS
* 
LEMS 1  LEMS 2  LEMS 3   LEMS 4  
TRP (mean)   2.46  2.16  1.8  2.67  1.49  2.56 
Standard deviation   1.63  1.26  0.34  1.68  1.34  0.94 
SEM  0.36  0.25  0.2  0.75  0.47  0.31 
Number of experiments   21  25  3  5  8  9 
Number of boutons   927  791  47  222  205  317 
Number of culture sets  9  9  1  2  3  3 
Table 4.2. Mean TRP size in LEMS treated neurons compared to control.  *Pooled data 
for all LEMS samples 
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Figure 4.6 Effect of LEMS and Control IgG on relative TRP size. (a) Cumulative 
distributions of mean TRP size values obtained in individual experiments (average of 
10-50 boutons in each experiment).  Data corresponding to samples obtained from each 
individual LEMS patient are shown as thin coloured lines.  LEMS samples 1-4 were 
used in 3, 9, 8 and 6 experiments respectively (b) Mean (± SEM) values for pooled data 
(LEMS IgG (red) n =26 experiments, Control IgG (black) n= 21 experiments) ns, non-
significant)  
 
4.5.3 Estimation of kSP in LEMS treated neurons compared to controls  
The rate of spontaneous neurotransmitter release was significantly reduced by LEMS 
IgG (p <0.05).  The overall effect was a reduction in the rate of spontaneous 
neurotransmitter release of 23% (range 18%-55% reduction for individual LEMS 
samples).  The mean kSP values for neurons treated with each LEMS sample and pooled 
control are shown in table 4.3 and figure 4.7.   
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  Control   LEMS*  LEMS 1  LEMS 2  LEMS 3   LEMS 4  
kSP x 103, s-1(mean)   0.32  0.24  0.14  0.24  0.26  0.27 
Standard deviation   0.07  0.12  0.14  0.11  0.02  0.10 
SEM  0.02  0.02  0.08  0.05  0.01  0.03 
Number of experiments   21  25  3  5  8  9 
Number of boutons   927  791  47  222  205  317 
Number of culture sets  9  9  1  2  3  3 
Table 4.3 Mean kSP in LEMS treated neurons compared to controls.  *Pooled data for 
all LEMS samples 
 
 
 
Figure 4.7 Effect of LEMs and Control IgG on kSP. (a) Cumulative distributions of mean 
kSP values obtained in individual experiments (10-50 boutons in each experiment).  Data 
corresponding to samples obtained from each individual LEMS patient are shown as thin 
coloured lines.  LEMS samples 1-4 were used in 3, 9, 8 and 6 experiments respectively. 
Thick red line =pooled LEMS IgG data; thick black line = control IgG data. (b) Mean (± 
SEM) values for pooled data (LEMS IgG (red) n =26 experiments, control IgG (black) 
n= 21 experiments) *, p < 0.05  
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4.5.4 Estimation of kEV in LEMS treated neurons compared to controls  
kEV was calculated as the rate of fluorescence decay during low frequency stimulation 
(0.5 Hz) and includes both spontaneous and action potential dependant synaptic vesicle 
release.  Overnight incubation with LEMS IgG caused a significant reduction in the rate 
of evoked synaptic vesicle release by an average of 24% (p<0.01).  The range of 
reduction in kEV was 20-47% (Table 4.4, Figure 4.8).   
 
  Control   LEMS*  LEMS 1  LEMS 2  LEMS 3   LEMS 4  
kEV x 103, s-1 (mean)   0.96  0.73  0.5  0.75  0.77  0.75 
Standard deviation   0.22  0.16  0.18  0.13  0.21  0.1 
SEM  0.05  0.03  0.1  0.06  0.07  0.03 
Number of experiments   21  25  3  5  8  9 
Number of boutons   927  791  47  222  205  317 
Number of culture sets  9  9  1  2  3  3 
Table 4.4 Mean kEV in LEMS treated neurons compared to controls.  *Pooled data for 
all LEMS samples 
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Figure 4.8 Effect of LEMs and control IgG on kEV. (a) Cumulative distributions of mean 
kEV values obtained in individual experiments (average of 10-50 boutons in each 
experiment).  Data corresponding to samples obtained from each individual LEMS 
patients are shown as thin coloured lines.  LEMS samples 1-4 were used in 3, 9, 8 and 6 
experiments respectively. (b) Mean (± SEM) values for pooled data (LEMS IgG (red) n 
=26 experiments, control IgG (black) n= 21 experiments) ** p<0.01 
 
4.5.5 Estimation of kAP in LEMS treated neurons compared to controls  
We next analysed the rate of action potential evoked synaptic vesicle release in neurons 
treated with LEMS IgG compared to those treated with control IgG.  Overnight 
incubation with LEMS IgG (1mg/ml) reduced the rate of AP-dependent destaining by 
an average of 25% compared to neurons treated with control IgG (p <0.05).  LEMS 
samples from all four patients resulted in a lower rate of exocytosis that the pooled 
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control sample with the size of the reduction ranging from 20% to 43% (Table 4.5; 
Figure 4.9).   
 
  Control   LEMS
* 
LEMS 1  LEMS 2  LEMS 3   LEMS 4  
kAP x 103, s-1(mean)   0.65  0.49  0.37  0.51  0.51  0.48 
Standard deviation   0.21  0.20  0.30  0.2  0.23  0.17 
SEM  0.05  0.04  0.17  0.09  0.08  0.06 
Number of 
experiments  
21  25  3  5  8  9 
Number of boutons   927  791  47  222  205  317 
Number of culture 
sets 
9  9  1  2  3  3 
Table 4.5 Mean kAP in LEMS treated neurons compared to control.  *Pooled data for all 
LEMS samples 
 
 
Figure 4.9 Effect of LEMS and Control IgG on kAP. (a) Cumulative distributions of 
mean kAP values obtained in individual experiments (average of 10-50 boutons in each 
experiment).  Data corresponding to samples obtained from each individual LEMS 
patient are shown as thin coloured lines.  LEMS samples 1-4 were used in 3, 9, 8 and 6 
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experiments respectively (b) Mean (± SEM values for pooled data (LEMS IgG (red) n 
=26 experiments, control IgG (black) n= 21 experiments) *  p<0.05   
 
4.6 Effect of seronegative LEMS IgG on synaptic transmission  
 
Having confirmed that LEMS samples that contain antibodies directed against P/Q type 
channels reduce action potential evoked synaptic vesicle release; the next step was to 
test the effect of IgG from a patient with clinically confirmed LEMS but no 
demonstrable antibodies on radioimmunoprecipitation assay, either to either N or P/Q-
type VGCCs.  
The experiments were conducted in the same way as described above.   
 
4.6.1 Effect of seronegative LEMS IgG on TRP size  
Incubation of neuronal cultures with seronegative IgG overnight had no significant 
effect on the mean TRP size compared to incubation with control IgG (p=0.5) (Table 
4.6, Figure 4.10). 
 
  Control   Seronegative LEMS 
Normalised TRP  3.98  2.2 
Standard deviation   2.45  1.38 
SEM  1.4  0.69 
Number of experiments   3  4 
Number of boutons   158  271 
Number of cultures  1  1 
Table 4.6 Mean TRP size in seronegative LEMS treated neurons compared to controls 226 
 
 
Figure 4.10 Effect of Seronegative LEMS and Control IgG on relative TRP size. (a) 
Cumulative distribution of TRP size in seronegative LEMS (red) compared to control 
IgG (black) (b) Mean (± SEM values) for pooled data (LEMS IgG n=4 experiments, 
Control IgG n= 3 experiments) ns, non-significant.  
 
4.6.2 Effect of seronegative LEMS IgG on kSP  
Treatment with seronegative LEMS IgG did not cause a significant alteration in the rate 
of spontaneous synaptic vesicle release in neurons in culture (p=0.22) (Table 4.7, Figure 
4.11)  
 
  Control   Seronegative LEMS 
kSP x 103, s-1  0.3  0.18 
Standard deviation   0.11  0.1 
SEM  0.06  0.05 
Number of experiments   3  4 
Number of boutons   158  271 
Number of cultures  1  1 
Table 4.7 Mean kSP size in seronegative LEMS treated neurons compared to controls 
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Figure 4.11 Effect of seronegative LEMS and control IgG on kSP. (a) Cumulative 
distributions of mean kSP values obtained in seronegative LEMS experiments (red) and 
control IgG experiments (black) (b) Mean (± SEM) values for pooled data 
(Seronegative LEMS IgG n =4 experiments, Control IgG n= 3 experiments) ns, non-
significant  
 
4.6.3 Effect of seronegative LEMS IgG on kEV 
The kEV was not significantly different in neurons treated with seronegative LEMS IgG 
compared to those treated with control IgG (p=0.5) (Table 4.8, Figure 4.12).   
  Control   Seronegative LEMS 
kEV x103 , s-1  0.82  0.7 
Standard deviation   0.2  0.24 
SEM  0.13  0.06 
Number of experiments   3  4 
Number of boutons   158  271 
Number of cultures  1  1 
Table 4.8 Mean kEV in seronegative LEMS treated neurons compared to controls 
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Fig. 4.12 Effect of seronegative LEMS and control IgG on kEV. (a) Cumulative 
distributions of mean kEV values obtained in seronegative LEMs experiments (red) and 
control IgG experiments (black) (b) Mean (± SEM) values for pooled data 
(Seronegative LEMS IgG n =4 experiments, control IgG n= 3 experiments) ns, non-
significant)  
 
4.6.4 Effect of seronegative LEMS IgG on kAP 
The results for action potential evoked synaptic vesicle release are displayed in Table 
4.9 and Figure 4.14.  There was no significant difference in the rate of action potential 
evoked synaptic vesicle release (p=0.95) (Table 4.9, Figure 4.13). 
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Treatment   Control  Seronegative  LEMS  
kAP x 103, s-1 (mean)   0.52  0.51 
Standard Deviation   0.12  0.28 
SEM   0.07  0.14 
Number of experiments   3  4 
Number of boutons   158  271 
Number of cultures  1  1 
Table 4.9 Mean kAP in seronegative LEMS compared to control IgG  
 
Fig 4.13 Effect of seronegative LEMS and control IgG on kAP. (a) Cumulative 
distributions of mean kAP values obtained in seronegative LEMS experiments (red) and 
control IgG experiments (black) (b) Mean (± SEM) values for pooled data 
(Seronegative LEMS IgG n =4 experiments, control IgG n= 3 experiments) ns, non-
significant  
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4.7 Discussion 
 
It has been accepted for many years that LEMS is an autoimmune disease and that 
LEMS antibodies affect synaptic transmission.  Recordings from intercostal muscle 
biopsies of patients with LEMS have shown that the amplitudes of the EPP evoked by 
nerve stimulation are significantly reduced compared to controls (Lambert and 
Elmqvist, 1971).  Similar findings have been described in passive transfer models of 
LEMS, where mice treated with LEMs IgG show a significant reduction in quantal 
content/ EPP amplitude (Lang et al., 1987; Giovannini et al., 2002; Flink et al., 2002).  
Curves of log EPP quantal content vs calcium concentration, are shifted to the right by 
LEMS IgG (Lang et al., 1987).  As LEMS antibodies have been shown to reduce 
calcium current in a wide variety of cell types and IgG from LEMS patients can 
immunoprecipitate VGCCs in vitro, it has been proposed that LEMS antibodies affect 
synaptic transmission by binding to VGCCs and reducing the nerve action potential 
evoked Ca2+ influx that is necessary for the release of vesicles containing acetylcholine.  
This hypothesis is supported by the phenomenon of facilitation of the postsynaptic 
response in response to high frequency stimulation that occurs in LEMS.   
 
Previously, evidence for the effect of LEMS antibodies on synaptic vesicle release has 
been indirect.  The presynaptic imaging data described here directly show that LEMS 
IgG decreases AP-dependent synaptic vesicle release in rat hippocampal neuronal 
cultures.  Although this finding was not unexpected, this work provides the missing link 
and conclusively shows that the rate of synaptic vesicle release is reduced at LEMS 
treated synapses.   231 
 
 
VGCCs, mainly of the P/Q- and N- type are known to play a major role in action 
potential evoked synaptic transmission both at central synapses and at the 
neuromuscular junction and antibodies that affect these channels, as is thought to be the 
case in LEMs, would be expected to impede evoked neurotransmitter release.  However, 
the role of VGCCs in spontaneous neurotransmission has up to recently been less clear 
and therefore the effect of LEMS IgG on spontaneous vesicle release could be 
considered surprising.  In the past, mEPP amplitudes were shown not to be reduced in 
muscle biopsies from LEMS patients (Lambert and Elmqvist, 1972) or in passive 
transfer models of LEMS.  (Lang et al., 1987; Giovannini et al., 2002; Flink et al., 
2002.)  However, mEPP frequency was found to be reduced when recorded in solutions 
containing high K+ concentrations (Lang et al., 1987; Kim et al., 1986).   
 
Spontaneous (action potential independent) neurotransmitter release occurs at the 
majority of synapses (Xu et al., 2009) and can be measured at the muscle fibre end plate 
as mEPPS and at neuronal synapses as “minis” or miniature excitatory or inhibitory post 
synaptic currents (mEPSC or mIPSCs).  As outlined previously, it is now known that a 
large part of spontaneous neurotransmitter release is Ca2+ dependent and moreover, it 
was recently found in our laboratory that 50% of mEPSCs depend on the stochastic 
opening of VGCCs (Ermolyuk et al., 2013).  The observation in the experiments 
described above, that spontaneous neurotransmitter release is reduced in the presence of 
LEMS IgG is in keeping with this.  These data are also in keeping with the findings of 
Lang et al., who found that there was a reduced rate of spontaneous ACh release from 
nerve diaphragm preparations of mice passively treated with LEMS IgG (Lang et al,. 232 
 
1984).  However, my experiments were not specifically designed to measure 
spontaneous vesicle release.  Action potentials were not blocked with tetrodotoxin and 
as many other factors such as cell health can affect the rate of spontaneous synaptic 
vesicle release, there are limitations to the conclusions that can be drawn about the 
effect of LEMS IgG on spontaneous exocytosis.   
 
All four LEMS samples that had high titres of anti P/Q-type antibodies that were tested 
caused a reduction in the spontaneous and evoked synaptic vesicle release.  However, 
the magnitude of the effect varied from sample to sample and this could not be 
correlated to the titre of antibodies in each sample.  It was found, however, that there 
was substantial variability in kSP values obtained from different boutons on the same 
coverslip and also between different experiments.  The values for kAP also varied 
substantially.  Variability of neurotransmitter release at hippocampal synapses depends 
on a number of different factors, including the number of release ready vesicles (which 
is influenced by synaptic bouton size) and the fusion probability of individual vesicles 
(Ermolyuk et al., 2012).  A strong correlation has been found between the fusion 
probability of synaptic vesicles and the magnitude of AP- evoked presynaptic Ca2+ 
influx amongst synaptic boutons located along the same axon (Ermolyuk et al., 2012).  
This could, at least in part, explain the variability in the kSP and kAP values in these 
experiments.   
 
An effect on synaptic vesicle release from a “seronegative” LEMS sample could not be 
demonstrated in these experiments.  Passive transfer of LEMS samples that lack any 
detectable antibodies have been shown to transfer the electrophysiological features of 233 
 
LEMS to animals (Nakao et al., 2002) suggesting that the disease is antibody mediated 
and therefore these results are somewhat surprising.  However, only a limited number of 
experiments with “seronegative” IgG were performed on only one culture set and 
therefore these results must be interpreted with caution; perhaps a larger sample number 
is required to detect a subtle effect, particularly considering the high degree of 
variability intrinsic to these experiments.  Alternatively the mechanism of action of 
these antibodies may be different to that of classical “seropositive” LEMS.  Further 
studies with more seronegative LEMS IgG samples would be required to resolve this 
question.     234 
 
5 The effect of LEMS IgG in neurons lacking P/Q- calcium 
channels 
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5.1 Background 
It was shown in the previous chapter that LEMS antibodies reduce the rate of synaptic 
vesicle release.  The next step was to use this information to define the antigenic target 
of LEMS IgG.  Although a compelling account of the pathophysiology of LEMS is that 
IgG binding to P/Q-type VGCCs lead to a decrease in neurotransmitter release, 
available data do not exclude the possibility that different antibodies to different 
antigens affect current through VGCCs and hence, exocytosis of synaptic vesicles. 
 
5.1.1 Antigenic target in LEMS – radioimmunoprecipitation assays  
The antigenic target of antibodies in LEMS is thought to be the presynaptic VGCC. 
Radioimmunoprecipitation assays using 125-I-ω-contoxin MVIIC (125I-ω-CnTx) labelled 
VGCCs precipitated from mammalian brain detect antibodies against P/Q- type 
channels in over 90% of LEMS patients (Motomura et al., 1997).  A variable proportion 
of LEMS patients also have antibodies to N-type channels that are precipitated with 125I-
ω-conotoxin GVIA (125 I-ω-CgTx) (Sher et al., 1989; Lennon et al., 1989; Leys et al., 
1991; Leys et al., 1989; Lennon et al., 1995; Suenaga et al., 1996).  In the most specific 
assay for LEMS antibodies described by Motormura et al., 92% of LEMS patients have 
antibodies against P/Q type VGCCs and 33% have antibodies to N-type channels 
detected using 125I--Conotoxin-GVIA (Motomura et al., 1995; 1997).  In this group, 
all patients with N-type antibodies also had antibodies directed against P/Q- type 
VGCCs.  However the functional significance of N-type antibodies is unknown 
(Motomura et al., 1997).  
 236 
 
5.1.2 Antigenic target in LEMS – functional studies  
Functional studies have attempted to define the specific targets of antibodies in LEMS.  
As discussed in the Introduction, the effect of LEMS IgG on Ca2+ current was first 
shown in SCLC cells, which are known to express VGCCs (Roberts et al., 1985; 
Johnston et al., 1994; Lang et al., 1989; Viglione et al., 1995), suggesting this as the 
antigenic target.  LEMS IgG has also been shown to reduce Ca2+ currents in a variety of 
other cell types including bovine adrenal chromaffin cells (Kim and Neher, 1988), 
motor neurons, (Garcia et al,. 1996), neuroblastoma cells, (Peers et al., 1990) 
insulinoma cells, (Magnelli et al., 1996) and IMR 32 cells (Grassi et al., 1994), all of 
which express VGCCs.  Additionally passive transfer of LEMS IgG has been shown to 
reduce Ca2+ currents at the motor nerve terminals of mice by over 50% (Smith et al., 
1995), where VGCCs are also expressed.   
 
5.1.3 Specific calcium channel targeted by LEMS IgG  
A number of studies have employed specific Ca2+ channel toxins to help determine 
which specific types of VGCCs are affected by LEMS IgG.  Some of these studies have 
suggested that LEMS IgG can target multiple different VGCC subtypes.  Engisch et al. 
studied the effect of LEMS antibodies on Ca2+ currents and exocytosis in bovine adrenal 
chromaffin cells (Engisch et al., 1999).  By pharmacologically isolating specific calcium 
channels, they showed that IgG from all five of their LEMS patients significantly 
inhibited P/Q –type current and in addition, two of the five samples also significantly 
reduced N-type current.  This implied that IgG from a single patient can act on at least 
two different VGCC subtypes (Engisch et al., 1999).  There have been conflicting data 
regarding the effect of LEMS IgG on VGCCs in SCLC cells.  In one study application 237 
 
of LEMS IgG decreased P/Q type currents and to a lesser extent, L-type currents, 
whereas N-type currents were unaffected (Viglione et al., 1995).  However another 
study of the effects of LEMS IgG on SCLC VGCC currents showed that multiple 
different types of High Voltage Activated (HVA) VGCCs were affected including both 
P/Q- type and N-type currents (Meriney et al., 1996).  In motor neurons LEMS sera 
reduced both HVA and Low Voltage Activated (LVA) components of the Ca2+ current; 
but within the HVA component, L-type currents were spared (Garcia and Beam, 1996).  
In contrast, an earlier study found that LEMS IgG selectively reduced L-type currents in 
neuroblasotoma x glioma hybrid cell lines but did not affect T-type VGCCs (Peers et 
al., 1990).  LEMS IgG was also found to reduce current thorough L-type VGCCs in 
IMR32 cells, but N-type currents were more severely affected by LEMS IgG in these 
experiments (Grassi et al., 1994).  In the rat insulinoma RINm5F cell line, LEMS IgG 
reduced the dihyrdropyridine sensitive L-type current by 20-30% but current through Q-
type channels was reduced by 31-36% (Magnelli et al., 1996). 
 
There have been a number of studies that have suggested that the effect of LEMS IgG is 
specific for P/Q-type VGCCs.  LEMS IgG has been found to affect Ca2+ currents from 
murine neonatal motor neurons to a greater extent than in murine neonatal sensory 
neurons (Garcia and Beam, 1996).  As the predominant VGCC subtype in sensory 
neurons are N-type channels and P/Q-type are the predominant type in motor neurons 
(Mintz et al., 1992), these findings may also be taken as  evidence supporting 
pathogenic effects of LEMS IgG through their actions on P/Q-type channels (and also 
may explain the lack of sensory findings in LEMS patients).  Moreover, LEMS IgG has 
been shown to decrease neurotransmitter release from autonomic nerve terminals 
subserved by P/Q- but not N- type channels (Houzen et al., 1998).   238 
 
 
The use of HEK 293 cells transfected with cDNA closes encoding human VGCCs 
proteins has provided strong evidence that P/Q type channels are specifically affected 
by LEMS IgG.  Voltage dependent Ca2+ entry into cell lines expressing P/Q-type 
VGCCs was reduced by LEMS IgG whereas current through N- type channels was not 
affected (Pinto et al., 2002).  These findings were particularly interesting as two of the 
six samples used in these experiments were shown to bind to 125I--ctx-GVIA-labelled 
(N-type) channels expressed in a cell line.  Even LEMS samples that were shown to 
bind to extracellular antigens of N-type VGCCs did not reduce current through N-type 
VGCCs (Pinto et al. 2002).  Incubation of cerebellar granule and Purkinje cells with 
LEMS IgG was also shown to lead to a significant reduction in the ω-aga-IVA sensitive 
Ca 2+ current (P/Q-type) whereas the ω-ctx-GVIA sensitive (N-type) current was 
unaffected (Pinto et al. 1998).  This suggested that LEMS IgG exerts its effect 
exclusively through an action on P/Q-type channels with no functional effect on N-type 
currents.   
 
The above studies are conflicting and show that the effect of LEMS IgG on non P/Q 
VGCCs is far from certain.  In particular, it is not clear whether N-type channels are 
affected by LEMS IgG.  This is relevant as up to 33% of LEMS patients have antibodies 
against N-type channels detectable in their serum and the pathological significance of 
these antibodies is unknown (Motormura et al., 1997).  There are a couple of possible 
reasons for the discrepancies in the literature.  It is possible that the effect on certain 
VGCCs is specific to individual patients’ sera with some sera reducing current through 
N-type channels and other sera having no effect.  It is also possible that N-type current 239 
 
is affected by LEMs IgG but that the smaller relative effect is more difficult to detect in 
certain cell types. 
 
P/Q-type channels are the predominant VGCC required for Ca2+ entry during synaptic 
transmission both at central and peripheral synapses (Protti and Uchitel, 1993; Uchitel 
et al., 1992; Cao and Tsien, 2010; Luebke et al., 1993; Takahashi et al., 1993; Wheeler 
et al. 1994) and hence any disruption to the function of P/Q type VGCCs would be 
expected to impair neuromuscular transmission.  However, N-type channels do play a 
role in synaptic transmission and it is important to define specifically which VGCCs are 
affected in LEMS.   
 
5.2 Specific aims of this chapter 
 
Using the SRC1 fluorescent imaging approach outlined in Chapter 4, the aim of the 
experiments in this chapter was to measure the rate of spontaneous and action potential 
evoked synaptic vesicle release in synapses lacking P/Q channels from Cacna1a 
knockout (KO) mice.  I was particularly interested to ascertain whether LEMS IgG 
would reduce the rate of evoked release in these neurons compared to wild type (WT) 
cells.  A colony of Cacna1a knockout mice was established in our laboratory, which 
were a kind gift of A Van den Maagdenberg.  As outlined in the Introduction, these 
mice are normal in utero and at birth, but develop a rapidly progressive ataxic and 
dystonic phenotype from postnatal day 10 resulting in death after three weeks (Jun et 
al., 1999).   240 
 
 
The specific aim of these experiments was firstly to define the electrophysiological 
characteristics of WT and Cacna1a KO neuronal cultures and then to compare the effect 
of LEMS IgG on synaptic transmission in cultures lacking P/Q-calcium channels to the 
effect of LEMS IgG in WT synapses. 
 
5.3. Results 
 
5.3.1. Electrophysiological characteristics of Cacna1a knockout neurons  
The first step was to define the electrophysiological characteristics of Cacna1a 
knockout neurons.  Specifically the aim was to define which VGCCs contributed to 
synaptic transmission in synapses lacking P/Q-type channels.  Whole cell patch clamp 
experiments were performed and excitatory postsynaptic currents (EPSCs) were 
recorded from postsynaptic cells after stimulation with an extracellular electrode.  
EPSCs were recorded at baseline and after sequential application of specific VGCCs 
antagonists to block P/Q-type, N-type and R-type VGCCS (agatoxin IVA 250 nM, 
conotoxin GVIA 5μM and SNX 482 200 nM respectively).  The EPSC amplitudes at 
baseline (before addition of toxins) was normalised to 1 to allow comparison of the 
effect of the individual toxins between WT and Cacna1a knockout experiments.   
 
In wild type neurons it was found that blocking P/Q-type VGCCs with agatoxin IVA 
reduced the amplitude of the EPSC by 70%.  Subsequent application of conotoxin 
GVIA reduced EPSC amplitude to 9% of baseline and finally application of SNX 482 241 
 
almost completely obliterated the post synaptic response.  In contrast, application of 
agatoxin IVA to synapses lacking P/Q-type channels did not cause any significant effect 
to EPSC amplitude.  However, blockage of N-type channels with conotoxin GVIA 
reduced EPSC amplitude by 70% and SNX 482 reduced EPSC amplitude by a further 
20%.  After application of the three calcium channel toxins, there remained a residual 
postsynaptic response, at 10% of baseline (Table 5.1).  
 
  EPSC amplitude (normalised to EPSC amplitude at baseline)  
  Baseline  Agatoxin IVA   Conotoxin GVIA   SNX 482  
Control (n=10)     
SD                               
SEM 
1  0.3                           
0.16                  
0.04                      
0.09                     
0.17                  
0.02             
0.02                           
0.03                             
0.01 
KO (n=6)          
SD                       
SEM 
1  0.94                        
0.3                                          
0.18 
0.29                      
0.21                   
0.03               
0.1                      
0.16                       
0.02 
Table 5.1. EPSC amplitude in WT and KO neuronal cultures at baseline and after 
sequential treatment with specific VGCC toxins (normalised to EPSC at baseline).  242 
 
 
Figure 5.1 Synaptic transmission in Cacna1a-/- neurons depends on N- and R-type 
VGCCs. (a) Typical experiments showing evoked excitatory postsynaptic current 
(EPSC) amplitude plotted against time in WT (left) and Cacna1a knockout (KO, right) 
neurons before (black) and after sequential application of the P/Q-type blocker ω-Aga 
IVA (250 nM; red), the N-type blocker ω-Ctx GVIA (5 μM; blue), and the R-type 
blocker SNX-482 (200 nM; grey). Insets: representative EPSCs before (black) and after 
addition of each blocker (colours as for scatter plot). Scale bar: 50 pA, 20 ms. (b): 
normalized EPSC amplitudes in WT (left) and Cacna1a knockout (right) neurons after 
sequential application of the VGCC blockers (WT, n = 10; KO, n = 6; *, p < 0.05).  
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5.3.2 Effect of LEMS IgG in synapses lacking P/Q-type VGCCs 
The above experiments demonstrated that neuronal cultures from Cacna1a knockout 
mice lack functional P/Q-type VGCCs and synaptic transmission is largely dependent 
on current through N-type VGCCs.  The next step was to test whether LEMS IgG 
reduced synaptic vesicle release in these neuronal cultures lacking functional P/Q-type 
VGCCs. 
 
One LEMS IgG sample was selected to use in these experiments.  The sample was 
chosen precipitated a high titre of P/Q-antibodies and also N-type antibodies at a lower 
titre.  This was sample 3 highlighted in Chapter 4.  It was hypothesised that if the N-
type antibodies in this sample were pathogenic, this would be revealed by difference 
between LEMS IgG and Control IgG treated Cacna1a KO cultures, which lack P/Q-type 
channels but retain N-type channels.  
 
The experiments were conducted in the same way as described in Chapter 4. 
Representative bouton traces and destaining profiles for WT and KO samples treated 
with control or LEMS IgG are shown in Figure 5.2. 
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Fig 5.2 (a,b,c,d,) Representative SRC1 imaging experiments in WT cultures treated with 
control (a) or with LEMS IgG (b) and KO cultures treated with control (c) or with 
LEMS IgG (d). Fluorescence microscopy images (top) show loss of fluorescence at 
different time points during the experiment.  Fluorescence time-courses in two pairs of 
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representative boutons (arrows) are shown below.  Spontaneous and evoked destaining 
rates were fitted with monoexponential curves. Scale bars: 10 μm. 
 
5.3.2.1 TRP 
Firstly, the size of the TRP in LEMS treated neurons compared to controls in KO and 
WT neurons was analysed.  There was no significant difference in the size of the TRP in 
LEMS treated neurons compared to neurons treated with control IgG in both WT 
neurons (p=0.6) and KO neurons (p =0.9) (Table 5.2, Figure 5.3).   
 
  Control IgG 
treated WT 
neurons  
LEMS IgG 
treated WT 
neurons  
Control IgG 
treated KO 
neurons  
LEMS IgG 
treated KO 
neurons  
TRP (mean)  2.14  2.5  1.9  1.8 
SD  0.97  1.34  1.8  1.1 
SEM  0.24  0.61  0.23  0.53 
Number of 
experiments 
16  5  12  5 
Number of 
boutons 
602  108  300  143 
Number of 
cultures 
10  5  9  5 
Table 5.2. Mean TRP size in LEMS treated neurons compared to control  
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Figure 5.3 Effects of LEMS and Control IgG on relative TRP size in WT and Cacna1a+/- 
(knockout, KO) neurons. (a) Cumulative distributions of mean TRP size values obtained 
in individual experiments. Data are from 602 boutons in 15 experiments (WT, Control, 
black line), 138 boutons in five experiments (WT, LEMS, grey), 303 boutons in 15 
experiments (KO, Control, red), and 175 boutons in 6 experiments (KO, LEMS, pink). 
(b) Mean (± SEM) values for the pooled data.  NS, non-significant. 
 
5.3.2.2 kSP 
The next step was to analyse the effect of LEMS IgG on spontaneous synaptic vesicle 
release.  LEMS IgG caused a significant increase in the rate of spontaneous synaptic 
vesicle release in WT neurons (p<0.01) but not in KO cultures (p=0.61) (Table 5.3, 
Figure 5.4).   
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  Control IgG treated 
WT neurons  
LEMS IgG 
treated WT 
neurons  
Control IgG 
treated KO 
neurons  
LEMS IgG 
treated KO 
neurons  
kSP x103, s-1 
(mean) 
0.3  0.4  0.3  0.27 
SD  0.06  0.04  0.047  0.09 
SEM  0.02  0.02  0.02  0.04 
Number of 
experiments 
16  5  12  5 
Number of 
boutons 
602  108  300  143 
Number of 
cultures 
10  5  9  5 
Table 5.3. Mean kSP in LEMS treated neurons compared to neurons treated with control 
IgG at WT and KO synapses  
 
Figure 5.4 Effects of LEMS and control IgG on kSP in WT and Cacna1a+/- (knockout, 
KO) neurons. (a) Cumulative distributions of kSP values obtained in individual 
experiments. Data are from 602 boutons in 15 experiments (WT, Control, black line), 
138 boutons in five experiments (WT, LEMS, grey), 303 boutons in 15 experiments (KO, 
Control, red), and 175 boutons in 6 experiments (KO, LEMS, pink). (b) Mean (± SEM) 
values for the pooled data. **, p < 0.01; ns, non-significant. 
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5.3.2.3 Effect of LEMS IgG kEV in neurons lacking P/Q-type VGCCs 
Next, the effect of LEMS IgG on the rate of evoked synaptic vesicle release in WT and 
KO neuronal cultures was analysed.  Treatment with LEMS IgG significantly reduced 
the kEV in WT neurons (p <0.01) but had no significant effect in neurons lacking P/Q 
type channels (p=0.8) (Table 5.4, Figure 5.5).   
 
  Control IgG 
treated WT 
neurons  
LEMS IgG 
treated WT 
neurons  
Control IgG 
treated KO 
neurons  
LEMS IgG 
treated KO 
neurons  
kEV x 103, s-1 
(mean) 
1.13  0.72  1.17  1.1 
SD  0.37  0.19  0.51  0.49 
SEM  0.09  0.08  0.15  0.22 
Number of 
experiments 
16  5  12  5 
Number of 
boutons 
602  108  300  143 
Number of 
cultures 
10  5  9  5 
Table 5.4 Mean kEV in LEMS treated neurons compared to neurons treated with control 
IgG at WT and KO synapses  
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Figure 5.5 Effects of LEMS and control IgG on kEV in WT and Cacna1a+/- (knockout, 
KO) neurons.  (a) Cumulative distributions of kEV values obtained in individual 
experiments.  Data are from 602 boutons in 15 experiments (WT, Control, black line), 
138 boutons in five experiments (WT, LEMS, gray), 303 boutons in 15 experiments (KO, 
Control, red), and 175 boutons in 6 experiments (KO, LEMS, pink). (b) Mean (± SEM) 
values for the pooled data.  **, p < 0.01; ns, non-significant. 
 
5.3.2.4. kAP 
The rate of action potential evoked release in wild type and Cacna1a -/- neurons is 
shown in figure 5.5 and table 5.5.  As was shown in the previous chapter, LEMS IgG 
caused a significant reduction in the rate of action potential evoked release in WT 
cultures (p<0.01).   
However, there was no significant effect on the rate of action potential evoked synaptic 
vesicle release in synapses lacking P/Q type channels (p = 0.8)  (Table 5.5, Figure 5.6).   
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  Control IgG treated 
WT neurons 
LEMS IgG 
treated WT 
neurons  
Control IgG 
treated KO 
neurons  
LEMS IgG 
treated KO 
neurons 
kAP x 10-3, s-1 
(mean) 
1.65  0.73  1.86  1.43 
SD  0.8  0.34  1.11  1.03 
Number of 
experiments  
15  6  15  6 
Number of 
boutons  
602  138  303  175 
Number of 
cultures 
10  5  9  5 
Table 5.5. Mean kAP in LEMS treated neurons compared to neurons treated with control 
IgG in WT and KO neuronal cultures 
 
Fig 5.6 Effects of LEMS and control IgG on kAP in WT and Cacna1a+/- (knockout, KO) 
neurons. (a) Cumulative distributions of kEV values obtained in individual experiments.  
Data are from 602 boutons in 15 experiments (WT, Control, black line), 138 boutons in 
five experiments (WT, LEMS, grey), 303 boutons in 15 experiments (KO, Control, red), 
and 175 boutons in 6 experiments (KO, LEMS, pink) (b) Mean (± SEM) values for the 
pooled data. **, p < 0.01; ns, non-significant. 
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5.4 Discussion  
 
In this chapter, my first task was to characterise the electrophysiology of synaptic 
transmission in Cacna1a -/- neuronal cultures.  The calcium channels involved in 
synaptic transmission were identified by sequential application of toxins to block 
specific VGCC types while recording EPSC amplitude in whole cell voltage clamp 
experiments.  It was found that ω-Aga IVA had no effect on synaptic transmission in 
KO cultures but that there was an enhanced dependence on N-type VGCCs.  Synaptic 
transmission in WT cultures was mainly dependent on Ca2+ current through P/Q type 
VGCCs.  These data were consistent with similar experiments performed in cultured 
hippocampal cells by Cao and Tsien (Cao and Tsien, 2010) and with previous work 
performed in hippocampal brain slices and neuromuscular end plates from knockout 
mice (Jun et al., 1999; Urbano et al., 2003).   
 
Having confirmed that synaptic transmission in cultures from P/Q- knockout mice was 
dependent on N- and R-type VGCCs, the effect of LEMS IgG on action potential 
evoked synaptic vesicle release at these synapses was tested.  As was demonstrated for 
WT rat cultured hippocampal neurons in Chapter 4, LEMS IgG significantly impaired 
synaptic transmission in WT synapses.  However, there was no significant effect of 
LEMS IgG in synapses lacking P/Q-type channels.  This is the first time to our 
knowledge that the effect of LEMS IgG has been tested in synapses lacking P/Q-type 
channels.   
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These findings are consistent with our knowledge regarding which VGGCs are 
responsible for neurotransmitter release at the NMJ and at central synapses (Protti and 
Uchitel, 1993; Cao and Tsien, 2010; Luebke et al., 1993; Takahashi and Momiyama,. 
1993; Wheeler et al., 1994).  The data are also consistent with the work of Pinto et al 
(Pinto et al. 1998; 2002) in which LEMS IgG decreased current through HEK cells 
transfected with P/Q-type VGCC subunits but not with N-type subunits.  However, 
transfected VGCCs in HEK cells may not always be an accurate representation of 
VGCCs in vivo due to splice variations or different subunit combinations.  Furthermore, 
the efficiency of transfection may differ for different subunits and thereby alter the size 
of the currents, raising the possibility of masking a real effect of LEMS IgG on N-type 
channels if the transfection efficiency is high (Flink and Atchison 2003).  The work 
described here, demonstrating that LEMS IgG has no effect on neuronal synapses that 
lack P/Q-type channels provides further evidence about the VGCC specificity of LEMS 
IgG.  These data are also consistent with results from passive transfer studies where ω-
aga IVA is 30% less effective in reducing the amplitude of Ca2+ currents recorded from 
motor nerve terminals of mice passively injected with LEMS IgG compared to controls 
(Xu et al., 1998) suggesting a prominent effect on P/Q-type VGCCs.   
 
The conclusions are limited by the fact that only one IgG sample was tested on KO 
cultures in these experiments.  However, as this sample precipitated N-type VGCCs in 
radioimmunoprecpitation assay, one would expect to see an effect if one existed, as 
synaptic vesicle release in these synapses is largely dependent on Ca2+ entry through N-
type channels.   
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Spontaneous neurotransmitter release was not reduced by LEMS IgG in these 
experiments. In fact, an increase in the spontaneous vesicle release was seen in WT 
neurons treated with LEMS IgG.  This contrasts with the experiments in WT rat 
neuronal cultures where LEMS IgG reduced the rate of spontaneous synaptic vesicle 
release by 24%.  The reason for this discrepancy is unclear.  The IgG sample that was 
used in these experiments had not caused a statistically significant reduction in the 
spontaneous release rate in WT rat experiments and this lack of an effect could be 
sample specific.   
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6 Thymectomy in the management of MG   
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6.1 Background  
Advances in the treatments for MG have improved the mortality and morbidity from 
MG considerably in recent years – the mortality of MG has reduced from over 30% in 
the 1930s to below 5% now (Christensen et al., 1998).  Therapy for MG takes the form 
of symptomatic treatment with pyridostigmine or immunomodulatory treatment with 
steroids, steroid sparing agents, plasma exchange and IVIG.  Despite these advances in 
medical therapy thymectomy remains an integral part of the treatment with MG.    
 
Thymectomy has been used in the management of MG since the 1930s when Blalock et 
al. reported the remission of generalized MG in a 21 year old woman following removal 
of a thymic tumour (Blalock et al., 1939).  Subsequently thymectomy was performed on 
patients without thymoma (Gronseth and Baron, 2000) and a good outcome was 
especially described in patients who had a hyperplastic gland. 
 
Thymectomy is always indicated in patients who have a thymoma because of the risk of 
invasiveness and metastatic spread (Lanska, 1990).  However, over 80% of MG cases 
are non-thymomatous and the evidence for the use of thymectomy in these cases is less 
certain.  There is a clear rationale for the use of thymectomy in MG as the site of anti 
AChR antibody production is likely located in the activated areas of thymic tissue 
including B cell follicles and germinal centres (Ambrogi et al., 2011).  Although there 
are no randomised controlled trials to date, one is underway (Newsom-Davis et al., 
2008).   
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There have been many reports of non-randomised studies examining the effect of 
thymectomy in nonthymomatous MG and in general these studies support its use.  In the 
year 2000, the American Academy of Neurology systematically analysed retrospective 
non-randomised studies describing the use of thymectomy in MG (Gronseth and 
Barohn, 2000).  In total 28 studies were analysed that described the outcome in 
thymectomised versus non-thymectomised patients.  The studies quoted were 
inconsistent in terms of definitions of remission, patients included and surgical 
techniques and no study described formal selection for MG patients undergoing 
thymectomy.  However, in general, positive associations were found in most studies 
between thymectomy and MG remission/improvement.  The relative rate of medication 
free remission in patients who underwent thymectomy compared to those that did not 
was 2.1.  Persistent positive associations between thymectomy and improved MG 
outcome were found when single confounding variables such as age, gender and 
severity of MG were controlled for.  However, when multiple confounders were taken 
into account, the results from different studies were conflicting (Gronseth and Barohn, 
2000).  The authors could only conclude from this research that the benefit of 
thymectomy in non-thymomatous MG had not been established conclusively.  They 
recommended thymectomy as an option to increase the probability of remission or 
improvement in MG – a Class II recommendation. 
 
A previous group in our institution had investigated the use of thymectomy in the 
management of Myasthenia Gravis (O’Riordan et al., 1998).  Fifty-three patients who 
underwent thymectomy were identified.  In general, the outcome was positive with 35% 
of patients in remission at two years and 46% of patients having mild generalised or 
ocular symptoms only.  The procedure itself was well tolerated, however, 23% of 258 
 
patients required prolonged intubation and 3.8% of patients required plasma exchange 
for prolonged myasthenic weakness post operatively.  This group found that the 
beneficial effect of thymectomy was clearest for those patients with thymic follicular 
hyperplasia.  Patients with a thymoma had the poorest outcome.  However, thymectomy 
was felt to be still indicated in these patients because of the risk of tumour invasion, 
metastases and the poor response to medical therapy (O’Riordan et al., 1998; Lanska et 
al., 1990).   
 
A longterm follow up study of almost 2000 patients (Grob et al., 2008) found that 
thymectomy was generally followed by an improvement in myasthenic symptoms.  
However, it was noted that it may now be more difficult to demonstrate a beneficial 
effect of thymectomy than before because of concurrent improvement in the nonsurgical 
management of MG patients (Grob et al., 2008).  Thymectomy has also been shown to 
have a significant impact on quality of life in both physical and psychosocial domains 
(Ambrogi et al., 2011).  
 
Currently the decision about which myasthenic patients should proceed to thymectomy 
is often based on the preferences of the treating neurologist. Generally, the indications 
for thymectomy are early generalised myasthenia and resistant ocular disease.  As the 
natural history of MG is that 20-29% can spontaneously improve, it can be difficult to 
judge the beneficial effect of thymectomy (Hennessey et al., 2011).    
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6.2 Specific aims of this chapter 
 
In the absence of randomised data, it is essential to constantly review clinical practice.  
The National Hospital for Neurology (NHNNN) has a large cohort of patients with MG 
and performs an average of seven thymectomies a year.  The aim of this chapter was to 
take advantage of this patient cohort and examine the outcome of patients who had 
undergone thymectomy both in the short and long term.   
 
6.3 Methods 
 
All patients undergoing thymectomy for MG at the NHNN are admitted to the 
neurological intensive care unit (N-ICU) for perioperative care and thus patients who 
had undergone thymectomy were identified from the N-ICU log between January 1999 
and December 2011.  The medical case notes of each patient were reviewed 
retrospectively and where possible the patients were also reviewed in clinic.  A 
diagnosis of MG was made based on clinical findings and, at least one of the following; 
EMG findings of increased jitter/block with a decremental response to repetitive nerve 
stimulation, positive acetylcholine receptor antibodies or a positive erdrophonium 
(Tensilon) test.   
 
Patient characteristics at baseline were recorded including the severity of MG, 
immunosuppressive treatment, age at onset of symptoms and duration of MG prior to 
thymectomy.  The duration of admission to ITU, the total hospital stay and any post-260 
 
operative complications were recorded for the perioperative period.  Post operatively the 
patients were assessed at six, twelve and twenty four months.  When longer follow up 
was available, the MG status at the latest clinical review was also recorded.  MG 
severity was assessed according to the Myasthenia Gravis Foundation of America 
(MGFA) clinical classification system.  The MGFA post intervention status was used to 
assess the response to thymectomy at the last clinical review.  These measures were 
specifically chosen as in the past, the lack of universally accepted outcome measures 
has made it difficult to compare between older studies and a reliance on relatively 
subjective measures of outcome has hindered the interpretation of previous studies.  The 
Medical Scientific Advisory Board of the MGFA established a task force in 1997 to 
address these issues.  A number of clinical classification systems and outcome measures 
were defined including the MGFA Clinical Classification and the Post Intervention 
Status (Table 6.1 and Table 6.2) (Jaretzki et al., 2000).   
 
  MGFA Clinical Classification  
Class I  Only ocular muscle weakness 
Class II (a*, b**)  Mild weakness affecting other than ocular muscles  
Class III (a*, **)  Moderate weakness affecting other than ocular muscles 
Class IV (a*, b**)  Severe weakness affecting other than ocular muscles 
Class V   Defined by intubation with or without mechanical ventilation  
  *a: Predominantly affecting limb, axial muscles or both 
**b: Predominantly affecting oropharyngeal, respiratory muscles or both  
Table 6.1 MGFA Clinical Classification 261 
 
  MGFA Post Intervention Status  
Complete Stable 
Remission  
(CSR) 
No symptoms or signs of MG for at least 1 year and has received no 
therapy for MG during that time. No weakness of any muscle on careful 
examination. Isolated weakness of eyelid closure is accepted. 
Pharmacologic Remission 
(PR) 
Same criteria as for CSR except that the patient continues to take some 
form of therapy for MG. Patients taking cholinesterase are excluded 
from this category. 
Minimal Manifestations 
(MM) 
No symptoms of functional limitation from MG but has some weakness 
on examination 
Improved (I)  A substantial decrease in pre-treatment clinical manifestations or 
sustained substantial reduction in MG medications. 
Unchanged  (U)  No substantial change in pre-treatment clinical manifestations or 
reduction in MG medications 
Worse (W)  A substantial increase in pre-treatment clinical manifestations or a 
substantial increase in MG medications. 
Exacerbations (E)  Patients who have fulfilled criteria of CSR, PR or MM but subsequently 
developed clinical finding greater than permitted by these criteria. 
Died of MG  Patients who died of MG, of complications of MG therapy or within 30 
days after thymectomy 
Table 6.2 MGFA Post-intervention Status 
 
The NHNN is a tertiary referral centre and patients are often referred to a local 
neurology centre for continued follow up meaning that some patients are lost to follow 
up. In such cases, the patient’s neurologist was contacted where possible.  
 
6.4 Results 
6.4.1 Patient characteristics  
Eighty-nine patients were admitted to the NHNN for a thymectomy during the study 
period.  Sixty -eight (76%) were female and 21(24%) were male.  The average age at 
surgery was 33 years with a range from 18-74.  The average duration of MG prior to 
surgery was 31.4 months with a range of one month to 120 months.  The vast majority 
(98%) of the patients were positive for anti AChR antibodies.  One patient was found to 262 
 
be positive for MuSK antibodies five years after thymectomy and a further patient was 
seronegative on routine antibody assay. (Table 6.3) 
 
Prior to surgery, 56% of patients had a history of mild generalised myasthenia gravis 
(MGFA II), 29% had moderately severe myasthenia (MGFA III) and 3% had severe 
symptoms (MGVA IV).  Ocular symptoms only (MGFA I) were present in 11% of 
patients.  Prior to thymectomy 73% were treated with oral prednisolone at an average 
dose of 28 mg.  Twenty one percent were treated with additional immunosuppressant 
agents (all of these patients were treated with azathioprine).  Twenty four percent were 
not on any immunosuppressant agent at the time of thymectomy.  Tables 6.5 and 6.7 
outline clinical severity of MG and treatment prior to thymectomy.   
 
  Total  Thymoma  Hyperplasia  Normal   Atrophic 
Number 
Male n, (percent) 
Female n, (percent) 
89 
21(24%) 
68(76%) 
21(24%) 
6 
15 
43(48%) 
8 
35 
17(19%) 
7 
10 
8(9%) 
0 
8 
Mean age at surgery  
(range) 
32.5 
(18-74) 
46 
(28-74) 
29 
(19-44) 
29.5 
 (18-56) 
27 
(22-33) 
Mean time from MG diagnosis 
to thymectomy (months) 
                                                   
(range) 
31.43 
 
(1-120) 
10.5  
 
(1-24) 
31 
 
(12-120) 
29 
 
(2-60) 
40 
 
(12-84) 
AChR antibody positive  
(number) 
(percent) 
87  
(98%) 
21  
(100%) 
43 
 (100%) 
16  
(94%)  
(1 MuSK) 
7 
 (88%)  
(1 SNMG) 
Mean ICU stay (days) 
 (SD) (median) 
2.45                     
(6.4) (1) 
2.4  
(2.3) (1) 
1.4 
(0.65) (1) 
5.4  
(14.6)(1) 
1.75  
(0.96)(1.5) 
Mean hospital stay(days)           
(SD) (median) 
11.2 
(17.3)(8) 
12.5 (4-27) 
(2)(8) 
8 (5-15) 
(7.1)(9) 
19 (5-150) 
(39.4)(9) 
8.75 (7-12) 
(3.3)(9) 
Thymic enlargement on CT (%)  44(49%)  20(95%)  15(35%)  8/(47%)  1(12%) 
Table 6.3 Clinical details of patients undergoing thymectomy  263 
 
 
6.4.2 Preoperative imaging 
All patients underwent a CT or MRI prior to surgery.  Overall half of all patients had 
evidence of thymic enlargement on CT or MRI scan.  All but one of the patients with a 
thymoma had enlargement of the thymus reported.  Seventeen of patients who had 
thymic hyperplasia had an enlarged gland on radiology but almost half of the patients 
who were subsequently found to have normal thymic histology also were shown to have 
an enlarged gland on imaging.  One of the eight patients who had an atrophic gland had 
an enlarged thymus on preoperative imaging.   
 
6.4.3 Hospital stay and complications post thymectomy 
All patients underwent extended transsternal thymectomy and all were admitted to ICU 
post operatively.  The mean duration of ICU stay was 2.5 days (SD 6.4).  The mean 
total hospital stay was 11.2 days (SD 17.3).  There were no perioperative deaths.  Eight 
patients (9%) had a peri or post-operative complication; three had a pneumothorax, 
three required a blood transfusion and two patients developed a wound infection.  In 
addition, one patient developed a post thymectomy myasthenic crisis (MC).  Seven 
patients (8%) developed a keloid scar and two patients had persistent sternal pain in the 
years following thymectomy (Table 6.4).   
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Complications   Number of patients (%) 
Early  
 
Pneumothorax  3 (3%) 
Wound infection  2(2%) 
Blood transfusion  3 (3%) 
Post-operative myasthenic crisis  1 (1%) 
Late  Persistent sternal pain   2 (2%) 
Keloid scarring   7(8%) 
Table 6.4 Early and late complications after thymectomy  
 
6.4.4. Histological subtype 
On analysis of the histological subtype 24% had a thymoma, 48% had a hyperplastic 
gland and 19% had normal thymic histology.  An atrophic gland was seen in 8% of 
cases.  Patients who had a thymoma were older on average (46 years compared to 29, 
29.5 and 27 years for hyperplastic, normal and atrophic thymic histology respectively).  
Patients who had a thymoma detected on imaging, proceeded to thymectomy sooner 
after a diagnosis of MG compared to non-thymomatus patients (10.5 months compared 
to 33 months). (Table 6.3).  
 
6.4.5. Clinical outcome after thymectomy  
Follow up at 6, 12 and 24 months was available for 86/89 (97%), 73/89 (82%) and 
66/89 (74%) patient respectively.  Severity of MG as measured by MGFA grade 
gradually improved throughout the follow up period (Table 6.5.).   
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  MGFA  Baseline  6 months  12 months  24 months 
Thymoma  Asymptomatic  
 I 
II 
III 
IV/V 
Unknown  
- 
2 
9 
9 
1 
- 
8 
1 
8 
2 
- 
2 
11 
- 
6 
- 
- 
4 
7 
2 
3 
- 
- 
9 
Hyperplasia   Asymptomatic  
I 
II 
III 
IV/V 
Unknown  
- 
3 
26 
13 
1 
- 
20 
2 
19 
1 
- 
1 
23 
2 
6 
2 
- 
10 
23 
2 
6 
- 
- 
12 
Normal   Asymptomatic 
I 
II 
III 
IV/V 
Unknown  
- 
2 
11 
2 
2 
- 
9 
2 
4 
1 
1 
9 
1 
5 
- 
1 
1 
9 
1 
5 
- 
1 
1 
Atrophic   Asymptomatic  
I 
II 
III 
IV/V 
Unknown  
- 
1 
6 
1 
- 
- 
3 
1 
3 
1 
- 
- 
3 
1 
3 
- 
- 
1 
2 
3 
2 
- 
- 
1 
Table 6.5 MG severity as measured by the Myasthenia Gravis Foundation of America 
(MGFA) clinical classification at baseline and at 6, 12 and 24 months after 
thymectomy.  
 
The last clinical review occurred at a mean of 3.8 years post thymectomy (0.5-11 years).  
Thirty four per cent of patients had achieved complete stable remission at this point, 
meaning that they were asymptomatic from their MG and did not require ongoing 
pharmacological treatment.  An additional 33% achieved pharmacological remission 
(PR).  Twelve percent of patients had residual myasthenic symptoms/signs that did not 266 
 
require immunomodulatory therapy – minimal manifestations of disease.  An improved 
status compared to before thymectomy was reported for 13% of patients.  One patient 
died during the follow up period and there was no follow up available for three patients. 
 
Table 6.6 outlines the post intervention status for patients with each histological 
subtype.  When outcomes for different histological subtypes were assessed, a 
hyperplastic gland was associated with a significantly better outcome compared to other 
histological diagnoses.  Complete stable remission was achieved by 42% of those with a 
hyperplastic gland compared to 26% for other histological diagnoses (p <0.05).   
 
MGFA post 
intervention status 
All 
(n=89) 
Thymoma 
(n=21) 
Hyperplastic 
(n=43) 
Atrophic 
(n=8) 
Normal  
(n=17) 
CSR   30(34%)  5 (24%)  18(42%)  2(25%)  5(29%)  
PR  29(33%)  5(24%)  13(30%)  4(50%)  7(41%) 
MM  11(12%)  3(14%)  6(14%)  2(25%)  - 
Improved  12(13%)  4(19%)  5(12%)    3(18%) 
Unchanged  2 (2%)  1(5%)      1(6%) 
Exacerbations  1(1%)        1 
Died  1(1%)  1(5%)       
No follow up   3(3%)  2(10%)  1(5%)     
Table 6.6 MGFA post intervention status at last clinical review; CRS: complete stable 
remission; PR: pharmacological remission; MM: minimal manifestation 
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There was a trend towards the incidence of CSR increasing with time after thymectomy.  
Twenty eight percent (12/43) of patients with a follow up duration of two years or less 
after thymectomy achieved CSR in comparison to 43% of those who had a longer 
duration of follow up, although this finding did not achieve statistical significance 
(p=0.06).   
 
The duration of non thymomatous MG prior to thymectomy did not correlate with 
outcome; 40% of those with a duration of non-thymomatous MG of two years achieved 
CSR in comparison to 33% (8/24) of those with a disease duration of two years or 
greater (p=0.19).  
 
6.4.6. Immunosuppressive treatment after thymectomy 
Treatment at baseline and during the follow up period is outlined in Table 6.7.  Steroid 
requirements fell continuously during the follow up period but the proportion of patients 
taking additional steroid sparing immunosuppressant agents increased (Table 6.6.)  
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  Treatment   Baseline  6 months  12 months  24 months 
Thymoma  Prednisolone 
No pred 
Dose  
Aza 
No aza  
Other  
Unknown   
12 
9 
35mg 
5 
16 
- 
- 
13 
6 
20 mg 
8 
11 
- 
2 
11 
6 
12 mg 
6 
11 
- 
4 
8 
4 
8mg 
5 
6 
1 
9 
Hyperplasia   Prednisolone 
No pred 
Dose 
Aza 
No aza  
Other  
Unknown   
30 
13 
25mg 
8 
35 
- 
- 
 
27 
15 
20 mg 
11 
31 
- 
1 
 
17 
16 
15 mg  
8 
24 
1 
10 
13 
18 
15 mg 
8 
21 
2 
12 
Normal   Prednisolone 
No pred 
Dose 
Aza 
No aza  
Other  
Unknown   
15 
2 
30 mg  
4 
13 
- 
- 
16 
1 
20 mg 
6 
11 
- 
- 
 
11 
5 
8 mg 
7 
8 
1  
1 
8 
8 
8 mg 
5 
9 
2 
1 
Atrophic   Prednisolone 
No pred 
Dose  
Aza 
No aza  
Other  
Unknown   
8 
0 
35 mg  
3 
5 
- 
0 
8 
0 
15 mg  
3 
5 
- 
0 
6 
1 
10 mg  
3 
4 
- 
1 
4 
3 
9mg 
3 
4 
0 
1  
Table 6.7 Treatment at baseline and at 6, 12 and 24 months post thymectomy; Aza: 
azathioprine; Pred: prednisone  
 
The proportion of patients taking additional oral immunosuppressant agents such as 
azathioprine or mycophenolate mofetil increased from 21% (19/89) before thymectomy 269 
 
to 33% (28/86) at last clinical review (p <0.05).  However, the proportion of patients not 
taking any immunosuppressive therapy increased from 27% (24/89 post thymectomy) to 
40% (35/86) post thymectomy (p < 0.05) (table 6.8).   
 
Treatment at last 
clinical review  
All 
N= 89 
Thymoma 
N= 21 
Hyperplasia  
N= 43 
Atrophy 
N= 8 
Normal  
N= 17 
No treatment  35 (39%)  6 (29%)  21 (49%)  3 (38%)  5 (29%) 
Prednisolone alone  23 (26%)  5 (24%)  8 (19%)  4 (50%)  5 (29%) 
Oral IS alone   10 (11%)  1 (5%)  5 (12%)  1 (13%)  3 (18%) 
Prednisolone and oral 
IS 
18 (20%)  6 (29%)  8 (19%)  -  4(24%) 
Unknown   3 (3%)  2 (10%)  1 (2%)     
Dead   1 (1%)  1 (5%)       
Table 6.8 Treatment at last clinical review  
 
6.5 Discussion 
 
Despite a lack of randomised data, thymectomy is frequently used in the treatment of 
MG.  My aim was to perform a retrospective study to assess short and long term 
prognosis after thymectomy.  This study has a number of limitations, not least its 
retrospective nature and relatively small sample size.  However, in general, it was found 
that thymectomy was associated with a substantial and prolonged improvement in 
myasthenic symptoms.  Severity, as measured by MGFA grade fell progressively 270 
 
throughout the follow up period.  Steroid requirements, both in terms of the proportion 
of patients requiring steroids and the dose also fell from 6 months post thymectomy.  
There was a slight increase in the proportion of patients taking additional 
immunosuppressant agents such as azathioprine and mycophenolate but it was felt that 
it was unlikely that this would be sufficient to account for the substantial clinical 
improvement seen.   
 
A significantly greater incidence of complete stable remission (CSR) was seen in 
patients who had a hyperplastic thymus gland on histology compared to other 
histological subtypes.  Previous studies have also suggested that the presence of thymic 
hyperplasia correlated with improvement after thymectomy (Jaretzki et al., 1988; 
Lanska, 1990; Klein et al., 1999, Nicolaou et al., 1996).  The benefit of thymectomy in 
patients with an atrophic thymus is less certain.  There were few patients with an 
atrophic thymus in this study (n=8) but a significant proportion of these achieved either 
complete stable remission or pharmacological remission.  It can be difficult to identify 
patients with an atrophic gland from radiological features alone; one of the patients with 
an atrophic gland in this study was thought to have an enlarged thymus on initial 
imaging.  It was therefore interesting to assess the response to thymectomy in the small 
number of patients in our group who had an atrophic thymus gland.  Atrophy of the 
thymus with an associated reduction in thymic size and activity is generally considered 
to be an age associated phenomenon (Chen et al., 2011).  As the thymus ages, the 
thymic epithelial space begins to atrophy and the adipose tissue increases with thymic 
size and activity becoming greatly reduced.  However atrophic thymus tissue has been 
shown to secrete immunoglobulins and AChR antibodies in vitro – particularly with 
MG duration of two years or less (Katzberg et al., 2001).  Although thymic atrophy is 271 
 
an age associated phenomenon, a significant difference was not detected in the age of 
the patients with an atrophic gland compared to those with a hyperplastic gland.  There 
have been suggestions in the past that thymectomy of an atrophic gland can be 
associated with a good prognosis after thymectomy (Shahrizaila et al., 2005; Chen et al 
2011).  In one study the immune response, as determined by B cell activation, was 
similar in hyperplastic and atrophic thymuses and that the probability of remission was 
similar (Chen et al 2011).  These data concur with these findings but the number of 
patients is too small to draw any firm conclusions.   
 
In this cohort, patients with a thymoma did demonstrate improvement after 
thymectomy, but in general the response was less favourable compared to patients with 
nonthymomatous MG.  This finding is consistent with previous studies (O’Riordan et 
al., 1998; Budde et al., 2001; Masaoka et al., 1996).  Nevertheless thymectomy is still 
warranted in patients with a thymoma to reduce the risk of metastatic spread or local 
invasion  
 
Somewhat surprisingly, a difference in outcome was not found in patients with a longer 
disease duration before thymectomy compared to those with a shorter disease duration.  
Previously it had been suggested that there was an increased likelihood of benefit from 
thymectomy when it is performed earlier in the disease course (Monden et al., 1984).  
However, there is a natural spontaneous remission rate in MG and this is not linear.  
MG patients in general are more likely to remit earlier in their disease course regardless 
of therapy.  This study is in agreement of that of Budde et al. (Budde et al., 2001) who 272 
 
found that thymic histology and age at operation were correlated to outcome but disease 
duration was not.  
 
It is unknown whether MG classification has any bearing on outcome after thymectomy 
– it is generally thought that patients with mild – moderate generalized MG benefit most 
from thymectomy.  The question of whether ocular MG responds to thymectomy is less 
certain with some series reporting that patients with purely ocular MG do benefit from 
thymectomy (Masaoka et al 1996) and other studies showing that ocular MG more 
resistant to surgery (Budde et al., 2001).   
 
My data did suggest that the incidence of CSR increased with a longer duration of 
follow up.  This did not reach statistical significance but a trend was observed.  Twenty 
eight percent (12/43) of patients with a follow up duration of two years or less from 
thymectomy achieved CSR in comparison to 43% of patients who had a longer duration 
of follow up (p=0.06).  The continued benefit of thymectomy many years after surgery 
has been described previously and a peak rate of remission has been seen up to 15 years 
after thymectomy (Chen et al., 2011; Tomulescu et al., 2011; Masaoka et al., 1996).  
The slope of the remission curve in thymectomised patients has been shown to increase 
suddenly between 5 and 6 years (Tomulescu et al 2006, 2011).  The average follow up 
time in this study was comparatively short at 45.6 months.  It is possible that, with 
continued follow up of our cohort, an increased rate of CSR may be demonstrated. 
 
In the past, no significant association between CSR rate at 24 months and sex, age, 
preoperative use of steroids, histology (in non thymomatous MG) or need of post-273 
 
operative intubation has been demonstrated (Ambrogi et al., 2011).  However, shorter 
duration of disease, oropharyngeal involvement, presence of germinal centres in native 
or ectopic thymus and presence of ectopic thymus were negative predictors (Ambrogi et 
al., 2011).   
 
In general, thymectomy is a well-tolerated procedure and the 9% perioperative 
morbidity rate seen in this cohort corresponds well to previous studies (O’Riordan et al., 
1998; Takanami et al., 2009).  Apart from the immediate risks of any operation 
including infection, bleeding and risks from general anesthesia, one of the main risks of 
a thymectomy is damage to the phrenic, recurrent laryngeal and left vagus nerves.  
Damage to these structures can be devastating, particularly in MG when patients are 
already prone to bulbar weakness and respiratory failure (Jaretzki et al., 2003).  
However this was not seen in any of the patients in this study.  
 
One of the patients in the cohort did develop a post-operative myasthenic crisis (MC).  
However, previous studies have noted a much higher proportion of patients developing 
MC after thymectomy; up to 19% in some groups (Takanami et al., 2009).  The low rate 
of MC after thymectomy in this cohort was attributed to adequate immunosuppressive 
treatment before thymectomy and post-operative care in a neurointensive care facility.  
The main factor that has been found to significantly increase the risk of Myasthenic 
Crisis after thymectomy is a history of Myasthenic Crisis before thymectomy (Nam et 
al., 2011).  Other factors associated with a post-operative MC include severity of 
disease, Body Mass Index (BMI) > 28 and duration of symptoms for > 2 years (Leuzzi 
et al., 2014).  274 
 
 
Interestingly, the one patient in our cohort who developed MC was found to have anti-
MuSK antibodies four years after thymectomy.  This patient had treatment resistant 
MG, requiring ongoing nocturnal noninvasive ventilation and regular IVIG for many 
years.  She subsequently improved after being commenced on mycophenolate.  It was 
noted previously that patients with MuSK MG tend not to respond to thymectomy 
(Evoli et al., 2008; Ponseti et al., 2009). 
 
It was found that a significant proportion of patients had an enlarged gland on 
preoperative mediastinal imaging.  As would be expected, all but one of our patients 
with a thymoma had an enlarged thymus or had an obvious tumour on imaging.  Just 
under half of the patients with a hyperplastic gland had evidence of an enlarged thymus 
and a significant proportion of those with normal thymic histology also had an enlarged 
gland.  Previously, Pirronti et al. found that CT was 88.5% sensitive for thymoma and 
36% sensitive for thymic hyperplasia (Pirronti et al., 2002).  Thymic hyperplasia can 
have various different appearances on CT/MRI.  Typically, up to 45% of cases may 
have normal radiological appearances; 35% are diffusely enlarged and up to 20% may 
appear as a focal thymic mass (Priola and Priola, 2014).  This present study was not 
intended to review this in detail and the scans were not independently reviewed.  
However, from my small study it would seem reasonable to conclude that a completely 
normal CT/MRI of the mediastinum makes a thymoma unlikely.   
 
In recent years, there has been much debate about the surgical technique used in 
thymectomy.  If a thymoma is present, completeness of resection is one of the most 275 
 
important prognostic factors (Murthy et al., 2009).  This is also the case for 
nonthymomatous MG.  In fact, the presence of ectopic thymic tissue has been 
considered one of the most significant predictors of outcome after thymectomy for MG 
(Ambrogi et al., 2011; Mori et al., 2007; Roxanis et al., 2002).  Removal of as little as 
2g of residual thymic tissue at reoperation has been shown to be therapeutic (Masaoka 
et al., 1982).  Hyperplastic areas of thymic tissue are believed to be the site of antibody 
production and hence removal of as much thymic tissue as possible is considered to be 
the mainstay of a successful thymectomy (Jaretzki et al., 1998).  It is for this reason that 
transcervical thymectomy is believed to be inferior with a reduced remission rate 
(Papatestas et al., 1987).  The rationale for transsternal thymectomy is based on the 
thymus arising from several sites thymic tissue can be scattered throughout the anterior 
mediastinum and even in the retrothyroid space and that the thymus itself is known to 
consist of multiple lobules that are often separately encapsulated and not necessarily 
contiguous (Takanami et al., 2009; Jaretzki et al., 2003).  In recent years, however, 
thorascopic thymectomy is increasingly used and has been shown to have a low 
morbidity and equivalent efficacy to open surgery (Tomulescu et al, 2011).  Recovery 
seems to be faster, pulmonary function is less impaired and the length of post-operative 
hospitalization is shorter (Palace et al., 2001).   
 
The vast majority of the patients in this study were acetylcholine receptor antibody 
positive.  One patient who was initially thought to be seronegative tested positive to anti 
MuSK antibodies some years after her thymectomy.  Interestingly this is the patient 
who remained most symptomatic suffering severe respiratory weakness after 
thymectomy.  Conclusions cannot be drawn from a single case but the literature to date 
does not support the use of thymectomy in anti-MuSK patients (Ponseti, 2009).  There 276 
 
is controversy about whether AChR titres decrease after thymectomy with some reports 
showing that in the long term titres do not decrease after thymectomy (Tsinzerling et al., 
2007) and other reports showing that AChR titres decreased soon after surgery and 
remained low in patients that showed a good response (Seto et al., 1993)  
 
Apart from a number of cases with recurrent thymoma, none of our patients underwent 
reoperation for persistent myasthenic symptoms post thymectomy.  It is recommended 
that reoperation should be considered in cases where the patient has severe or worsening 
myasthenic symptoms 3-5 years following a basic transcervial or standard transsternal 
thymectomy.  
 
This research shows that transternal thymectomy is generally safe and well tolerated.  It 
was associated with a good outcome in the majority of patients with a reduction in 
prednisolone dose and an improvement of myasthenic symptoms. 
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7 Recurrent thymoma – evidence for late recurrence  
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7.1 Background  
 
Thymomas are the most common tumour of the mediastinum but are still relatively rare 
with an incidence of 0.15 per 100,000 person years (Engels and Pfeiffer, 2003), 
representing 0.2%-1.5% of all malignancies (Margaritora et al., 2010) and 20% of all 
mediastinal tumours in adults (Priola and Priola, 2014).  Approximately 10-20% of 
patients with MG have a thymoma and in turn approximately 20-25% of patients with a 
thymoma have MG (Lucchi et al., 2009).  Histopathologically, thymomas are composed 
of neoplastic thymic epithelial cells with varying proportions of non neoplastic 
lymphocytes and are classified and staged according to the WHO and Masaoka systems 
respectively (Okumura et al., 2002; Masaoka et al., 1981).   
 
As thymomas are rare there is little randomised evidence to guide treatment but a 
consensus based approach has been used to develop treatment recommendations 
(Falkson et al., 2009).  The choice of treatment depends on the Masaoka stage but 
surgery forms the cornerstone of treatment regimens.  Radiotherapy is considered in the 
case of Stage III and above tumours and in high risk Stage II tumours (Benveniste et al., 
2011).  For bulky tumours, chemotherapy as well as radiotherapy may be considered 
(Falkson et al., 2009).  Chemotherapy and radiotherapy are considered in medically and 
technically inoperable patients (Falkson et al., 2009).  
 
The prognosis of thymoma depends on the tumour stage, WHO histology, completeness 
of removal and type of treatment (Urgesi et al., 1992; Wilkins et al., 1991, Strobel et al., 279 
 
2004).  Thymomas are generally characterized by an indolent growth and the overall ten 
year survival after surgery is estimated at 85.7% (Sakamoto et al., 2011).  Despite this 
good prognosis, recurrence of thymoma following surgical removal is not uncommon; 
between 7% and 30% of patients develop recurrence of thymoma (Ciccone and 
Rendina, 2005; Regnard et al., 1997).  Recurrence occurs more frequently in stage III or 
IV thymomas and in epithelial rich histological subtypes (type 3 and 4) (Regnard et al., 
1997) but can occur in any disease stage or histological subtype and has been rarely 
reported after removal of encapsulated thymoma (Regnard et al 1996; Masunaga et al., 
1995).  The origins of thymoma recurrences are likely to be either tumour remnants due 
to incomplete surgical resection or pleural seedings that were undetected at the initial 
operation or occurred due to surgical manipulation (Evoli et al., 1998).  Most 
recurrences occur in the intrathoracic cavity rather than by haematogenous spread 
(Regnard et al., 1997)  
 
7.2 Specific aims of this chapter  
 
Myasthenic symptoms often remain following removal of a thymoma with over 80% of 
patients requiring continued immunosuppression during follow up (Evoli et al., 2002).  
These patients remain under the care of neurologists.  In this study, my aim was to 
highlight the possibility of late thymoma recurrence in patients attending a neurology 
clinic.   280 
 
7.3 Methods  
 
A review of the patient records of the dedicated MG clinic in the NHNN was 
undertaken and cases of late thymoma recurrence were identified and case notes were 
reviewed.  When possible the patients were also interviewed and examined in the clinic.  
“Late” was defined as recurrence occurring at least six years after the initial tumour 
resection.  This cutoff was chosen based on a study that showed that recurrence was 
usually observed within a mean of 5 years after resection and our personal experience 
(Strobel et al., 2008).   
 
7.4 Results  
 
Five patients who attended the specialist MG clinic with a diagnosis of late recurrent 
thymoma were identified.  Four were male.  All had a thymoma that was resected by 
open thoracotomy and all attended the specialist MG clinic for follow up.  The average 
age at onset at initial thymoma resection was 47.6 years (30-60) and all patients were 
strongly positive for antibodies against the acetylcholine receptor.  Four of the patients 
had myasthenic symptoms at the time of diagnosis of the thymoma whereas the fifth 
patient developed MG symptoms post operatively.  
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7.3.1 Clinical Vignettes 
Clinical vignettes for each patient are outlined below.  
 
Patient 1: A 26 year old man presented with mild generalised myasthenic symptoms.  A 
thymoma was diagnosed radiologically and he underwent a thymectomy. A WHO grade 
B1/B2 thymoma completely removed.  He was treated with prednisolone and 
azathioprine and a surveillance CT scan performed five years after the initial 
thymectomy was normal.  Twelve years post initial resection, a CT scan revealed a 
mediastinal mass.  Repeat thoracotomy was undertaken which confirmed the presence 
of a B3 thymoma with pericardial and pleural metastases.  He underwent post-operative 
radiotherapy.  Four years after the repeat thymectomy he developed Morvan’s 
Syndrome – symptoms of which initially responded to plasma exchange.  However, he 
died two years later of metastatic thymoma.   
 
Patient 2: A 46 year old man developed generalized MG and underwent a thymectomy.  
Histology revealed a stage II, type B2 thymoma, which was completely resected.  He 
remained well for 11 years after surgery when routine surveillance imaging 
demonstrated thymoma recurrence.  He underwent repeat thoracotomy and 
thymectomy, which once again revealed a B2 thymic tumour.  He made a good post-
operative recovery but over the following twelve months developed generalised 
weakness with foot drop and muscle cramps.  Electrophysiological tests revealed a 
pattern consistent with anterior horn cell syndrome and he was diagnosed with 
amytrophic lateral sclerosis (ALS).  He died from ALS related respiratory failure four 
years later.  There was no evidence of thymoma recurrence at this time.   282 
 
 
Patient 3: A 51 year old man was incidentally noted to have a large thymic mass on 
routine chest radiograph.  An AB thymoma with clear margins and an intact capsule 
was excised.  At the time of his operation he had no myasthenic symptoms but three 
years later he developed fatigable weakness.  There was no evidence of recurrent 
thymoma at this time and he was treated with prednisolone.  Six years after the initial 
thymectomy a CT scan demonstrated a diaphragmatic nodule.  Histology confirmed an 
AB thymoma recurrence and he underwent repeat thoracotomy with postoperative 
radiotherapy.  Regular surveillance for the past six years has not demonstrated any 
further recurrence.   
 
Patient 4: A 40 year old man presented with ocular MG and imaging demonstrated a 
mass.  He underwent thymectomy and histology showed a WHO B1 thymoma with 
incomplete resection (Masaoka Stage II).  He underwent postoperative radiotherapy and 
remained well for fourteen years at which point he developed chest pain and dyspnoea.  
Imaging one year previously had been normal but CT at this stage showed a left 
superior mediastinal mass with pulmonary nodules PET scanning showed appearances 
consistent with malignancy.  Both medastinoscopy and open biopsy were attempted but 
were unsuccessful.  He was deemed not to be a surgical candidate and was treated with 
cisplatin and ifosfamide chemotherapy.  He died eighteen months later.   
 
Patient 5: A 43 year old woman presented with generalised MG and underwent 
thymectomy.  A WHO Type A thymoma was completely excised and she was treated 
with prednisolone and mycophenolate.  Fourteen years after thymectomy a routine CT 283 
 
scan demonstrated recurrence of the tumour with extensive mediastinal metastases.  
Pleural biopsy revealed a B1 thymoma.  She was not a candidate for surgery and was 
treated with carboplatin and paclitaxel chemotherapy.  Despite this, her disease 
progressed and she died of malignant meningitis two years later. 
 
The average time from initial resection to diagnosis of recurrence in this cohort was 
12.3 years (6-16.25).  All patients had ongoing MG symptoms after resection and all 
required immunosuppression.  No patient had a relapse of myasthenic symptoms at the 
time of recurrence.  Outcome was generally poor with three of five patients dying as a 
direct result of thymoma recurrence (Table 7.1). 284 
 
Patient  1  2  3  4  5 
Age at first 
presentation 
26 (Male)  46 (Male)  51 (Male)  40 (Male)  43 (Female) 
Presentation   Generalised 
MG  
Generalised 
MG  
Thymic mass 
found incidentally 
on routine CXR 
Ocular MG   Generalised 
MG  
Initial 
histology  
(WHO type)  
B2  
 
B2    AB    B3  A  
Masaoka 
stage 
I  II  I  IIB  I 
Initial 
resection 
complete? 
yes  yes  yes   no  yes 
Adjuvant 
therapy 
no  no  no  yes 
radiotherapy  
no 
Disease-free 
interval (yrs)  
13  12  6  15 
 
14 
Repeat 
surgery 
Repeat 
thoractomy  
Repeat 
thoractomy  
Repeat 
thoractomy, 
pedunculated 
nodule removed 
from diaphragm  
no   no  
Repeat 
histology 
(WHO type 
and Masaoka 
stage) 
B3 IVA 
metastases 
to lung and 
pericardium 
B2 II  AB III  (Mediastinal 
biopsy 
attempted but 
unsuccessful) 
B1 IVA 
metastases to 
lung and 
pericardium  
Adjuvant 
therapy 
Post-
operative 
radiotherapy  
Post-
operative 
radiotherapy  
Post-operative 
radiotherapy  
Cisplatin and 
isfosfamide 
chemotherapy  
Carboplatin 
and pacitaxel 
chemotherapy  
Radiotherapy 
to spinal mass 
AChR titre 
at diagnosis 
At recurrence  
 
33 
Negative 
 
166 
197 
 
- 
221 
 
- 
237 
 
185 
269 
Outcome   Died 6 years 
after 
diagnosis of 
recurrence  
Developed 
sporadic 
ALS and 
died of ALS-
related 
respiratory 
failure  
No further 
thymoma 
recurrence  
Died 18 
months after 
diagnosis of 
recurrence  
Died 2 years 
after diagnosis 
of recurrence  
Table 7.1 Clinical characteristics of patients with late recurrent thymoma  
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7.5 Discussion  
 
Although thymomas are rare tumours, patients who have had a thymoma resected are 
commonly seen for many years in neurology clinics.  Therefore it is vital that 
neurologists are alert to the possibility of late thymoma recurrence.  There have been 
some previous reports of late recurrence of thymoma in the literature with recurrences 
presenting as late as 19 or 20 years post initial thymectomy (Gotti et al., 1995; Lava et 
al., 1976; Evoli et al., 2002; Naniwa et al., 2002).  However, this study is the first to 
look at a small group of these patients in depth.   
 
I have described a series of five patients who developed a recurrent thymoma at a mean 
of 12.25 years post initial thymectomy.  Recurrence of thymoma is a well-reported 
phenomenon with recurrence rates of 10-30% described in the literature (Regnard et al., 
1997, Ruffini et al., 1997).  Recurrence rates of 9% have been described when 
specifically assessing thymoma associated with MG (Evoli et al., 1998; Maggi et al., 
2008).  Recurrence risk is higher in patients with invasive disease compared to 
encapsulated thymomas (Ruffini et al., 1997) but this series has demonstrated that 
recurrence can occur in cases with low grade encapsulated tumours when initial 
resection of the tumour has been deemed to be complete. 
  
It is known that completeness of resection is one of the main prognostic factors 
regarding thymoma recurrence.  In cases of incomplete resection the use of post-
operative radiotherapy in an attempt to reduce the risk of recurrence is well established 286 
 
but there is no consensus about radiotherapy after a thymoma is completely resected 
(Ogawa et al., 2002).  Currently radiotherapy is not recommended for patients with 
Stage I disease (Falkson et al., 2009).  Recent recommendations suggest that patients 
with Stage II disease should have radiotherapy if they are considered to have factors 
indicative of a higher risk of recurrence including invasion through the capsule (Stage 
IIB), WHO Grade B tumours, if tumour is adherent to the pericardium or if resection is 
incomplete (Sakamoto et al., 2011).  Only one of the patients in our cohort received 
adjuvant radiotherapy after initial surgery (Patient 3) as he was the only patient with an 
incomplete resection.  A retrospective review has suggested that post-operative 
radiation can prevent mediastinal recurrence in patients with thymoma that has been 
completely resected (Ogawa et al., 2002).  However, one of our patients had pleural 
based recurrence and it has been suggested that mediastinal radiation alone will not 
prevent this (Ogawa et al., 2002).  Moreover, the use of adjuvant therapy such as 
radiotherapy has been shown to have no effect on prolonging the disease free interval in 
patients with invasive thymomas (Ruffini et al., 1997).   
 
The prognosis of recurrent thymoma can be poor – three of the patients in this study 
died as a direct consequence of thymoma recurrence.  Nevertheless, recurrent thymoma 
is more likely to be treatable if it is recognized earlier.  There are currently no published 
guidelines regarding the frequency, duration or mode of radiological surveillance for 
thymoma recurrence (Regnard et al., 1997).  CT is said to be equal or superior to MRI 
in the diagnosis of mediastinal tumours but concerns about the risk of repeated radiation 
exposure often make the latter the modality of choice, particularly when interval scans 
are required (Tomiyama et al., 2009).  However, there is also a suggestion that PET-CT 287 
 
is advantageous over CT in follow up after thymoma removal as CT changes may be 
subtle (Rosado-De-Christenson and Marom, 2008) 
 
In this small case series I tried to ascertain any clinical features that could herald a 
thymoma recurrence.  All the patients continued to have symptoms of generalised MG 
after thymectomy and required ongoing immunosuppression.  This is in keeping with 
previous studies on thymomatous MG (Margaritora et al., 2010).   However, none of the 
patients had an exacerbation of their myasthenic symptoms when recurrence was 
diagnosed.  This lack of correlation between MG symptoms and tumour recurrence has 
been described previously (Margaritora et al., 2010).  However, paraneoplastic 
syndromes other than MG have been reported to accompany thymoma and could herald 
a recurrence.  Approximately 10-15% of patients with a thymoma can have a 
paraneoplastic syndrome other than MG (Evoli et al., 2007).  One of the patients in our 
cohort developed Morvan’s Syndrome with associated voltage gated potassium complex 
antibodies associated with the thymoma recurrence.  Recently, acquired neuromyotonia 
with anti LGI1 and CASPR2 antibodies has been reported as the heralding symptom of 
recurrent thymoma in a patient with MG (Fleisher et al., 2013).  Good’s Syndrome 
(hypogammaglobinemia) has also been reported in association with late recurrence of 
thymoma (Naniwa et al., 2002).   
 
As thymomas often occur locally, re- operation is advised if the recurrence is deemed to 
be resectable (Regnard et al., 1997; Maggi et al., 1991).  The five and ten year survival 
rates after re-resection have been found to be between 51% - 71% and 43% respectively 
(Regnard et al., 1997; Maggi et al., 1991).  The prognosis after recurrence of a thymoma 288 
 
is dependent on total resection of the recurrent tumour and the presence of local 
recurrence rather than intrathoracic metastases (Ruffini et al., 1997).  However optimal 
surgical treatment of recurrent thymoma may be difficult due to technical difficulties of 
second operation, possibility of involvement of intrathoracic organs, the possibility of 
intrathoracic dissemination of the recurrence the possibility of associated myasthenic 
symptoms (Ruffini et al., 1997).  In general, surgery is recommended if possible but 
there are limited data comparing the results of radiotherapy for treatment of recurrence 
to surgery (Ruffini et al,. 1997).  Total resection seems to offer the best chance of long-
term survival but the difference between surgery and radiotherapy in treatment of 
recurrence has not been found to be significantly different in the past (Maggi et al., 
1991; Urgesi et al., 1992).  Only two of our patients had resectable disease at recurrence 
and underwent surgery.  A third patient had a repeat thoracotomy but had metastatic 
disease and so this procedure was largely palliative.  The two remaining patients were 
not candidates for surgery due to widely disseminated disease and were treated with 
radiotherapy and/or chemotherapy.   
 
This small case series has demonstrated that recurrence of thymoma can occur many 
years after thymectomy.  An important finding was that none of our patients had a flare 
of their myasthenic symptoms around the time of their tumour recurrence.  Prognosis is 
likely to better if the tumour is diagnosed earlier and so some form of screening is 
necessary.  There are no guidelines regarding this but the practice in our institution is 
yearly or two yearly imaging with CT or MRI, the latter increasingly becoming the 
imaging modality of choice due to concerns about radiation.  I did not find that AChR 
antibody levels were appreciably correlated with recurrence although I did not have the 
full data regarding this for all patients.  There has been a search for other serum markers 289 
 
of thymoma recurrence.  Anti titin antibodies are associated with the presence of a 
thymoma but are also found in non –thymomatous older patients with MG and so are 
only useful in patients less than 60 (Buckley et al., 2001).  In contrast, serum antibodies 
against cytokines, interleukin alpha and interleukin -12, have been found to be useful in 
identifying patients with tumour recurrence, especially if imaging is equivocal (Buckely 
et al., 2001).  Anti titin antibodies were found to be elevated in patients with an 
underlying thymoma even in the context of well controlled MG and 
immunosuppression.  I did not measure these antibodies in our patients but it would be 
possibly useful in the future.  
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8 Severe exacerbations of Myasthenia Gravis- management 
and long-term outcome  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   291 
 
8.1 Background  
 
Myasthenic crisis (MC) is one of the most serious complications of MG and occurs on 
average in 10-15% of myasthenic patients during the course of their disease (Thomas et 
al., 1997; Berrouschot et al., 1997; Sellmann and Mayer, 1985).  A population based 
study that followed myasthenic patients for an average of 12 years suggested an annual 
myasthenic crisis incidence of 2.5% (Berrouschot et al., 1997).  The incidence does not 
seem to have changed appreciably over the past four or five decades despite 
improvements in the immunotherapy of MG (Cohen and Younger, 1981; Ronager et al., 
2001).  Myasthenic Crisis is traditionally defined as “weakness from acquired 
myasthenia gravis that is severe enough to necessitate intubation for ventilatory support 
or airway protection” (Jani-Acsadi et al., 2007; Bedlack and Sanders, 2002).  Usually if 
extubation after a general anaesthetic is delayed for more than 24 hours after surgery, 
this is also defined as a myasthenic crisis (Bedlack and Sanders, 2002).  As the decision 
regarding whether a patient requires intubation can be quite subjective and individual, 
this is not a rigid definition and so it can be difficult to compare the treatment and 
outcome of myasthenic crisis from different studies.   
 
Respiratory insufficiency in MG patients develops as a result of worsening respiratory 
muscle weakness due to neuromuscular dysfunction-it can be exacerbated or 
complicated by respiratory tract infection or aspiration pneumonia secondary to 
associated bulbar dysfunction  
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Fifty years ago the mortality of MC was typically between 50 and 80% (Rowland et al., 
1958) but with improvements in the medical management of these patients, particularly 
the improvement in respiratory care in the Intensive Care Unit (ICU), mortality is now 
reported to be less than 5% (Jani-Acsadi et al., 2007; Cohen and Younger, 1981; 
Alshekhlee et al., 2009).  MC typically develops in the first two years after diagnosis of 
MG (Bedlack and Sanders 2002).  On average each episode of MC requires a hospital 
admission of over a month, more than half of which is spent on the intensive care unit 
(Thomas et al., 1997).  
 
Patients may also develop acute exacerbations of MG that do not require mechanical 
intubation and hence do not meet the criteria for a diagnosis of MC but nevertheless 
require close observation and immediate access to resuscitation facilities, often in an 
Intensive Care Unit.  As MG is increasingly recognised in older patients the proportion 
of elderly patients with severe exacerbations of MG that are admitted to the ICU has 
increased.   
Little is known about the long-term outcome after an acute severe exacerbation of MG, 
particularly in the older MG cohort.   
 
8.2 Specific aims of this chapter  
 
The objective was to describe the current management and long term prognosis of 
severe exacerbations of MG in patients with early and late onset disease.  As our 
institution has a large cohort of myasthenic patients and a dedicated neuro-medical ICU 293 
 
(N-ICU) it was decided to conduct a retrospective review of all patients admitted with 
an acute severe exacerbation of MG over an extended period.  
 
I wished to examine the management of acute exacerbations of MG in a N-ICU and to 
examine both short and long term outcomes in patients with early and late onset MG.   
 
8.3 Methods 
 
All patients admitted to the N-ICU are recorded in the ICU admission log book.  All 
patients admitted to the N-ICU with acute exacerbations of MG between January 1999 
and January 2011 were identified from this source and the case notes were 
retrospectively reviewed.   
The severity of MG was classified according to the Myasthenia Gravis Foundation of 
America (MGFA) clinical grading system (Jaretzki et al., 2000) (see fig 6.1).  
 
Patients were included in the study if they were admitted to the N-ICU because of 
acutely developing fatigable muscle weakness with severely impaired bulbar or 
respiratory function (MGFA IVb or V).  Patients that were admitted to the N-ICU 
electively post thymectomy or for routine plasma exchange were excluded.   
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SPSS (Chicago, IL, USA version 20) was used for statistical analysis.  Categorical data 
were analysed by Fisher’s exact test and continuous data were analysed using Student’s 
t-test. 
 
8.4 Results 
 
8.4.1 Patient characteristics  
Thirty-eight patients (23 female, 15 male) were admitted to the N-ICU with acute 
exacerbations of MG during the study period.  The average age at admission was 57 
years (range 19-81 years) and the average age at onset of MG was 53 years (range 17-81 
years).  Thirty-one patients (82%) were acetylcholine receptor (AChR) antibody 
positive, four (11%) had antibodies to Muscle Specific Tyrosine Kinase (MuSK) and 
three patients (8%) were seronegative on routine antibody assay.  Twenty-nine (76%) of 
the admissions were transferred from other hospitals, often from other ITUs.  
 
 
Figure 8.1 Age of patients at time of ITU admission  295 
 
 
Twenty four patients (63%) were over the age of 50 years on ICU admission and 11 of 
these (46%) had no previous diagnosis of MG; the diagnosis was newly made on 
admission to N-ICU.  The average duration of MG in those with an established 
diagnosis was 4 years (0.5-9 years).  In the 14 patients who were under the age of 50 on 
ICU admission, three (21%) were new presentations of MG.  In the 11 patients (29%) 
with an established diagnosis, the average duration of MG was the same as in the older 
age group 4 years (0.5-9 years).  
 
8.4.2 MG treatment prior to ICU admission  
Sixty three percent (15/24) of those with known MG were treated with prednisolone 
prior to the acute exacerbation of MG.  This figure was similar in the younger and older 
age groups (7/11 and 8/13 respectively).  Younger patients with an established diagnosis 
of MG were more likely to have been treated with a steroid sparing agent such as 
azathioprine than the older age group (4/11; 36% compared to 1/13, 8%) although this 
figure did not reach statistical significance (p=0.11).  In total, three patients had also 
received IVIG on at least one occasion prior to ICU admission.   
 
Seven patients had undergone thymectomy at some stage prior to the ICU admission, 
4/11 were in the younger age group and 3/13 were in the older age group.  All of the 
older cohort who had undergone thymectomy had a thymoma.  One of the younger 
cohort had a thymoma but the remainder had a hyperplastic gland.  The difference 
between older and younger age groups with regards to thymectomy did not reach 
statistical significance (p =0.28) 296 
 
 
8.4.3 Triggering factors for acute exacerbation 
A factor that precipitated the acute exacerbation was identified in 22 patients (58%).  
One patient deteriorated during high dose steroid treatment.  Another patient developed 
post-operative myasthenic crisis after thymectomy (MCAT).  Sepsis was the main 
precipitating factor identified and was seen in 20 patients (53%).  However no factor 
that precipitated the acute exacerbation of MG was identified in the remaining 16 
patients (42%) and the deterioration appeared to be spontaneous.   
 
8.4.4 Treatment in ICU 
The mean duration of the ICU stay for the group as a whole was 18.7 days (1-111 SD 
21.7) and the mean total hospital stay was 38.9 days (4-157; SD 31.1).  Those with a 
new diagnosis of MG had a trend towards a longer hospital stay than those with an 
established diagnosis although this did not reach statistical significance (p=0.17).  There 
was no significant difference in ICU stay length in the older group compared to the 
younger cohort (p=0.42).   
 
The FVC was monitored in all patients – typically tracheal intubation was performed in 
the FVC fell below 15ml/kg, if there was severe bulbar weakness or if there were 
indications that the patient was tiring.  Intubation and mechanical ventilation were 
required in 24 patients in total (63%) and subsequent tracheostomy was required in 18 
cases (47%).  The mean duration of ventilation was 28 days (6-102) with a median of 14 
days.  Seventy one per cent (17/24) of those requiring intubation had a lower respiratory 297 
 
tract infection compared to 14% (2/14) who did not require intubation (p < 0.01).  Four 
patients did not require intubation and mechanical intubation but did receive non-
invasive ventilation as bi-level positive airways pressure (BiPAP).  There were no 
significant differences between the two age groups with regard to the need for 
mechanical ventilation (p=0.56).   
 
The vast majority of patients 37/38 (97%) were treated with oral prednisolone with an 
average dose of 50mg (range 20-80mg) and 87% (33/38) received intravenous 
immunoglobulin (IVIG).  Seven patients underwent plasma exchange as they had 
ongoing myasthenic weakness.  Additional immunosuppression was initiated in the N-
ICU in 17 patients (45%).  There were no significant differences in the management of 
the acute exacerbation of MG in the younger age group compared to the older age 
group.  When intubation was required, pyridostigmine was generally discontinued.   
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Clinical Details  Young onset MG         
(<50 yrs) 
Older onset MG              
(>50 yrs) 
Number  
Male  
Female 
14 
5 
9 
24 
10  
14 
New Diagnosis  3 (21%)  11(46%) 
Established diagnosis 
Average disease  duration  
     Treatment  prior to ICU admission 
     Prednisolone 
     Azathioprine 
     IVIG 
     Plasma exchange 
11(29%) 
3.5 yrs (0.5-14 yrs) 
 
     7(64%) 
     4(36%) 
     2(18%) 
     2(18%) 
13(54%) 
4 yrs (0.5-9 yrs) 
 
     8(62%) 
     1(8%) 
     1(8%) 
     - 
Antibody Status 
AChR  
MuSK 
Seronegative 
 
11(79%) 
3(21%) 
- 
 
20(83%) 
1(4%) 
3(13%) 
Mean duration of  ICU admission (days)(SD) 
(median )  
22.4 (19.8) (14.5)  16.7 (SD 22.9) (9) 
Mean Total Stay (days) (SD) (median)   42.1(28.7) (42.5)   37.1(32.9) (26.5)  
Intubation   9(64%)  15 (63%) 
Thymectomy 
Before ICU admission 
After ICU admission  
No thymectomy 
Thymoma 
 
4(29%) 
5(36%) 
5(36%) 
4(29%) 
 
3(13%) 
1(4%) 
20(83%) 
4(17%) 
Treatment in ICU  
Intubation 
Prednisolone 
IVIG 
Plasma exchange 
 
Other immunosuppressant agent 
Azathioprine 
Mycophenolate 
Rituximab 
Cyclophosphamide  
 
9(64%) 
114(100%) 
13(93%) 
3 (4%) 
 
 
6(43%) 
2(14%) 
- 
1 
 
15(63%) 
23(96%) 
20(83%) 
4(17%) 
 
 
8(33%) 
2(8%) 
1 
0 
Table 8.1 Patient characteristics at time of ICU admission  
 
8.4.4 Mortality in ICU 
In total three patients died in ICU.  One was a male, aged 74 with multiple 
comorbidities including a previous stroke, epilepsy and gastric malignancy.  He 
required intubation and ventilation for MC complicated by pneumonia and cardiac 
failure.  He died of sepsis in association with respiratory failure after 30 days in ICU.   299 
 
 
The second patient was a 37 year old female with a two year history of seropostitive 
MG.  She had brittle MG requiring azathioprine, prednisolone, plasma exchange and 
IVIG in the twelve months prior to ICU admission.  Despite intubation and mechanical 
ventilation and treatment with prednisolone, IVIG, plasma exchange and antibiotics for 
respiratory sepsis, she died 21 days after admission to ITU. 
 
The third patient was a 23 year old female who presented in myasthenic crisis and was 
found to have a thymoma with positive AChR antibodies.  She required intubation for 
acute respiratory distress and underwent a thymectomy, which revealed a necrotic B2 
thymoma.  Her illness was complicated by sepsis, gastroparesis, progressive weakness 
and severe autonomic instability.  She was treated with IV methylprednisolone, IVIG, 
plasma exchange and cyclophosphamide but died 100 days after admission to ICU.   
 
8.4.5 Outcome after discharge from ICU  
One patient died after discharge from ICU.  He was 40 years old and had a five year 
history of thymomatous MG for which he had declined a thymectomy.  He was 
intubated and ventilated for four weeks and was treated with prednisolone, IVIG and 
subsequently plasma exchange.  His admission was complicated by Morvan’s 
Syndrome.  He was weaned from ventilation successfully and was discharged from 
ICU.  However, he developed respiratory arrest two days after discharge and died due to 
a pulmonary embolism.   
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The majority of patients (29/36; 81%) had mild –moderate myasthenic symptoms on 
discharge from ICU (MGFA Grades I II III).  Five patients had severe myasthenic 
weakness (MGFA Grade 4) and one patient had a tracheostomy in situ for respiratory 
support (MGFA V).   
 
Seven patients were lost to follow up.  One patient died two years after ICU discharge 
of acute respiratory failure.  She had brittle MuSK positive MG and had required 
frequent IVIG and plasma exchange as well as non-invasive ventilation after ICU 
discharge.  There was follow up data available for the remaining 26 patients for a mean 
of 4 years (range 6 months -12 years). 
 
Six patients underwent thymectomy after ICU discharge.  Five of these were in the 
younger age group – three had a thymoma and two had a hyperplastic gland.  The one 
patient in the older cohort who underwent thymectomy after ICU discharge was found 
to have a thymoma.  Generally, thymectomy was not performed directly after ICU 
discharge.  Patients were treated with immunosuppressive agents until the MG 
symptoms were under control and were then subsequently readmitted for thymectomy.  
An exception was made for a young female patient with severe myasthenic symptoms 
and a B2 thymoma who presented in myasthenic crisis and had severe autonomic 
instability.  
 
In general, there was a continued improvement in MGFA status during follow up in 
both age groups.  At the last clinical review which was at a mean of four years after ICU 301 
 
discharge, 19% (6/31) of patients for whom follow up was available were asymptomatic 
and 48% (15/31) had either purely ocular symptoms or mild generalised disease. 
 
Clinical Severity (MGFA)  Number of patients 
ICU discharge  
Number of patients  
Last clinical review  
(mean time from ICU 
discharge)  
Age (yrs)  < 50 (n=14)  >50(n=24)  < 50 (n=14) 
6.3 yrs  
>50 (n=24) 
2.7 yrs 
Asymptomatic  
I 
II 
III 
IV 
V 
Died  
Lost to follow up 
- 
1 
2 
6 
3 
- 
2 
- 
- 
2 
14 
4 
2 
1 
1 
- 
2 
1 
5 
1 
- 
- 
4 
1 
4 
1 
8 
4 
- 
- 
1 
6 
Table 8.2 Clinical outcome after ICU discharge  
 
Sixty five per cent of patients (20/31) remained on oral prednisolone at an average dose 
of 12.5 mg at last clinical review.  Forty eight per cent took additional oral 
immunosuppression (8/31 on azathioprine, 6/31 on mycophenolate mofetil and 1/31 on 
methotrexate).  Three patients (10%) required IVIG.   
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Treatment   Number of patients  
Last clinical review  
(Mean time from ICU discharge)  
Age (yrs.)  < 50 (n=14) 
6.3 yrs.  
>50 (n=24) 
2.7 yrs. 
No immunosuppressive treatment  1  2 
Prednisolone  
Average dose  
6  
10mg 
14                                                       
15mg  
Azathioprine             
Mycophenolate              
Methotrexate  
Rituximab                               
Regular IVIG  
2                                
4                                
1                                
2                                  
2 
6                                                          
2                                                       
 
1                                                            
1  
Lost to follow up   1  6 
Died   4  1 
Table 8.3 Treatment at last clinical review  
 
8.5 Discussion  
 
This study is limited by its small size and retrospective nature.  However, it is clear that 
acute severe exacerbations of MG continue to be associated with significant morbidity 
and mortality.  The mortality rate in ICU in our study was 8% which is higher than that 
quoted in some previous studies (Thomas et al., 1997; Cohen and Younger, 1981).  Our 
centre is a specialist referral centre and over 70% of the admissions to ICU in our cohort 
were transfers from different centres.  It is possible that our ICU is biased towards 
admission of more severe cases of MG, which could explain the high mortality rate in 
our group.  However it is clear that with modern intensive care treatment of acute 
exacerbations of MG the mortality rate has fallen significantly from a rate of 
approximately 80% in the 1940s (Osserman et al., 1963).   
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This study has highlighted the need to be vigilant for MG as a differential diagnosis of 
acute respiratory failure, particularly in older adults.  MG is increasingly recognised in 
the older population- 60% of our cohort were over the age of 50 and MG was newly 
diagnosed in 40% of these patients.  There were no significant differences in short-term 
outcome between older and younger patients and the long-term prognosis after 
discharge from ICU was good in both groups.  
Predicting the onset of an acute exacerbation of MG can be difficult.  There was no 
obvious precipitant of myasthenic crisis in 42% of our patients.  In those  patients in 
whom a precipitant was identified, infection, mainly respiratory sepsis was the most 
common.  Respiratory sepsis was also an overwhelming risk factor for intubation, a 
factor that has been noted previously (Cohen and Younger, 1981; Ferguson et al., 1982).  
Infection is a well-known and common cause for acute exacerbations of MG (Kalita et 
al., 2014; Thomas et al., 1997, Aggarwal et al., 2002).  Other precipitating factors noted 
in the past include inadequate treatment, use of offending drugs and surgery (Bedlack et 
al., 2002; Kalita et al., 2014) but these factors were not observed in the majority of our 
patients.   
 
It has been suggested in the past that thymoma may be a risk factor for myasthenic 
crisis as there is a relatively well-accepted association between thymoma and a more 
severe myasthenic phenotype (Thomas et al., 1997; Grob et al., 1987).  A thymoma was 
present in 21% of the patients – approximately 10-20% of patients with MG have a 
thymoma (Lucchi et al., 2009) and so patients with a thymoma were not significantly 
over represented in our cohort.  Previous studies of myasthenic crisis have found higher 
proportions of patient with thymoma, up to 32% (Thomas et al., 1997).   304 
 
 
This study attempted to define some of the factors that are associated with a poorer 
prognosis in acute exacerbations of MG.  As well as being a factor associated with 
intubation, sepsis, particularly respiratory sepsis was also implicated in the deaths in the 
three patients who died on ICU.  Another comorbidity was pulmonary embolism, which 
was implicated in the death of the patient who died after discharge from ICU.  Similar 
comorbidities in myasthenic crisis have been reported previously but none were 
independent predictors of death (Alshekhlee et al. 2009).   
 
In the past intubation but not non-invasive ventilation has been found to be an 
independent risk factor for mortality (Alshekhlee et al., 2009).  Advanced age has been 
reported to be an independent risk factor for mortality in MG crisis (Alshekhelee et al., 
2009).  However our data show that older MG patients have a similar prognosis to 
younger patients in ICU and also in the longer term.   
 
The management of myasthenic crisis has changed considerably in recent years.  The 
mortality of MC is now generally considered to be less than 5% due, in a large part to 
improvements in the respiratory care of patients.  Intubation and mechanical ventilation 
were required in 63% of our patients.  The average duration of intubation was 28 days.  
An additional four patients were treated with BiPAP.  Non-invasive ventilation is 
increasingly used and has been shown to help reduce the need for intubation in patients 
with myasthenic crisis (Rabinstein and Wijdicks, 2002).  Patients were monitored 
clinically regarding the need for intubation.  Forced vital capacity was routinely 
measured on the ITU with the aim to perform intubation before significant hypoxia 305 
 
developed.  The average duration of intubation in our patients was longer (on average) 
than that described in previous studies.  It has been described previously that 25% of 
patients with myasthenic crisis will be extubated after one week, 50% by two weeks and 
75% by one month (Thomas et al., 1997).  The mean duration of ventilation in our 
cohort was skewed somewhat by two outliers.  Analysing the data in more depth 
revealed that 30% (7/24) of patients were extubated within one week.  As mentioned 
before, the majority of the patients in our cohort were transferred from other hospitals, 
suggesting that they may be more severely affected or more treatment resistant than 
other patients.  Intubation for more than three weeks has been associated with a 
threefold increase in hospital stay and a two-fold increase in functional dependence at 
discharge (Thomas et al., 1997).  Twenty five per cent (6/24) of our patients required 
mechanical ventilation for longer than three weeks.  
 
IVIG is increasingly used in the management of myasthenic crisis.  The vast majority 
(87%) of our cohort received IVIG.  Ten years ago only 11.4% of a similar cohort in our 
institution received IVIG whereas 60% underwent plasma exchange (O’Riordan et al., 
1998a).  IVIG and plasma exchange have recently been found to be equally effective for 
exacerbations of MG but the former is better tolerated and is used increasingly (Barth et 
al., 2011) and has a lower risk of adverse events such as hypotension, coagulopathy and 
sepsis (Qureschi et al., 1999).  
 
Little is known about the long-term outcome of patients with acute severe exacerbations 
of MG following hospital discharge.  I have follow-up data for 82% of our patients for a 
mean of four years and have found that that the vast majority of our patients were 306 
 
asymptomatic or had mild manifestations of MG at final review.  In particular, there 
were no significant differences in long-term outcome between the older and younger 
patients.  In the past, even if patients survived the initial acute exacerbation, the overall 
outlook was thought to be poor with up to 30% of patients having repeated myasthenic 
crisis and almost half of patients continuing to demonstrate loss of muscle strength or 
becoming functionally dependant (Thomas et al., 1997; Richman and Agius, 2003).   
Poorer outcomes have been associated with long periods of mechanical ventilation, 
particularly in older patients (Thomas et al, 1997).  The outcomes that are described 
here are a lot more positive than this and indeed other authors have also described a 
good long-term outcome in myasthenic patients who survive the initial crisis.  Cohen 
and Younger found that out of 25 patients who survived a myasthenic crisis and were 
followed up, 32% (8 patients) achieved remission, 32% (8 patients) improved and 24% 
(6) were “stable”(Cohen and Younger, 1981).  Three of our patients had repeated 
admissions to ITU with severe exacerbations of MG, representing 8% of our total 
cohort.  This is a much smaller proportion than was described in previous studies where 
33-43% of patients had recurrent myasthenic crises (Thomas et al., 1997; Berrouschot et 
al., 1997).   
 
This study suggest that despite the acute risk of mortality associated with severe 
exacerbations of MG, with intensive treatment, the long- term outcome is favourable.  A 
matched nested case control study from hospital admissions of MG patients has 
previously shown that patients with MG are less likely to die if they are admitted under 
the care of a neurologist (Hill and Ben-Schlomo, 2007).  Prolonged treatment in a 
specialised neuro-intensive care environment may be required but even patients who 
were ill for many weeks on ITU can have a favourable prognosis in the long term.   307 
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In this thesis I set out to tackle a number of unresolved issues regarding the 
pathomechanisms involved in LEMS and the VGCC specificity of LEMS antibodies.  I 
also decided to take advantage of the large cohort of patients with MG that attend the 
NHNN to address unanswered questions with regard to clinical aspects of MG including 
outcome after thymectomy and long term prognosis after a severe exacerbation of MG.   
 
9.1. Immunohistochemistry experiments using LEMS IgG  
 
Initially with regard to LEMS, my first aim was to visualise the binding of antibodies 
from LEMS antibodies to cell surface antigens on cultured neuronal cells using high-
resolution microscopy.  Antibodies against LEMS are currently detected by 
radioimmunopreciptiation assay but the use of cell based assays to detect IgG binding to 
cell surface antigens in a variety of other autoimmune diseases including Myasthenia 
Gravis and diseases associated with antibodies to the VGKC complex has enhanced our 
knowledge about antibody specificity in these conditions.   
Hitherto it has been difficult to visualize binding of LEMS IgG to cell surface antigens 
because of the low density of VGCCs at the cell surface and also because one of the 
mechanisms of action of LEMS IgG is the cross linking and internalization of these 
receptors.   
 
In my experiments I mainly used non-permeabilised hippocampal cultures that were 
incubated with LEMS IgG or control IgG and used anti human IgG Alexa 594 as a 
secondary antibody.  I was able to detect IgG binding to cell surface antigens in all 309 
 
seropositive LEMS samples tested but non-specific cell surface binding was seen with 
control IgG.  Further experiments attempted to co-localise binding of LEMS IgG to 
synapses/VGCCs using GFP-tagged VGCC and co-staining with synapsin.  
Unfortunately I was not able to reliably  detect co-localisation of LEMS IgG to 
synapses in this way.  I was also unable to specifically detect binding of one LEMS IgG 
sample to P/Q-channels using neurons cultured from Cacna1a KO mice and their WT 
littermates.  It is possible that the staining we saw was due to the individual patients 
having additional antibodies in their serum.  Patients with SCLC may have antibodies to 
a variety of antigens as well as VGCCs.  Antibodies to GABA(B) receptors have been 
described in patients with SCLC associated with limbic encephalitis (Boronat et al., 
2011).  A case of VGCC antibody positive LEMS in association with antibodies against 
the VGKC complex has also been described (Kalra et al., 2014).   It is possible that I 
was detecting antibodies that are specific for antigens other than VGCCs with this 
assay.  
 
Further studies using LEMS IgG from a large number of patients are required to 
determine whether cell surface binding is specific for VGCCs.  If these further studies 
were to be successful it is likely that a cell based assay for LEMS could be developed.  
This would be extremely beneficial, as not only would it reduce the need for radioactive 
immunopreciptiation techniques, but it would also allow us to detect the exact antigenic 
target(s) of LEMS antibodies.   
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As my efforts to reliably detect specific binding of IgG from LEMS patients to cell 
surface antigens were unsuccessful, I decided to focus on functional effects of LEMS 
antibodies.   
 
9.2 Functional effects of LEMS IgG on synaptic vesicle release 
 
9.2. 1 LEMS IgG significantly reduces the rate of action potential evoked synaptic 
vesicle release 
It has been known for some time that LEMS antibodies reduce the amplitude of 
postsynaptic responses (EPP) at the neuromuscular junction and the current through 
VGCCs in a wide variety of cell types.  It has therefore been postulated that muscle 
weakness in LEMS results from a decrease in presynaptic neurotransmitter release due 
to a reduction in Ca2+ entry in response to an action potential but the evidence for this to 
date has been indirect.  I tested the effect of LEMS IgG on synaptic vesicle release in 
hippocampal neuronal cultures using FM dyes.   
My fluorescent imaging data show definitively that LEMS IgG significantly decreases 
AP evoked synaptic vesicle release in rat hippocampal neuronal cultures.  A similar 
effect was seen on spontaneous neurotransmitter release although my experiments were 
not specifically designed to measure this.  All four samples that I tested caused a 
reduction in spontaneous and evoked transmitter release.   
I was not able to correlate the magnitude of the effect in each individual sample to 
antibody titre.  Further experiments with a large number of LEMS samples with 
different titres would be required to clarify this.  I was also unable to demonstrate a 311 
 
significant effect of “seronegative” LEMS sample on neurotransmitter release. However 
I only performed a limited number of experiments with this sample and it is difficult to 
draw firm conclusions regarding the pathomechanism of “seronegative” LEMS.   
Nevertheless, my data provide definitive evidence regarding the pathomechanism of 
antibodies in LEMS.  To my knowledge, FM dyes have not been used to investigate the 
action of LEMS IgG in the past.  My successful use of this technique has provided a 
new tool for studies of the functional effects of LEMS antibodies in the future.  
 
9.2.2 The action of LEMS IgG is specific for P/Q- VGCC 
Although it has been known for some time that LEMS antibodies decrease voltage 
dependent Ca2+ entry into cells, it has been less certain which specific Ca2+ channel 
subtypes are affected.  There have been conflicting studies in the literature regarding 
this and in particular it has been uncertain whether LEMS IgG affects N-type VGCCs.  
This is particularly relevant as up to 33% of patients with LEMS have antibodies 
against N-type channels.  The available literature also does not rule out the hypothesis 
that different antibodies affect P/Q-type VGCCs and neurotransmitter release. 
 
I studied the effect of a LEMS sample that had antibodies against both P/Q-and N-type 
VGCCs on synaptic vesicle release in neuronal cultures from a Cacna1a knockout 
mouse that lacks P/Q-type Ca2+ channels.  LEMS IgG significantly reduced action 
potential evoked neurotransmitter release in WT synapses but had no significant effect 
in KO samples, implying that the effect of LEMS IgG is specific for P/Q type channels.  
To my knowledge, this was the first time that LEMS IgG was tested in synapses lacking 
P/Q-type channels.   312 
 
 
The LEMS sample I used had antibodies detected against both P/Q- and N- type 
VGCCs on radioimmunoprecipitation assay so if there were an effect on N-channels I 
would expect to see it in these experiments.  However, further experiments with LEMS 
samples from different patients are required to corroborate our findings.   
 
9.2.3 Limitations of our experiments  
There are a number of limitations to my experiments that must be considered when 
interpreting the data.  I used a model system of central synapses derived from 
hippocampal neuronal cultures.  Ideally, I would have chosen to test the effect of LEMS 
IgG on synaptic transmission at the neuromuscular junction.  There were a number of 
practical reasons why this was not feasible.  There are conflicting data as to whether 
LEMS IgG can exert its effect acutely when applied acutely to neuromuscular junction 
preparations.  In general, when NMJ preparations are used, IgG is passively transferred 
rather than being acutely applied.  This option was not available to me as I used 
Cacna1a KO mice.  These mice become progressively ataxic from postnatal day 10 and 
thus would not survive long enough to allow us to passively transfer the IgG.  However, 
hippocampal neuronal cultures have been validated previously in experiments using FM 
dye (Ermolyuk et al., 2013) and furthermore, the degree of contribution of hippocampal 
P/Q-type VGCCs to synaptic vesicle release is similar to that at the neuromuscular 
junction (Cao and Tsien, 2010; Protti et al., 1996; Uchitel et al., 1992). 
 
Another potential weakness of my study was the limited number of IgG samples used.  
Ideally a large number of LEMS samples would be used to corroborate our findings.  313 
 
However LEMS is a rare disease and thus the sera available was limited.  However, I 
saw consistent results with all four LEMS samples we tested.  Nevertheless, repeating 
the above experiments with a larger number of samples is a next step for this project.   
 
9.3 Long-term prognosis in MG  
 
9.3.1 Trans-sternal thymectomy is associated with a good prognosis in the majority of 
patients with MG 
Thymectomy has been used since the 1930s for the treatment of MG.  It is always 
indicated when a patient has a thymoma because of the risk of local invasion and 
metastatic spread but its use in non-thymomatous MG, although widespread, remains 
controversial.  Persistent positive associations have been found in retrospective non-
controlled studies between thymectomy and improvement of myasthenic symptoms.  A 
randomised controlled trial comparing thymectomy combined with prednisolone 
therapy to treatment with prednisolone alone is currently underway and was designed to 
answer three questions (Newsom –Davis et al. 2008): 
 (1) Whether thymectomy results in a greater improvement in myasthenic weakness; 
(2) Whether thymectomy allows a lower dose of prednisolone and  
(3) Whether thymectomy enhances quality of life by reducing adverse events associated 
with therapies.  
This trial is currently closed to recruitment and results are expected in the next few 
years.  However, as the NHNN has a large cohort of patients with MG, I decided to 
perform a follow up study on all patients who had undergone thymectomy over the 314 
 
previous twelve years.  Eighty-nine patients were identified, of which 24% had a 
thymoma, 48% had a hyperplastic gland and 19% and 8% had normal and atrophic 
thymic histology respectively.  I was interested firstly, whether trans-steranl 
thymectomy was well tolerated and I found that it in general it was a safe and well 
tolerated procedure.  Early complications were rare and were not associated with long-
term morbidity with the exception of one patient who developed a post-operative 
myasthenic crisis.  My main focus of interest, however, was whether thymectomy was 
associated with an improvement in myasthenic symptoms and a decreased steroid 
requirement in the long term.  I found that 34% and 33% of patients achieved CSR and 
PR respectively at last clinical review, which was a mean of 3.8 years post thymectomy.  
Patients with a hyperplastic gland had a significantly higher chance of achieving CSR 
compared to other histological subtypes.  There was a trend towards the incidence of 
CSR increasing with time after thymectomy.  These data are in line with previous 
studies (Jaretzki et al., 1988; Klein et al., 1999, Chen et al., 2011; Tomulescu et al., 
2011; Masaoka et al., 1996).  Prednisolone doses progressively decreased during follow 
up and although the use of immunosuppressants such as azathioprine and 
mycophenolate mofetil increased, I felt that this was unlikely to account for the clinical 
improvement seen.  
 
My study is limited by its retrospective nature and the relatively small number of 
patients.  However, whilst the results of the randomised controlled trial are awaited, my 
data add to the previous studies regarding the effectiveness of thymectomy in MG and 
suggest that thymectomy is a safe well tolerated procedure that can result in a good long 
–term outcome in MG – particularly in those patient who have a hyperplastic gland 
detected on imaging.  315 
 
 
9.3.2 Recurrence of thymoma can occur many years after initial surgery  
Thymomas are rare tumours but approximately 15% of patients with MG have a 
thymoma and conversely 20-25% of patients with a thymoma have MG (Lucchi et al., 
2009).  Myasthenic symptoms often remain after thymectomy and patients remain under 
the care of neurologists.  My aim in this chapter was to highlight the risk of late 
recurrent thymoma as it is a rarely reported but important phenomenon.  I described six 
patients who had recurrence of a previously resected thymoma between six and fifteen 
years after their original surgery.  Initial resection was complete in four of these patients 
and the remaining patient had received post-operative radiotherapy.  I demonstrated that 
prognosis was poor after thymoma recurrence, three of our patients died as a direct 
recurrence of recurrence of their tumour.  There are currently no published guidelines 
regarding the frequency, duration or mode of radiological surveillance for thymoma 
recurrence (Regnard et al., 1997).  I did not demonstrate any reliable clinical clues that 
could alert the clinician to the possibility of recurrence; none of our patients had an 
exacerbation of myasthenic symptoms at the time of their recurrence and I did not find 
that AChR antibody levels were appreciably correlated with recurrence although we did 
not have the full data regarding this for all patients.  There are data suggesting various 
other antibodies including antibodies against cytokines, interleukin alpha, interleukin -
12 and anti titin antibodies that may be useful in identifying patients with tumour 
recurrence, especially if imaging is equivocal (Buckely et al., 2001).  I could not 
measure these antibodies in the patients in my study as it was retrospective but it would 
be useful in the future to validate the use of these antibodies in identifying patients at 
risk of thymoma recurrence.  In the meantime I have suggested that post-operative 316 
 
radiological surveillance after thymectomy is necessary and should continue 
indefinitely.  
 
9.3.3 Severe exacerbations of MG are associated with a good prognosis in the 
majority of patients  
The most serious complication of MG is MC- defined as respiratory failure due to 
myasthenic weakness – approximately 10-15% of patients with MG will develop this 
complication during the course of their disease (Thomas et al., 1997; Berrouschot et al., 
1997; Sellmann and Mayer, 1985).  Fifty years ago the mortality of MC was between 50 
and 80% (Rowland et al., 1956) with advances in immunomodulatory treatments and in 
particular, improvements in ventilatory care, mortality has now improved to 
approximately 5% (Jani-Acsadi et al, 2007; Cohen and Younger 1981; Alshekhlee et al 
2009).  MG is increasingly recognised in older adults and hence, the proportion of older 
patients admitted to ICU with severe exacerbations of MG is set to rise.  Little is known 
about the long- term prognosis of MG after discharge from ITU, particularly in older 
patients. 
 
My aim was to examine the current management of severe exacerbations of MG in the 
ICU and, in particular to study the long-term prognosis in older and younger patients.   
I identified 38 patients, 63% of whom were over the age of 50 at admission to ICU – 
46% of this group were newly diagnosed with MG during the admission to ICU.  Thus, 
my study highlighted the need to be aware of MG in the differential diagnosis of 
respiratory failure especially in older patients.  The mortality rate in my study was 
relatively high compared to other studies at 8%- this is likely due to the fact that our 317 
 
centre is biased in favour of seeing patients with more severe exacerbations of MG as 
over 70% of patients were transferred from other hospitals, often from other ICUs.  In 
42% of our patients there was no obvious identifiable reason for the acute deterioration 
in symptoms of MG- however sepsis, particularly respiratory sepsis was seen in 53% of 
patients and was a significant risk factor for intubation.  I highlighted differences 
compared to previous studies in our institution regarding the acute treatment of 
exacerbations of MG- over 85% of our patients received IVIG compared to only 11.4% 
of a similar cohort ten years ago (O’Riordan et al., 1998a).  Although 8% of our patients 
required repeated admissions to ITU for recurrent exacerbations of MG, I found that 
overall the long-term outcome was good.  I had follow up data for over 80% of our 
patients for a mean of four years and found that the majority were asymptomatic or had 
only mild symptoms of MG at final review.  In particular there were no significant 
differences in outcome between older and younger patients in our cohort.  Hence, severe 
exacerbations of MG can be associated with a good prognosis in older patients even if a 
prolonged ITU admission is required.  Further prospective studies with larger numbers 
of patients are required to identify factors that are associated with a good prognosis.   
 
9.4. Final summary  
 
This thesis has built on previous knowledge regarding the benefit of thymectomy in MG 
and provides new insight into the long term prognosis after a severe exacerbation of the 
disease requiring ICU admission.  Further prospective studies are needed to clarify our 
knowledge in this area.   
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This work also sheds new light on the pathomechanisms of LEMS IgG, showing that 
LEMS IgG reduces the rate of synaptic vesicle release and that this effect is specific for 
P/Q- VGCCs.  Further experiments using samples from a greater number of patients are 
required to fully examine the mechanism of action of LEMS IgG which should help 
identify new targets for treatment of this autoimmune disease.  
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